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This thesis investigates the interactions of lysogenic bacteriophage with
Streptococcus pyogenes.  We were specifically interested in elucidating novel
ways in which the prophage influence GrAS virulence and survival either within
the host cell or within the bacterial population.  In turn, we also hoped to
determine how the bacteria (and possibly other integrated phage) might influence
prophage activity or gene expression. Our studies focused on two poly-
lysogenized GrAS strains, a M6 serotype (MGAS10394) and a M1 serotype
(SF370).
In our M6 studies, we chose a streptococcal strain lysogenized by a chimeric
bacteriophage element (Φ10394.4), which contains the erythromycin resistance
gene mefA, in order to elucidate why genomes of certain erythromycin-resistant
isolates of group A streptococci are resistant to SmaI endonuclease cleavage.  In
the work presented here, we identified a restriction modification system
contained on the bacteriophage chimeric-element and successfully characterized
the first methyltransferase (M.SpyI) encoded in S. pyogenes.
In the M1 strain, allelic recombination techniques were used to begin to analyze
the role and regulation of a bacteriophage-encoded potential superantigen,
SpeH.  Next, we designed a novel system to specifically select for the loss of
integrated phages entirely from the genome. This technique allowed us to study
the novel role that two SF370 phage play in regulating GrAS chromosomal genes
involved in bacterial metabolism, DNA repair and mutagenesis.  We were also
able to begin to elucidate the effects that individual and multiple phage loss have
on SF370 virulence and survival, as we successfully constructed the first strain of
GrAS that is completely devoid of bacteriophages.
In the course of these studies, we also manipulated lytic bacteriophage genes
from two different Staphylococcus phage genomes to genetically engineer a
novel chimeric endolysin (ClyS).  We demonstrated the antimicrobial lytic activity
of ClyS against methicillin-resistant Staphylococcus aureus (MRSA) in both in
vivo colonization and septicemia models, and were also able to show its
synergistic activity with oxacillin in in vitro and in vivo models.  This work
highlights the potential of ClyS as a novel therapeutic agent for the treatment of
MRSA and other staphylococcal infections.
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15 Introduction
Describing bacterial pathogenesis, Felix dʼHerelle wrote, “… the actions and
reactions are not solely between these two beings, man and bacterium, for the
bacteriophage also intervenes; -a third living being and, hence, a third variable is
introduced” (d'Herelle 1930).
5.1 Bacteriophages
Bacteriophages (phages) are ubiquitous viruses that can infect bacteria.
Independently discovered by Felix dʼHerelle and Fredrick Twort in the early
1920ʼs, bacteriophage research has made many contributions to the fields of
genetics and molecular biology, including an understanding of genetic mutation
(Luria and Delbruck 1943; Lederberg and Lederberg 1952), the discovery of a
genetic code (Crick, Barnett et al. 1961), and the detection and manipulation of
restriction enzymes (Luria and Human 1952).  Phage research has also included
therapeutic applications of phage as treatments against bacterial infections, as
well as the role phage play in many diseases caused by bacterial pathogens
(Waldor, Friedman et al. 2005).
2Figure 5.1.  Bacteriophage lifecycle has two phases:  Lytic and lysogenic.
Adapted from http://inst.bact.wisc.edu/inst with permission.
5.2 Lytic Phage in Treatment of Bacterial Disease
Phages exhibit two distinct lifecycles:  a lytic phase and a lysogenic phase
(Figure 5.1).  The lytic phase consists of phage infection of the host bacteria,
replication of the viral genome, production and assembly of new viral particles,
and then the rupture of the host bacterial cell to release the phage progeny.  This
phase, which ends with the death of the bacteria and further spread of the virus,
3has been the focus of using “lytic phage” as therapeutic agents.  dʼHerelleʼs own
work throughout the early 1900ʼs focused on using phage preparations isolated
from sterile culture supernatants of phage-infected bacteria to treat numerous
bacterial diseases.  His initial work focused on the use of phage to treat livestock
animals suffering from avian typhosis (Salmonella gallinarum) and bovine
hemorrhagic septicemia (Pasteurella multocida).  He later used “shiga-
bacteriophage” and “plague-phage” to successfully treat human patients suffering
from dysentery and bubonic plague, respectively (d'Herelle 1930; Summers
2001).  These studies, together with successful phage treatment regimes by
other scientist increased interest in “phage therapy” to such an extent that
several US pharmaceutical companies, including Eli-Lilly, commercialized
products containing phage lysates for several target diseases (Summers 2001;
Deresinski 2009).  But since the discovery of antibiotics during World War II,
interest in phage therapy fell in the United States as the use of antibiotics, which
were cheaper to produce and could act against a wider spectrum of bacterial
pathogens, dramatically increased throughout the decades.  Since then, the
misappropriate overuse of antibiotics has selected for the emergence of several
bacterial pathogens that are now resistant to a majority of the current antibiotic
treatments (Fluit, Verhoef et al. 2001; Gill, Fouts et al. 2005).  The current state
of antibiotic resistant bacteria has encouraged researchers in academia and
biotechnology to look for alternative antimicrobials, and has stimulated a
renewed interest in using lytic phages or phage-lytic enzymes, termed “lysins”,
4(Figure 5.2) as a treatment against a number of different pathogens and drug
resistant bacteria (Fischetti, Nelson et al. 2006; Fischetti 2008; Deresinski 2009;
Daniel, Euler et al. 2010).
5
6Figure 5.2.  Bacterial lysis in phage therapy and lysin therapy.
Phage therapy (on the left) exploits a natural phage lytic cycle, which occurs over
30 min and is divided into three major steps, including the release of new virions
(in red) into the environment.  Subsequent infection of new hosts illustrates the
process of self-amplification.  The electron micrograph depicts phage particles
adhering to the debris of a lysed streptococcal cell.  In comparison, lysin therapy
and prophylaxis (on the right) is defined by only two steps, in which purified or
recombinant lysin (in blue) binds to, and rapidly kills through osmotic lysis, the
target pathogen.  The electron micrograph depicts a cross-section of Bacillus
anthracis treated with the purified PlyG lysin showing an externalized cytoplasmic
membrane just before lysis. Scale bar, 200 nm.  Adapted with permission from
(Fischetti, Nelson et al. 2006).
75.3 Bacteriophage Lysins
Phage lysins are cell wall hydrolases that are expressed late in the lytic cycle.
With the help of phage encoded holins, lysins are translocated across the
bacterial membrane and cleave the peptidoglycan bonds of the bacterial cell wall
resulting in hypotonic lysis of the bacteria and phage progeny release (Young
1992).  Fortuitously, the killing effect of lysins can also be elicited when their
purified recombinant forms are directly applied to susceptible Gram-positive
bacteria from the outside (Fischetti, Nelson et al. 2006).  Gram-negative bacteria
are protected from this lysis by their outer membrane, as the lysin cannot make
contact with the peptidoglycan cell wall.  The lytic spectrum of each lysin is
usually narrow (species or even strain specific) and is constrained by the
peptidoglycan-associated ligands, often carbohydrates, that serve as lysin
binding targets, which themselves are often distributed in a species or strain
specific manner.  These moieties are often essential for bacterial viability, making
it difficult for the bacteria to mutate these epitopes to become resistant to lysin
binding (e.g. choline for Streptococcus pneumoniae or polyrhamnose in
Streptococcus pyogenes) (Fischetti 2005).   The catalytic activities of lysins
generally fall into three classes based on bond specificity within the
peptidoglycan:  glycosidases that hydrolyze linkages within amino-sugar
moieties, amidases that hydrolyze amide bond between the glycan and the
pentapeptide, and endopeptidases that cleave within the pentapeptide or the
8peptide cross-bridge.  Significantly these bonds are invariant in all bacterial cell
walls.   A very important feature of lysins, with respect to their development as
antibacterials, is that they have structural versatility.  That is, the peptidoglycan
hydrolysis activity and the surface carbohydrate binding activity are encoded in
two distinct functional domains.  These domains remain active after separation
and can be recombined with complementary domains of other lysins to alter their
specificity and/or catalytic functions (Donovan, Dong et al. 2006).  In this manner
a number of distinct lysins can be recombined to generate a highly variable pool
of antimicrobials (Croux, Ronda et al. 1993; Lopez, Garcia et al. 1997; Daniel,
Euler et al. 2010).  Currently, some of the potential applications include
prophylactically decolonizing or treating infections of the mucous membranes,
skin and wounds with lysins that target Staphylococcus aureus, Streptococcus
agalactiae, or Streptococcus pyogenes (Nelson, Loomis et al. 2001; Cheng,
Nelson et al. 2005; Daniel, Euler et al. 2010), or treating systematic bacterial
infections with lysins designed against anthrax, pneumococcal septicemia and
enterococcal septicemia (Schuch, Nelson et al. 2002; Loeffler and Fischetti 2003;
Yoong, Schuch et al. 2004).
5.4 Lysogenic Phage in Bacterial Pathogenesis
The lysogenic phase of the phage lifecycle also involves infection of the host
bacteria, but instead of producing new viral particles, the phage genome is
integrated by site-specific recombination into the bacterial chromosome
9(Figure 5.1), at which time it is termed a prophage.  Expression of a phage lytic
repressor, encoded on the phage genome, allows the bacteriophage DNA to
remain integrated and to be stably replicated as part of the host chromosome.
The resulting prophage and host bacteria together form a lysogen.  Sometimes
lysogens can be induced to produce full phage particles once again, usually as a
result of DNA damage (e.g. exposure UV light or mitomycin-C in the laboratory
setting) or other environmental signals that result in the inactivation of the lytic
phage repressor (Broudy, Pancholi et al. 2001; Banks, Lei et al. 2003).
Integrated viral DNA then excises from the genome and enters lytic cycle
replication, resulting in the production and assembly of viral components and the
eventual rupture of the host bacteria.  While lysogenic phages have the potential
to kill their host bacteria, their stable integration often provides evolutionary
benefits to host.  For along with the genes necessary for the viral lifecycle,
phages often encode virulence factors that increase the pathogenic potential and
survival of the lysogen.  Genomic analysis of most human pathogenic bacteria
(gram positive and gram negative) shows that they can contain a number of
phages that encode virulence factors (Table 5.1).  These virulence proteins
provide additional mechanisms for bacterial attachment and colonization,
invasion into host tissue, antimicrobial resistance, damage to host cells (toxins),
and evasion or alteration of the host immune response (Brussow, Canchaya et
al. 2004). Furthermore, integrated phages also encode factors such as phage
repressors, super infection exclusion proteins, and restriction enzyme systems
10
that prevent other lytic phage from infecting and killing its host.  These phage-
associated attributes give lysogens an advantage for survival in the host and
over other bacteria, and thus increase the selection of bacteria that maintain the
DNA of a lysogenic phage.   Such selection is evident in the large number of
lysogenic bacteriophages that are integrated into the genomes of members of the
Genus Streptococcus (Beres and Musser 2007).
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Table 5.1.  Examples of bacteriophage encoded virulence factors
Virulence Protein Gene Phage Bacterial host
Extracellular toxins
Diphtheria toxin tox β-Phage C. diphtheriae
Neurotoxin C1 Phage C1 C. botulinum
Shiga toxins stx1, stx2 H-19B E. coli
Enterohaemolysin hly2 φFC3208 E. coli
Cytotoxin ctx φCTX P. aeruginosa
Enterotoxin see, sel NA S. aureus
Enterotoxin P sep φN315 S. aureus
Enterotoxin A entA φ13 S. aureus
Enterotoxin A sea Mu50A S. aureus
Exfoliative toxin A eta φETA S. aureus
Leukocidin pvl φPVL S. aureus
Cholera toxin ctxAB CTXφ V. cholerae
Superantigen speA T12 S. pyogenes
Superantigen speC CS112 S. pyogenes
Superantigens
speA1 , speA3 , speC , 
speI , speH , speM , speL , 
speK , ssa
8232.1, 315.5, 370.1, 
370.2, 8232.3, 315.4, 
315.2 S. pyogenes
Cytolethal distending toxin cdt Unnamed E. coli
Proteins altering antigenicity
Membrane proteins Mu-like Pnm1 N. meningitidis
Glucosylation rfb ε34 S. enterica
Glucosylation gtr P22 S. enterica
O-antigen acetylase oac Sf6 S. flexneri
Glucosyl transferase gtrII SfII, SfV, SfX S. flexneri
Proteins involved in invasion
Type III effector sopE SopEφ S. enterica
Type III effector sseI (gtgB) GIFSY-2 S. enterica
Type III effector sspH1 GIFSY-3 S. enterica
Enzymes
Superoxide dismutase sodC Sp4, 10 E. coli  O157
Superoxide dismutase sodC-I GIFSY-2 S. enterica
Superoxide dismutase sodC-III Fels-1 S. enterica
Neuraminidase nanH Fels-1 S. enterica
Hyaluronidase hylP H4489A S. pyogenes
Leukocidin pvl φPVL S. aureus
Staphylokinase sak φ13 S. aureus
Phospholipase sla 315.4 S. pyogenes
DNase/streptodornase sdn, sda, spd1,mf3, mf4
315.6, 8232.5, 370.1, 
370.2, 315.3 S. pyogenes
Serum resistance
Outer membrane protien (OMP) bor λ E. coli
OMP eib λ-like E. coli
Adhesions for bacterial attachment
Vir vir MAV1 M. arthritidis
Phage coat proteins pblA , pblB SM1 S. mitis
Others
Mitogenic factor toxA Unnamed P. multocida
Mitogenic factor Unnamed phisc 1 S. canis
Virulence gtgE GIFSY-2 S. enterica
Antivirulence grvA GIFSY-2, Fels-1 S. enterica
* Table adapted from Brussow, Canchaya et al. 2004 and Boyde and Brussow 2002 with permissions.
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5.5 Genus Streptococcus
Streptococci are gram-positive, non-motile bacteria that are spherical or oval in
shape and grow in chains or pairs.  For clinical purposes they are delineated by
their ability to lyse mammalian red blood cells, resulting in three hemolytic
patterns on sheep blood agar: i) alpha or partial hemolysis with greening; ii) beta
or total hemolysis with clearing; iii) gamma or no lysis of blood cells (Figure 5.3)
(Brown 1919).
Figure 5.3.  Example of the three hemolytic patterns of streptococci.
Alpha (α), beta (β), and gamma (γ), on sheep blood agar plates.  Reproduced
with permission from a photo taken by Rebecca Buxton, University of Utah.
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With the exception of the alpha-hemolytic human pathogen Streptococcus
pneumoniae, most alpha- and gamma-hemolytic streptococci are associated with
the normal flora of the upper respiratory and intestinal tracts, and as such, most
infections are usually opportunistic in nature, needing a predisposing factor such
as an immunocompromised host, tissue injury, or an anatomical abnormality.
Examples of such infections include sepsis in neutropenic patients; secondary
wound infections, urinary tract infections and endocarditis.  Conversely, beta-
hemolytic streptococci are pathogens that cause a variety of human and animal
diseases.  Beta-hemolytic streptococci can be further divided into Lancefield
serological groups (A-O) based on antigenic reactivity to group specific cell wall-
associated carbohydrates (Lancefield 1933).  While Lancefield groups, B, C, D,
and G are associated with a number of animal and human infections, group A
streptococci cause the majority and widest range of human infections amongst
the various streptococcal species (Fischetti 2006).
5.6 Group A Streptococcus
Beta-hemolytic group A streptococcus (GrAS) or Streptococcus pyogenes is one
of the most prevalent obligate human pathogens worldwide.  It has the ability to
asymptomatically colonize the human upper respiratory tract and skin (up to 25%
of the population), as well as cause a wide variety of human diseases (Table
5.2). There is a stronger association of GrAS carriage and infection in children
than in the adult population (Breese and Hall 1978).  Mild infections and diseases
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include: i) superficial infections of the skin, such as impetigo, polyderma, and
erysipelas; ii) relatively uncomplicated infections of the mucosa, such as otitis
media, sinusitis, and pharyngitis or “Strep throat”.  GrAS are the main bacterial
cause of acute pharyngitis and account for 15-30% of all pharyngitis cases in
children and 5-10% of adult cases around the world (Schroeder 2003; Carapetis,
Steer et al. 2005; Steer, Danchin et al. 2007).  While these diseases seem
relatively innocuous, it is estimated that there are over 111 million cases of GrAS
polyderma in children and over 616 million cases of streptococcal pharyngitis per
year worldwide (Carapetis, Steer et al. 2005).  These rates of illness cause a
significant burden on national healthcare systems and are a financial drain on
families due to loss of work hours and the cost of antibiotics or medications to
treat the disease symptoms.  Additionally, these initial infections have the
possibility of leading to more invasive streptococcal infections, such as cellulitis,
pneumonia, and meningitis (Brussow, Fremont et al.).  Occasionally, GrAS cause
severe invasive infections that can kill a human within a few hours, such as
streptococcal toxic shock syndrome, sepsis, and necrotizing fasciitis (reviewed in
(Cunningham 2000)).  If left untreated, GrAS infections can also lead to the
development of post-streptococcal sequelae, such as glomerulonephritis and
rheumatic fever (Cunningham 2000). Both are discussed below in more detail.
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Table 5.2.  Spectrum of clinical diseases caused by GrAS
  Table 2.  Spectrum of clinical diseases caused by the group A streptococcus
Asymptomatic colonisation Superficial infection
Throat Pharyngitis and pharyngotonsillitis
Skin (immediately preceding infection) Pyoderma
Also vagina, anus, scalp
Invasive disease
Suppurative respiratory disease Bacteraemia/septicaemia
Peritonsillar abscess Skin/soft tissue suppurative disease
Retropharyngeal abscess Erysipelas
Cervical lymphadenitis Cellulitis (including perianal cellulitis)
Sinusitis Wound infection
Otitis media Varicella superinfection
Pneumonia Necrotising fasciitis
Empyema Pyomyositis
Puerperal sepsis
Genitourinary Neonatal omphalitis
Urinary tract infection
Musculoskeletal
Central nervous system Osteomyelitis
Meningitis Septic arthritis
Brain abscess
Post-infectious sequelae
Cardiac Rheumatic fever
Endocarditis Acute post-streptococcal glomerulonephritis
Reactive arthritis
Gastrointestinal Erythema nodusum
Peritonitis P.A.N.D.A.S.
Hepatic
Liver abscess Toxin-mediated disease
Scarlet fever
Streptococcal toxic shock syndrome
Pediatric autoimmune 
neuropsychiatric disorder
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5.7 Post-streptococcal Glomerulonephritis
Acute post-streptococcal glomerulonephritis (APSGN) is an autoimmune renal
disease, which involves inflammation of the glomeruli or small blood vessels of
the kidney.  Symptoms usually appear within one to five weeks after a GrAS
infection, and are often associated with GrAS polyderma rather than pharyngitis
(Dillon 1979).  Accompanied by fever and general malaise, the major
manifestations of APSGN include:  hematuria (blood in the urine), oliguria
(reduced urine output), edema (accumulation of fluid in the body), and
hypertension (high blood pressure) (reviewed in (Yoshizawa 2000)).  The exact
mechanism of disease progression after a streptococcal infection is unknown;
however, studies indicate that kidney damage is often associated with
autoreactive antibodies that can cross-react to both GrAS bacterial epitopes and
different constitutes of the kidney (Wannamaker 1970; Goroncy-Bermes, Dale et
al. 1987).  These antibody-antigen immune complexes deposit in the kidney
glomeruli, and together with subsequent complement pathway activation, lead to
localized inflammation and tissue destruction (Westberg, Naff et al. 1971; Lange,
Seligson et al. 1983).  Further tissue damage and increased inflammatory
responses have been linked to a number of GrAS virulence factors including the
M-protein, the cysteine protease (SpeB), and the GrAS plasminogen activator
proteins like streptokinase (Cu, Mezzano et al. 1998; Nordstrand, Norgren et al.
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1998; Luo, Kuo et al. 2007) (see descriptions below).  It is estimated that 500,000
cases of APSGN occur annually worldwide, with the majority of cases seen in
less developed countries.  Of these cases, 1% lead to death due to chronic renal
failure or other hypertension associated diseases (Carapetis, Steer et al. 2005).
5.8 Post-streptococcal Rheumatic Fever
As with APSGN, rheumatic fever (Hirschman, Gerber et al.) is thought to be an
autoimmune disease that occurs, on average, three weeks after GrAS
pharyngitis (Cunningham 2000).  Disease symptoms can vary depending on
severity and location in the body. The major manifestations of ARF can include:
carditis (inflammation of the heart tissue), chorea (inflammation of the central
nervous system), migratory arthritis (inflammation of the joints), erythema
marginaum (inflammation of the skin), and subcutaneous nodules on joints or
bones (World Health Organization 2001).  While the exact triggers and
mechanisms of ARF have not been proven, studies indicate that an aberrant
immune responses (consisting of the production of autoreactive antibodies and
cross-reactive T-cells) develop against host tissues that share cross-reactive
antigens with components of the GrAS bacteria, a phenomenon known as
molecular mimicry (Kaplan and Svec 1964; Husby, van de Rijn et al. 1976;
Stollerman 1991; Cunningham 2000; Ellis, Li et al. 2005; Martins, Hoffman et al.
2008). The most severe pathology of ARF takes place in the heart, where
infiltrating immune cells, cytokines and auto-antibodies cause destruction of the
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heart muscle and permanent damage to the heart valves and the surrounding
tissue (Kaplan, Bolande et al. 1964; Quinn, Kosanke et al. 2001; Roberts,
Kosanke et al. 2001).  This inflammatory response can become chronic, i.e.
rheumatic heart disease, causing pancarditis and deformative scaring of the
heart valves that reduces blood flow in the host (Kaplan 1992).  Patients who
contract rheumatic fever are highly susceptible to recurrent bouts of disease
following new GrAS infections, and are often prescribed continuous prophylactic
antibiotics for years (Manyemba and Mayosi 2002; Cilliers 2006; Gerber,
Baltimore et al. 2009).  Eventually, patients may need heart valve replacement
surgery and/or suffer congestive heart failure, which often leads to death
(Carapetis, Steer et al. 2005; Cilliers 2006).
On a global scale, rheumatic heart disease causes the greatest burden of GrAS
disease, affecting an estimated eighteen million people (Carapetis, Steer et al.
2005).  It is the leading cause of preventable cardiovascular morbidity and
mortality in children worldwide (Agarwal 1981; Carapetis, Steer et al. 2005).
While today ARF occurs mainly in less developed countries (Agarwal 1981;
Stollerman 1997; Carapetis, Steer et al. 2005), an unexplained resurgence in
rheumatic outbreaks occurred in the United States in the previous two decades
(Veasy, Wiedmeier et al. 1987; Bisno 1990; Veasy, Tani et al. 1994).  In
accordance with this, there has also been a continuing rise in the number and
severity of invasive streptococcal diseases in North America, Europe, and Japan
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(Schwartz, Facklam et al. 1990; Hoge, Schwartz et al. 1993; Gunzenhauser,
Longfield et al. 1995; Holm 1996; Nakashima, Ichiyama et al. 1997; Eriksson,
Andersson et al. 1998; Svensson, Oberg et al. 2000).
5.9 Severe GrAS Invasive Infections
GrAS can disseminate and cause numerous invasive infections in different areas
of the body (Brussow, Fremont et al.).  Reports in the late 1980ʼs showed an
increase in two of the more severe life-threatening GrAS diseases: streptococcal
toxic shock syndrome (STSS) and necrotizing fasciitis (Cone, Woodard et al.
1987; Stevens, Tanner et al. 1989).  Streptococcal toxic shock syndrome is
characterized by fever, rash, and intense localized pain, which progresses to
hypotension, shock, and multiple organ failure, and can cause death of the host
within hours or a few days (McCormick, Yarwood et al. 2001).  As with other
GrAS diseases, a complete understanding of the mechanisms behind STSS is
not yet available, but streptococcal superantigens are thought to play a role
(discussed below).  These toxins nonspecifically activate the host immune
system causing a massive liberation of host cytokines.  The cytokines in turn,
induce a systemic inflammatory response, which results in increased vasodilation
and capillary permeability, that leads to internal bleeding, hypotension and
decreased perfusion to host organs (Kotb, Fraser et al. 2007).
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STSS is often accompanied by necrotizing fasciitis (NF), termed “flesh eating
disease” due to rapid and progressive tissue destruction involving the skin,
subcutaneous tissue, deep fascia, and muscle (Sonnenfeld, Nowak et al.).  This
rapidly disseminating GrAS infection is so dramatic that in a matter of hours a
small benign looking lesion can become a life threatening infection.  Necrotizing
fasciitis often requires high doses of intravenous antibiotics, rapid surgical
debridement and even limb amputation in order to assure patient survival
(Hasham, Matteucci et al. 2005).  Like STSS, necrotizing fasciitis tissue
destruction and bacterial spread is thought to be caused by a combination of an
aggressive host immune response (possibly superantigen induced) and
numerous GrAS secreted virulence factors that disrupt host tissue, such as
secreted proteases; SpeB, SpyCEP, Mac1/IdeS, lipases; SlaA, and esterases;
Sse. (Reviewed in Olson and Musser, 2009 and summarized in GrAS Virulence
Factors below).
Altogether the estimated number of GrAS invasive deaths in the world is
estimated to be greater 163,000 per year (Carapetis, Steer et al. 2005).  The
clinical severity of STSS and necrotizing fasciitis, along with their high mortality
rates (30-60%), and increased incidences of these infections in the United States
and around the world, has raised public health concerns (Stevens 2000;
McCormick, Yarwood et al. 2001).  This has served as an impetus for scientists
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and epidemiologists to study the mechanisms that can lead to an increase of
virulence in streptococcal populations.
5.10 Epidemiology: M-types and T-types of Streptococcus pyogenes
GrAS isolates can be classified by either M-type or T-type serotypic differences
(Lancefield 1928; Swift, Wilson et al. 1943; Lancefield and Dole 1946).  M-type is
based on specific antigenic differences in M protein, the major antigenic
determinant and surface exposed virulence factor on GrAS (see Virulence factor
section below).  There are currently more than 80 M-types, but with the
progression of molecular biology, serological typing of the M-protein is being
replaced by sequencing of the 5ʼ end of the gene encoding the M protein (emm),
known as emm sequence typing (Beall, Facklam et al. 1996; Facklam, Beall et al.
1999).   There are currently over 124 such emm sequence types recognized by
the CDC (http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm).
T-typing was originally classified by the serologic variability of the trypsin “T”
resistant antigen on the surface a large number of GrAS isolates (Lancefield and
Dole 1946).  Unlike M typing, the genetic basis for T-typing was not fully known
until recently when the first T protein gene (tee6) was cloned and characterized
(Schneewind, Jones et al. 1990).  This was followed by localization of the tee
genes to a highly variable region in the streptococcal chromosome known to
contain genes associated with extracellular matrix (ECM) binding proteins. This
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region was subsequently termed the fibronectin-binding collagen-binding T
antigen (FCT) region (Bessen and Kalia 2002).  In 2005, Mora et. al. made a
landmark discovery that streptococci produce pili (once only thought to be
associated with gram negative bacteria), and such pili are composed of the gene
products encoded by the FCT region. Therefore, T antigens actually correspond
to trypsin resistant pili (Mora, Bensi et al. 2005).  Pili have since been shown to
play a role in GrAS adherence and biofilm formation (Manetti, Zingaretti et al.
2007; Ryan, Kirk et al. 2007).  To date, approximately twenty-five T-types have
been identified (Jones, Schneewind et al. 1991) and the relationship between T
type and pili sequence variation has led to the proposal of tee gene sequence
typing (Falugi, Zingaretti et al. 2008).  While there is an association between
certain T-types and M-types, the use of T-typing, together with emm sequence
typing allows for a better estimation of GrAS diversity (Beall, Facklam et al. 1997;
Beall, Facklam et al. 1998).
5.11 Epidemiology of Diseases Caused by S. pyogenes
Epidemiological studies based on M and T-typing are crucial for associating
certain serological types with tissue tropism and GrAS disease.  As such, some
M-types of (M1, 3, 5, 6, 14, 18, 19, 24) are associated with throat infections and
rheumatic fever.  Other M-types (M2, 49, 57, 59, 60, 61) are more commonly
associated with skin infections and acute glomerulonephritis (summarized in
(Cunningham 2000).  Of note, the association of M-type and streptococcal
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disease can vary with time, geography, population density, socio-economic
status, and access to healthcare (Bessen, Carapetis et al. 2000; Shulman,
Stollerman et al. 2006; McDonald, Brown et al. 2007; Steer, Law et al. 2009).
Thus serological typing together with newer molecular biology classification
methods (i.e. pulse field gel electrophoresis and multilocus sequence typing)
allow for more accurate surveillance of changes in diversity and virulence in
GrAS populations that may arise over time and geographical location (Chung, de
Lencastre et al. 2000; Enright, Spratt et al. 2001).
Recent epidemiological studies have shown that certain M protein serotype
strains are associated with the resurgence of rheumatic fever (M18 & M3) and
severe invasive diseases (M1T1 & M3) (Schwartz, Facklam et al. 1990; Johnson,
Stevens et al. 1992; Stollerman 1997).  While some studies suggested that the
latest increases in invasive disease could be linked temporally or geographically
to specific “virulent clones” of certain M-types (Cleary, Kaplan et al. 1992;
Johnson, Stevens et al. 1992; Musser, Kapur et al. 1995; Aziz and Kotb 2008),
other studies that surveyed more diverse streptococcal populations could not
support this hypothesis.  Instead, the latter studies suggested that the change in
disease might be due to either an increase in virulence in the overall GrAS
population or to more complex relationships between GrAS clones, host factors,
undiscovered bacterial virulence genes, and/or differences in bacterial genome
regulation (Eriksson, Andersson et al. 1999; Enright, Spratt et al. 2001; Johnson,
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Wotton et al. 2002; Vlaminckx, Schuren et al. 2007).  These different hypotheses,
each supported by differing sets of data, emphasize the need for alternative
methods to elaborate the true mechanisms behind changes in GrAS
pathogenesis.   An analysis of the virulence factors harbored within different
serological types has further elaborated novel potential mechanisms that could
be responsible for different streptococcal diseases and the resurgences of
particular types of infections (Yu and Ferretti 1991; Musser, Nelson et al. 1993;
Bessen, Izzo et al. 1999; Hoe, Vuopio-Varkila et al. 2001; Sitkiewicz, Nagiec et
al. 2006).
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5.12 GrAS Virulence Factors
Streptococci produce a large number of secreted and surface exposed virulence
factors that allow the bacteria to colonize and cause disease in humans.  The
number of virulence factors that GrAS encodes varies, even between strains of
the same serotype. The combination of different virulence factors in each strain is
thought to play a role in tissue tropism, virulence and the different disease
manifestations caused by GrAS.  These virulence factors can be encoded on the
streptococcal chromosome or located on lysogenic bacteriophage.  Some of the
major virulence factors of each group are discussed below. Others are
summarized in (Table 3) and are extensively reviewed in (Cunningham 2000;
Hynes 2004; Nobbs, Lamont et al. 2009).
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Table 5.3.  Examples of group A streptococcal virulence factors.
Chromosome encoded surface-associated Chromosome encoded secreted 
Attachment, Invasion, Immune evasion Cytotoxins, Immune evasion, Proteases, Spreading factors
GrAS cell wall carbohydrates & Lipoteichoic acid Streptolysin O (SLO)
Hyaluronic acid capsule Streptolysin S (SLS)
CAMP factor (Cfa)
emm  gene super-family NAD glycohydrolase
M protein Diphosphopyridine Nucleotidase (DPN-ase)
Emm-like (Mrp, Arp, FcrA, ProtH) Immunogenic secreted protein (Isp)
Enn and others Superantigenic exotoxins: SmeZ, SpeG, and SpeJ 
Immunoglobulin binding proteins Streptococcal inhibitor of complement (Sic)
Mac1 / IdeS
Non-emm like immunoglobulin binding proteins SPyCEP / ScpC
Collagen binding proteins,  Scl1, Cpa SpeB (cysteine protease)
R-proteins,  R28,  Alp3 Chromosomally encoded hyaluronidase (Hly)
Streptokinase
Fibronectin binding proteins: Other Plasminogen binding proteins
Pili Proteins: Streptococcal Esterase
Protein F , Prtf1, SfbI
PrtF2, FbaA, PFBP
Fbp54 Lysogenic bacteriophage encoded
SfbX
FbaB Cytotoxins, Immune Evasion, Spreading Factors, Antibiotic Resistance
GAPDH /  SDH
C5a peptidase (SCP) Phospholipase (SlaA2)
Superantigenic exotoxins: Ssa, SpeA, SpeC, SpeI, SpeH, SpeM, SpeL, speK
Streptococcal protective antigen DNAses & Streptodornases: Sdn, Sda, Spd1, Sda1, SdaD, Spd3 (MF3), Spd4
Heme-binding proteins,  Shr, Shp Phage encoded hyaluronidases:  Hlyp1, Hlyp2, Hlyp3
Protein G-related alpha2-M-binding protein (GRAB) MefA
Lipoprotein of S. pyogenes R6
CD15s-related antigen
Plasmin(ogen) binding proteins
*Not an exhaustive list.  Data was derived from multiple literature reviews  (Cunningham 2000; Hynes 2004; Nobbs, Lamont et al. 2009) .
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5.12.1 Chromosomally Encoded Surface-Associated Virulence Factors
The successful establishment of a GrAS infection depends largely on the many
cell-associated determinants that are displayed on the bacterial surface (Table
5.3).  These molecules, for example, allow GrAS to adhere to host cells, spread
further into host tissue, and subvert host defenses. Two important surface-
exposed virulence factors are discussed below.
5.12.1.1 M-protein
The most abundant protein attached to the cell surface, the M-protein, is the
major antigenic determinant of GrAS (Fischetti, Jones et al. 1988).  As such, it is
one of the most studied, and best characterized streptococcal virulence factors.
The M protein has been shown to play a role in most aspects of GrAS infection,
including resistance to phagocytosis, adherence, and intracellular invasion
(Cunningham 2000).  The structure of the protein has also been extensively
studied and is diagramed in Figure 5.4 (Fischetti 1989).
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Figure 5.4.  Characteristics of the complete M6 protein sequence.
Blocks A, B, C, and D designate the location of the sequence repeat blocks.
Shaded blocks indicate those in which the sequence diverges from the central
consensus sequence.  Pro/Gly denotes the proline-rich and glycine-rich region
likely located in the peptidoglycan. Pepsin identifies the position of the pepsin-
sensitive site after amino acid 228. The C-terminal end is located within the cell
wall and membrane. Reprinted from (Fischetti 2006), with permission.
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The cytoplasmic and cell anchored C-terminal portion of the M-protein consists of
a cytosolic charged tail and a hydrophobic region that spans the cell membrane.
This is followed by a conserved gram-positive LPXTG (LPSTGE) cell wall
anchoring motif. The surface exposed region of the protein is composed of 4 sets
of repeated amino acids in blocks (A-D) that differ in size and sequence.  These
repeat blocks have a seven-residue amino acid periodicity, which allows the
protein to form on the surface of streptococci as two polypeptide chains in an
alpha-helical coiled-coil conformation (Manjula and Fischetti 1980; Phillips,
Flicker et al. 1981). These M protein structures appear as fibrils on the surface of
GrAS when viewed by electron microscopy (Fischetti 1989).  Whereas the C-
terminal region of the exposed protein is conserved among GrAS serotypes, the
N-terminal region of the M-protein is highly variable (hypervariable) in amino acid
sequence between different serotypes (Jones, Manjula et al. 1985).  Antibodies
in immune patient sera that are directed against the hypervariable N-terminal
domain provide opsonic protection against strains of the same M-type through
the classical complement and phagocytic pathways. This phenomenon forms the
basis for Lancefieldʼs serological M-typing of GrAS (Lancefield 1959; Lancefield
1962).   In non-immune hosts, the negative charge of the distal amino acids in
the N-terminus of the M-protein provides basic protection from macrophage and
neutrophil phagocytosis through electrostatic repulsion.  Phagocytosis is also
inhibited by M protein binding to host proteins (fibrinogen, factor H, factor H-like
protein, and C4BP) that are inhibitory or regulatory to the alternative complement
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pathway (Horstmann, Sievertsen et al. 1988; Accardo, Sanchez-Corral et al.
1996; Johnsson, Berggard et al. 1998; Kotarsky, Hellwage et al. 1998).  The
decoration of these factors on the M-proteins of GrAS prevents deposition of the
alternative pathway protein C3b and thus inhibits opsonic recognition and
engulfment by phagocytic cells (Peterson, Schmeling et al. 1979).
Studies have shown that some M-types can exhibit different binding affinities to
host proteins and therefore have varying functions during GrAS infection
(Schmidt, Mann et al. 1993).  Certain M-types, such as M1, M3, M6, and M18 are
involved in adherence and internalization of cells at the mucosal surface and skin
(Cue, Dombek et al. 1998; Fluckiger, Jones et al. 1998; Berkower, Ravins et al.
1999; Dombek, Cue et al. 1999).  This is achieved either through the direct
interaction of the M-protein with host cell receptors (i.e. CD46) or through the
binding of fibronectin, which forms a cross-bridge between the M-protein and
integrin receptors (Okada, Pentland et al. 1994; Okada, Liszewski et al. 1995).
The formation of the complex of M protein, fibronectin, and integrin receptors on
the host cell surface can cause a conformation change in the host cell, which
then facilitates GrAS internalization (Molinari, Rohde et al. 2000).
Additionally, GrAS may contain other surface proteins that are structurally related
to M-Protein, which are encoded for by genes in close proximity to the M protein
gene (emm) in the mga regulon.  These M-like proteins (i.e. Enn, Mrp, FrcA, Arp)
31
bind a range of other human plasma proteins (albumin, fibrinogen, plasminogen,
complement, and IgG or IgA) and can share similar antiphagocytic, adherent,
and/or invasive properties (Thern, Stenberg et al. 1995; Podbielski, Schnitzler et
al. 1996; Ji, Schnitzler et al. 1998; Thern, Wastfelt et al. 1998; Sanderson-Smith,
Dinkla et al. 2008).
In addition to M and M-like proteins, other surface proteins of some GrAS strains
such as protein F, SfbI, SfbII, PFBP, FbaA, FbaB, and SOF, also bind fibronectin
with high affinity and serve as both adhesive and invasive factors (Kreikemeyer,
Talay et al. 1995; Okada, Tatsuno et al. 1998; Molinari and Chhatwal 1999;
Rocha and Fischetti 1999; Timmer, Kristian et al. 2006).
5.12.1.2 Capsule
The polysaccharide capsule of GrAS is composed of hyaluronic acid (HA), a high
molecular weight polymer containing repeating units of glucuronic acid and N-
acetylglucosamine. This chemical structure is similar to the hyaluronic acid found
in human connective tissue, and therefore may be recognized as “self” and is
poorly immunogenic (Bisno, Brito et al. 2003).  HA production by GrAS is
produced from a highly conserved three-gene operon (hasABC). The hasA gene
encodes a hyaluron synthase, hasB encodes an UDP-glucose dehydrogenase,
and hasC encodes an UDP-glucose pyrophosphorylase.  Only hasA and hasB
have been shown to be required by GrAS for capsular synthesis (Ashbaugh,
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Alberti et al. 1998).  Individual strains of GrAS differ greatly in the amount
capsule they produce.  On agar plates, high levels of HA production are
associated with a large mucoid or matte colony morphology, while lower levels of
HA produce a smaller, glossy colony (Wilson 1959).  The presence of the mucoid
or matte colony morphology has been associated with GrAS isolates from the
more severe infections, (i.e. ARF, STSS, and NF).  More virulent mucoid strains
have also been isolated after passage in human blood and murine infection
models (Wessels and Bronze 1994; Wessels, Goldberg et al. 1994; Ashbaugh,
Warren et al. 1998).  Studies comparing mucoid strains to isogenic acapsular
mutants have proven that the capsule plays a major role in GrAS resisting
complement-mediated phagocytic killing (Wessels, Moses et al. 1991; Wessels
and Bronze 1994; Wessels, Goldberg et al. 1994).  Additionally, the HA capsule
modulates attachment to host epithelial cells by either interfering with M-protein
mediated adherence or by promoting GrAS attachment through direct interaction
of the capsule as a ligand with CD44 on epithelial cell surfaces (Schrager,
Rheinwald et al. 1996).  Furthermore, although the presence of capsule reduces
intracellular invasion of human keratinocytes, the binding of capsule to the CD44
protein also has been shown to cause disruption of intercellular junctions in the
epithelium, allowing GrAS to invade further into tissues (Cywes and Wessels
2001).
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5.12.2 Chromosomally Encoded Secreted Virulence Factors
GrAS produce a wide variety of extracellular factors that are capable of diffusing
away the bacteria to aid in GrAS invasion and host immune subversion (Table
5.3).  These factors include: i) Toxins, such as streptolysins O and S, which lyse
host cells and are responsible for the β-hemolytic phenotype of GrAS; ii)
Degradative enzymes, such as streptokinase and hyaluronidase, which dissolve
blood clots and hydrolyze the extracellular matrix allowing GrAS to spread
through tissue barriers; iii) Immune modulators, such as SIC, MAC, SPyCEP,
and IdeS, which bind or degrade immune components to interfere with the
clearance of streptococcal infections (Hynes 2004).  One of the most studied
secreted virulence factors encoded on the chromosome, SpeB has been grouped
in to all three categories above.
5.12.2.1 SpeB, Streptococcal Proteinase
SpeB was originally described as two different proteins:  i) the streptococcal
pyogenic exotoxin B and ii) the streptococcal proteinase. Both were later shown
to have the same sequence (Bohach, Hauser et al. 1988; Hauser and Schlievert
1990). SpeB is thought to be a cysteine protease that is encoded on the
chromosome of almost all GrAS strains (Kapur, Topouzis et al. 1993).  While the
speB gene is highly conserved, expression of SpeB can be highly variable even
between clonally related strains (Kansal, McGeer et al. 2000; Svensson,
Scaramuzzino et al. 2000). SpeB is secreted as a 42 kDa zymogen that is self-
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cleaved and reduced to an active 28 kDa enzyme (Elliott and Dole 1947).  The
active protease is capable of cleaving a large number of substrates from the
GrAS bacteria as well as the host. The broad-spectrum protease activity has lead
researchers to associate SpeB with numerous GrAS virulence phenotypes and
diseases.  SpeB can cleave host tissues and extracellular matrix proteins such
as fibrin, fibronectin and vitronectin (Kapur, Topouzis et al. 1993).  Additionally,
SpeB activates host matrix metalloproteinases (MMP), which also remodel the
host matrix (Burns, Marciel et al. 1996).  These activities cause local tissue
damage as well as allow GrAS to penetrate host barriers and become
disseminated infections.  As such, a number of studies have linked the
expression of SpeB to invasive infections, STSS, and NF (Talkington, Schwartz
et al. 1993; Eriksson, Andersson et al. 1999; Lukomski, Montgomery et al. 1999;
Falugi, Zingaretti et al.).
SpeB is also capable of modulating the host immune system.  SpeB induces a
proinflammatory response by cleaving interleukin-1β and plasma kininogen
precursors to their biologically active forms and can stimulate release of
histamine and degranulation by mast cells (Kapur, Topouzis et al. 1993; Herwald,
Collin et al. 1996; Watanabe, Todome et al. 2002).  On the other hand, SpeB can
reduce the effectiveness of the immune system response to streptococci by
cleaving and inactivating antibodies, chemokines, C3B complement protein, and
antimicrobial peptides such as human cathelicidin LL-37 (Collin and Olsen 2001;
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Schmidtchen, Frick et al. 2002; Kuo, Lin et al. 2008; Terao, Mori et al. 2008;
Egesten, Olin et al. 2009).
Another important activity for SpeB is the modulation of GrAS encoded virulence
factors.  The protease is capable of degrading most of the GrAS surface and
secreted proteins, such as M-protein, protein F1, C5a peptidase, strepotolysin O,
streptokinase, numerous streptococcal superantigens and DNases (Brussow,
Fremont et al.) (Elliott 1945; Aziz, Pabst et al. 2004; Nooh, Aziz et al. 2006;
Walker, Hollands et al. 2007).  In accordance with this, the regulation and
expression of SpeB in different strains or at different times during infection has a
major impact on GrAS adherence, invasion, and host immune subversion (Burns,
Lukomski et al. 1998; Kuo, Wu et al. 1998; Lukomski, Burns et al. 1998).  This,
and the fact that all streptococcal isolates have a speB gene,  has lead most
researchers to postulate that SpeB is a major virulence factor involved in tissue
tropism and outcome of GrAS disease (Lukomski, Sreevatsan et al. 1997;
Kansal, McGeer et al. 2000; Svensson, Scaramuzzino et al. 2000; Sumby,
Whitney et al. 2006; Walker, Hollands et al. 2007; Hollands, Aziz et al. 2008).
5.12.3  Lysogenic Bacteriophage Encoded Virulence Factors
A majority of the secreted virulence factors associated with GrAS are encoded by
integrated prophage (Table 5.1).  Often a streptococcal strain will contain multiple
phages, with each phage containing one or more putative virulence factors
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(Beres and Musser 2007).  Since these factors are encoded on phage the
virulence genes have the possibility of being mobilized and horizontally
transferred to other streptococci or, with no selective pressure, lost by
recombinational events (Desiere, McShan et al. 2001; Vlaminckx, Schuren et al.
2007).   For this reason, one of the greatest variations in virulence between GrAS
strains is thought to be the phage virulence factors they encode.  Often secreted
and capable of aiding in GrAS infection and host immune subversion, these
factors also include: i) Toxins, such as phospholipase A2 (Sla), which shares
homology to snake toxin and can enhance GrAS colonization and tissue
destruction (Sitkiewicz, Nagiec et al. 2006); ii) Degradative enzymes, such as
phage-associated hyaluronidase, which may hydrolyze the extracellular matrix
allowing bacterial or other toxins to spread through tissue barriers (Benchetrit,
Gray et al. 1977); iii) Immune modulators and iv) Antibiotic resistant genes, as
well as, other examples of phage encoded virulence factors are discussed below
and in future chapters of this thesis.
5.12.3.1 Streptococcal Superantigens
Superantigens were first identified in the early 1920ʼs as scarlet fever toxins,
which were isolated from GrAS culture filtrates and capable of causing the scarlet
fever rash when injected subcutaneously into subjects (Dick and Dick 1983).
GrAS superantigens have had many names: erythrotoxins, mitogenic factors
(MFs) and/or streptococcal pyrogenic exotoxins (SPEs).  As the various names
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suggest, the functions of superantigens have classically been associated with
three different types of activities: T-cell mitogenesis, pyrogenicity, and
enhancement of susceptibility to endotoxic shock (Kim and Watson 1970; Schuh,
Hribalova et al. 1970).  All three manifestations are now thought to be the result
of exotoxin stimulation of lymphocytes and monocytes, which in turn, release
cytokines to further activate a massive systematic host inflammatory response
(Fast, Schlievert et al. 1989; Hackett and Stevens 1992).  Stimulation of these
immune cells results from the exotoxin binding to, and cross-linking, the Vβ
region on T-cell receptors with the major histocompatability II (MHC II) receptors
on antigen presenting cells (APCs) (Figure 5.5).  Thus, these exotoxins were
termed “superantigens” for their novel mechanism of T-cell stimulation and were
shown to be similar in both structure and function to the staphylococcal
enterotoxins (Kappler, Kotzin et al. 1989; Marrack and Kappler 1990).  Unlike
normal antigens, superantigens do not require internalization, processing, or
presentation by APCs, nor do they rely on TCR specificity for the antigen
peptide–MHC complex to activate specific T-cell clones (Figure 5.5).  Instead, the
crosslinking of the two receptors non-specifically activates up to twenty-five
percent of all the resting T-cell population; this action is based on the ability of
the superantigens to bind different TCR Vβ regions (reviewed in (Herman,
Kappler et al. 1991).
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Figure 5.5.  Schematic of the interactions of antigen or superantigen with the
antigen presenting cell and the T lymphocyte.
Antigen is processed internally and presented by the APC to the T-cell (left).
While superantigens bind and crosslink the MHCII and TCR Vβ region outside of
the antigen peptide groove, activating both cells (right).  Adapted from (Bisno,
Brito et al. 2003), with permission.
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The stimulation of large amounts T-cells and macrophages produces massive
amounts of inflammatory cytokines and chemokines (i.e. TNFα, TNFβ, IL-1,IL-2
IL-8 and INFγ) (Unnikrishnan, Altmann et al. 2002).  This “cytokine storm”
increases vascular permeability and other non-specific immune and autoimmune
responses, often leading to tissue damage, multiple organ failure, and even
death.  Thus, superantigenic effects have been associated with the symptoms of
GrAS invasive diseases like STSS and NF, and may play a role in the post
streptococcal autoimmune diseases of ARF and APSGN (Kotb 1995;
McCormick, Yarwood et al. 2001).  Three streptococcal pyrogenic exotoxins
(termed SpeA, SpeB and SpeC) were first cloned from GrAS scarlet fever
isolates.  The speA and speC genes were found to be located on
bacteriophages, supporting earlier evidence by Zabriskie that the SpeA toxin
could be transferred between GrAS strains by lysogenic phage (Zabriskie 1964;
Weeks and Ferretti 1986; Goshorn, Bohach et al. 1988).   The cloning of the
speB gene confirmed that it was identical to the streptococcal cysteine
proteinase (Bohach, Hauser et al. 1988; Hauser and Schlievert 1990).
Subsequently, its mitogenic effect was later proven to be the result of
contamination with other superantigens (Gerlach, Reichardt et al. 1994; Gerlach,
Fleischer et al. 2000).  Analysis of the published genomes of GrAS along with
biochemical and structural studies of the SPEs allowed the identification and
cloning of a number of other GrAS superantigens including: Spe- G, H, I, J, K, L,
M, SSA, SMEZ-1, SMEZ-2, SMEZ-3.  Further sequence analyses have revealed
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that these toxins can have minor allelic variations that may modulate their
virulence (Proft, Moffatt et al. 2000) (Nelson, Schlievert et al. 1991; Kapur,
Nelson et al. 1992).
Besides allowing for the spread of a localized infection, by causing cytokine
induced vascular permeability and tissue damage, other mechanisms by which
superantigens increase GrAS virulence are still unanswered.  It has been
hypothesized that superantigens allow GrAS to avert the immune system in three
ways.  First, they may be involved in superantigen-dependent cellular cytoxicity
(SDCC), in which superantigens induce cytotoxic T-cells to kill APCs expressing
MHC II-superantigen complexes (Dohlsten, Lando et al. 1990).  Second, when
superantigens bind T-cells only, and do not  crosslink the TCR to MHC II, an
absence of co-stimulatory signals from APCs can cause depletion of specific Vβ
T-cells through anergy or apoptosis (Hewitt, Lamb et al. 1992; McCormack,
Callahan et al. 1993).  Third, the generation of a massive nonspecific immune
response may divert attention away from a specific immune response to GrAS
(Kotb 1995). Thus, in each of these possible scenarios, the actions of the
superantigen eliminate immune cells, and/or limit a proper specific immune
response to streptococci.  Interestingly, while the genes for smeZ, speG, and
speJ are chromosomally encoded, the genes encoding the remaining GrAS
superantigens are located on lysogenic bacteriophage (summarized in (Beres
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and Musser 2007; Kotb, Fraser et al. 2007)), providing further evidence that
phage can potentially spread streptococcal virulence traits.
5.12.3.2 DNases
Historically GrAS have been known to secrete four antigenically distinct
deoxyribonucleases, (A, B, C, and D), which were characterized based on
immunological and biochemical properties (McCarty 1948; Wannamaker 1958;
Wannamaker, Hayes et al. 1967; Wannamaker and Yasmineh 1967).  Sera from
GrAS infected patients were found to react and neutralize DNAse activity in a
type (i.e. A, B, C, or D) specific manner.  Immunoreactiviy against DNase B was
most prominently found and has therefore been used diagnostically as an
indicator for recent GrAS infections (Tiesler and Beck 1976; Gerber, Gray et al.
1980).  DNase B was shown to be chromosomally encoded and was also
originally classified as both a mitogenic factor (MF) (Arraiano, Bamford et al.) and
SpeF because it was thought to have both mitogenic activity and cytokine-
inducing properties  (Yutsudo, Murai et al. 1992; Norrby-Teglund, Newton et al.
1994; Eriksson, Eriksson et al. 1999), but this was later linked to contamination
with the SpeX/SMEZ or SpeC superantigens (Gerlach, Schmidt et al. 2001).
Recently, molecular cloning techniques allowed the isolation and characterization
of new GrAS DNases:  streptodornase D (SdaD), streptococcal DNase α (Sdα),
and streptococcal phage-encoded DNase (Spd1) (Podbielski, Zarges et al. 1996;
Broudy, Pancholi et al. 2002; Hasegawa, Torii et al. 2002).  A sequence
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comparison of these DNase genes to the published streptococcal genomic DNA
sequences elucidated additional DNase coding sequences, which showed that all
GrAS contain multiple conserved DNases. The additional DNases identified
(MF2/spd1= DNase A, spd3/Mf3= DNase C, SdaD= DNAse D, Sdn, Sda,
MF4/Spd4, and Sda1) have since been localized to prophage elements
integrated into the GrAS genome (Beres, Sylva et al. 2002; Broudy, Pancholi et
al. 2002; Hasegawa, Torii et al. 2002; Smoot, Barbian et al. 2002; Nakagawa,
Kurokawa et al. 2003; Aziz, Ismail et al. 2004; Sumby, Barbian et al. 2005).
Because most DNases are encoded by bacteriophage, it has been hypothesized
that DNases may specifically aid in the in the spread of bacteriophage (Broudy,
Pancholi et al. 2002). It has also been postulated that DNases contribute to the
dissemination of GrAS into the surrounding tissue by liquefying pus at the site of
infection (Tillett, Sherry et al. 1948).   However, despite the extensive
characterization of streptococcal DNases, no direct evidence has proven that
DNAses are GrAS virulence factors.  This may be partly due to the fact that GrAS
strains can simultaneously express multiple DNases, so inactivation of a single
DNase gene would not eliminate all GrAS DNase expression and thus may not
attenuate virulence in mutants compared to the wild-type strains (Podbielski,
Zarges et al. 1996).
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In 2004, Brinkman et al. showed that neutrophils form neutrophil extracellular
traps (Knetsch, Schafers et al.), which trap and kill bacteria and fungi
extracellularly (Brinkmann, Reichard et al. 2004). NETs are composed of
neutrophil granule components (antimicrobial peptides and enzymes) linked to a
backbone of chromatin DNA and histones. Treatment with exogenous DNases
destroys the NETs (Brinkmann, Reichard et al. 2004), thus, suggesting a role for
secreted extracellular DNases in evasion of an innate immune response.  This
information combined with the knowledge that GrAS encode multiple DNases,
led to the development of a triple-mutant strain devoid of all secreted DNAses
(MF/Spd, SdaD, Spd3) (Sumby, Barbian et al. 2005).  Compared to wild-type, the
GrAS triple-mutant showed decreased survival in an in vitro neutrophil
extracellular killing assay.  Furthermore, the lack of all DNases reduced GrAS
virulence in both a murine invasive disease model, as well as a non-human
primate model of pharyngitis (Sumby, Barbian et al. 2005).  Buchanan et al.
further clarified the role of GrAS DNases by correlating virulence attenuation of
GrAS sda1 mutants in a murine NF model with lack of degradation of NETs in
vitro and in vivo (Buchanan, Simpson et al. 2006). It has even been postulated
that expression of DNase Sda1 serves a selective pressure for GrAS to mutate to
a more hyper-virulent phenotype (Walker, Hollands et al. 2007).  The fact that
Sda1 and most of the secreted GrAS DNases are encoded on bacteriophage
gives another example of how phage encoded virulence factors may modulate
streptococcal pathogenesis.
44
5.13 GrAS Genomic Sequences in Relation to Lysogenic Phage
The genome sequences of thirteen different strains of GrAS have now been
published, making it one of the most sequenced human pathogens to date
(Ferretti, McShan et al. 2001; Beres, Sylva et al. 2002; Smoot, Barbian et al.
2002; Nakagawa, Kurokawa et al. 2003; Banks, Porcella et al. 2004; Green,
Zhang et al. 2005; Beres and Musser 2007; Holden, Scott et al. 2007; McShan,
Ferretti et al. 2008).  The sequences represent 10 M types that make up more
than 70% of the serotypes associated with different GrAS diseases in the
western hemisphere including: invasive diseases (M1, M3, M3, M28),
noninvasive diseases (M1, M2, M12), ARF (M5, M18), APGN (M12, M49) and
erythromycin resistant isolates (M4, M6) (Beres and Musser 2007; McShan,
Ferretti et al. 2008).  Having genome sequences from different M types
associated with multiple diseases allows investigators to study the contribution of
strain genotype to the type and severity of streptococcal infection.
A comparison of the GrAS genomes showed that the overall chromosomal
content of the different M types is 90% similar in coding sequence (Beres and
Musser 2007).  The majority of the genetic variation results from numerous
lysogenic bacteriophage and bacteriophage-like elements or ICES (integrative
and conjugative elements, (Burrus, Pavlovic et al. 2002)), which have been
incorporated into the GrAS chromosomes (Beres and Musser 2007).  The
genome of each strain contains two to eight putative prophage elements for a
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total of 57 phages and 12 ICEs in the GrAS metagenome (Figure 5.1).  A
majority of the prophage elements contain genes encoding numerous virulence
factors including: superantigens (Spes, Ssa), phospholipases (Sla), DNases
(Spds, MFs, Sda, Sdn), and hyaluronidases (Beres and Musser 2007; McShan,
Ferretti et al. 2008).  Taken together, these data suggest that differences in
disease manifestation and severity of infection between different M types might
be affected by prophage-encoded virulence factors (Sitkiewicz, Nagiec et al.
2006).
As comparative genomic studies have demonstrated that prophages account for
most of the differences between M serotypes, comparative DNA microarray
analyses proved the same holds true for strains within the same M serotype
(Smoot, Barbian et al. 2002).   Furthermore, a retrospective analysis of the
bacteriophage content of M3-serotypes between 1920 and 2002 suggests that
the successive gain of prophages over time has lead to a contemporary M3
strain with increased virulence (Beres, Sylva et al. 2002).  Similarly, independent
studies that assessed the emergence of contemporary M1T1 isolates responsible
for severe invasive infections, have suggested that the acquisition of two phages
(containing speA2 and sdaD2) played a role in the emergence and persistence of
a more virulent GrAS strain during last 20 years (Cleary, LaPenta et al. 1998;
Sumby, Porcella et al. 2005; Aziz and Kotb 2008).   These analyses highlight the
role that GrAS bacteriophages play in interstrain diversity and provide evidence
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for a mechanism by which certain “virulent clones” of GrAS could evolve through
horizontal transfer of prophage-like elements.
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Figure 5.6.  GAS metagenome exogenous elements.
Illustrated are loci of integration of phages and ICEs into the core chromosome.
Prophages are indicated with triangles and ICEs with squares. Stacked triangles
and squares indicate a common integration site. Elements are color-coded to
indicate the source strain. Prophages and ICEs are numbered as they occur
clockwise around the core chromosome for each strain. Integration loci are
lettered alphabetically as they occur clockwise around the core chromosome.
The six rRNA operons are shown as green bars. Gene designations are as
follows: 1) secreted superantigens: speA, speC, speH, speI, speK, speL, speM,
and ssa; 2) secreted DNAses: sda, sdn, spd1, spd3, and spd4; 3) secreted
phospholipase: sla; 4) antimicrobial resistance: erm(A), mef(A), and tet(O); 5) cell
surface adhesins: R6 and R28; 6) none, these elements lack a known or obvious
virulence gene.  Adapted from (Beres and Musser 2007) with permission.
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5.14 Other Lysogenic Phage Effects on GrAS Virulence
Along with demonstrating the role of lysogeny in GrAS evolution, numerous
studies have demonstrated that within the human host, lysogenic phage can
infect non-toxigenic GrAS strains, and that these strains are lysogenically
converted to toxin producing strains. Thus, lysogeny may increase streptococcal
pathogenesis by directly increasing the number of virulent bacteria at the site of
infection or colonization (Broudy and Fischetti 2003).  Lysogenic phage induction
also may serve as a way for GrAS to coordinate the production and release of
multiple virulence factors at specific stages of host cell contact.   Human
pharyngeal cells produce a soluble phage-inducing factor, termed SPIF
(streptococcal phage inducing factor), which stimulates the production of both
streptococcal phages and their toxins (Broudy, Pancholi et al. 2001; Broudy,
Pancholi et al. 2002).  In addition to the potential to lysogenize neighboring
streptococci, the induced bacteriophage particles could directly contribute to
increased pathogenesis because they contain hyaluronidases and other
virulence factors on their surface (Benchetrit, Gray et al. 1977; Bensing, Siboo et
al. 2001; Starr and Engleberg 2006).  Furthermore, lysogenic and even lytic
phages can carry GrAS chromosomal encode genes that they have acquired
during inaccurate excision or recombination events and they can transfer these
potential virulence factors though a method of generalized transduction.
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Besides carrying genes for virulence factors, prophage may also influence GrAS
pathogenesis by encoding or interacting with regulatory factors that influence the
expression of chromosomally encoded virulence genes.  Spanier et al. showed
that prophage integration increases the expression of the M-protein, thus
increasing the bacteriaʼs ability to resist phagocytosis (Spanier and Cleary 1980).
Recently, Scott et al. showed that integration of a phage into a DNA repair
operon increases the mutation rate of an M1 strain (Scott, Thompson-Mayberry
et al. 2008).  There are also many examples of how bacteriophage modify
transcriptional regulation and the enzymatic modification of host bacterial
components to influence virulence in other types pathogenic bacteria (Wagner
and Waldor 2002).  This suggests that the complete role of lysogenic phage in
modulating GrAS virulence has yet to be fully elucidated.
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6 Objectives
The overall aim of this study was to more comprehensively investigate the many
ways in which bacteriophage interact with Streptococcus pyogenes in order to
elucidate novel phage-specific mechanisms that affect bacterial pathogenesis
and/ or survival.  In an M6 serotype of GrAS, we identified a restriction
modification (RM) system on a chimeric bacteriophage element (φ10394.4),
which encodes the erythromycin resistance gene, mefA.  Through a combination
of cloning, heterologous expression and allelic replacement techniques, we
characterized the activity of the methyltransferase (M.SpyI) from this RM system.
We found that M.SpyI specifically recognizes and methylates the DNA sequence:
5ʼ-CCmNGG. To our knowledge, this is the first methyltransferase gene from S.
pyogenes to be cloned and characterized.  Our findings also revealed the reason
why PFGE analysis of SmaI digested genomic DNA cannot be used to analyze
the clonality of streptococci containing Φ10394.4, and explains the inability of
previous epidemiological studies to use SmaI to analyze DNA from macrolide
resistant streptococci.  We speculate that the M.SpyI-RM cassette contained on
Φ10394.4 could impart a selective advantage on host strain survival and may
provide another explanation for the observed increase in macrolide resistant
streptococci.
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We also used allelic recombination techniques to analyze the role that a phage-
encoded superantigen, SpeH, may play in colonization of the host with a M1
serotype of GrAS (SF370).  In order to characterize additional phage genes that
might function during the initial interaction between GrAS and the host, we
developed novel techniques to specifically manipulate bacteriophage content in
the streptococcal genome.  Using this methodology, we systematically cured the
genome of strain SF370 of all lysogenic phage, which resulted in the creation of
the first strain of S. pyogenes that is devoid of all the major bacteriophage
elements.  The resulting mutants have allowed us to study the effects that
individual and multiple phage deletions have on streptococcal virulence and
survival.  We used these phage knockout mutants to further investigate the role
that two of the phage in this M1 strain play in regulating GrAS chromosomal
genes involved in bacterial metabolism, DNA repair and mutagenesis.
We also manipulated lytic bacteriophage genes to genetically engineer a novel
chimeric endolysin (ClyS) from the genomes of two different Staphylococcus
phages.  We demonstrated the lytic activity of ClyS against methicillin-resistant
Staphylococcus aureus (MRSA) in both in vivo colonization and septicemia
models, and determined its synergistic activity with oxacillin in in vitro and in vivo
models.  Our work highlights the potential of ClyS as a novel therapeutic agent
for the treatment of MRSA and other staphylococcal infections.
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7 Chapter 1
7.1 INTRODUCTION
The treatment of choice for streptococcal pharyngitis infections is penicillin V
(Bisno, Gerber et al. 2002), but in recent years macrolide antibiotics such as
azithromycin and erythromycin have been increasingly prescribed as an
alternative treatment (Cizman, Pokorn et al. 2001; Gonzales, Malone et al. 2001;
Linder and Stafford 2001; Coenen, Ferech et al. 2006).  Concomitantly, there has
been an increase of macrolide resistant strains of S. pyogenes (Cha, Lee et al.
2001; Cizman, Pokorn et al. 2001; Hsueh, Teng et al. 2002; Martin, Green et al.
2002; Bergman, Huikko et al. 2004; Green, Martin et al. 2004), posing a global
health problem for patients that are hyper-sensitive to β-lactam antibiotics (Bisno,
Gerber et al. 2002; Romano, Viola et al. 2002; Viola, Quaratino et al. 2005).
Macrolide resistance in streptococci is usually associated with the presence of
one of three genes:  i) ermB and ii) ermTR, both encode methyltransferases that
confer resistance to macrolides, lincosamide and streptogramin B (MLSB)
antibiotics by modifying a conserved adenine residue on the drug target site of
the 23S rRNA (Leclercq and Courvalin 1991; Seppala, Skurnik et al. 1998), and
iii) mefA, which encodes a macrolide efflux pump that imparts resistance to 14-
and 15- membered macrolides, such as erythromycin and azithromycin, but not
to the 16–membered MLSB antibiotics (classified as “M-phenotype” of macrolide
resistance) (Clancy, Petitpas et al. 1996).  The mefA gene is present in a number
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of phylogenetically unrelated serotypes of S. pyogenes (Cha, Lee et al. 2001;
Hsueh, Teng et al. 2002; Martin, Green et al. 2002; Bergman, Huikko et al. 2004)
and in some regions of the world is becoming the predominant erythromycin
resistance determinant in streptococcal isolates (Kataja, Huovinen et al. 1999;
Ripa, Zampaloni et al. 2001; Hsueh, Teng et al. 2002; Silva-Costa, Ramirez et al.
2006).  Earlier studies suggested that erythromycin resistance and the mefA
gene may be acquired through horizontal gene transfer; however, at that time,
the mechanisms were not clearly identified in S. pyogenes (Kataja, Huovinen et
al. 1999; Luna, Coates et al. 1999; Del Grosso, Iannelli et al. 2002).
Recently, the mefA gene was identified on three different DNA chimeric
elements, which have both transposon and prophage characteristics.  Santagati
et al. partially characterized a 52 kb chimeric element carrying the mefA gene,
which was integrated into the comEC gene of an erythromycin resistant strain of
S. pyogenes (Santagati, Iannelli et al. 2003).  They described 7.2 kb of the 52 kb
chimeric element as 100% identical to a defective mefA conjugative transposon,
Tn1207.1, from S. pneumoniae (Santagati, Iannelli et al. 2000; Santagati, Iannelli
et al. 2003).  Additionally, they demonstrated that the S. pyogenes 52 kb chimeric
element could be transferred by filter conjugation to different strains of S.
pyogenes, S. pneumoniae, and S. gordonii, conferring erythromycin resistance to
these species.  For these reasons, the 52 kb chimeric element was classified as
conjugative transposon Tn1207.3 (Santagati, Iannelli et al. 2003).
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Concurrently, during genomic sequencing of a S. pyogenes strain, MGAS10394,
isolated from an outbreak of erythromycin-resistant pharyngitis in elementary
school children in Pittsburgh, PA (Martin, Green et al. 2002), Banks et al.
identified a similar 58.8kb chimeric element (Banks, Porcella et al. 2003).  The
element was inserted into the same comEC site as Tn1207.3 and also contained
mefA on the 7.2 kb defective transposon Tn1207.1.  Nucleotide sequence
analysis of the entire chimeric element revealed that it was also composed of
conserved lysogenic bacteriophage genes.  Additionally, chimeric element DNA
was detected in bacteriophage particles released into the culture supernatant
after induction with mitomycin C (Banks, Porcella et al. 2003).  These results
suggested that this chimeric element was composed of the transposon Tn1207.1,
inserted into a functional prophage and thus it was classified as Φ10394.4
(Banks, Porcella et al. 2004).  Further sequence analysis revealed that Φ10394.4
and Tn1207.3 are essentially identical in nucleotide sequence except that
Φ10394.4 contains an additional 6 kb variable region upstream of the Tn1207.1
transposon (Banks, Porcella et al. 2004; Pozzi, Iannelli et al. 2004).  Lately, a
third chimeric element containing mefA and tetO, a tetracycline resistance gene,
was described to have both conjugative transposon and bacteriophage
characteristics (Giovanetti, Brenciani et al. 2003).  These tetO -mefA chimeric
elements are different from the other two elements, as they are composed of a
varying number of genes similar to those of Tn1207.1 that have combined with a
different set of bacteriophage genes, resulting in elements of various sizes (52 to
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60 kb), which are integrated into chromosomal locations outside of the comEC
gene (Giovanetti, Brenciani et al. 2003; Brenciani, Ojo et al. 2004; Giovanetti,
Brenciani et al. 2005).
All of the above studies suggest that recent increases in the “M phenotype” of
macrolide resistance may have been influenced by the acquisition and
dissemination of these mefA chimeric elements within the streptococcal
population (Giovanetti, Brenciani et al. 2003; Pozzi, Iannelli et al. 2004;
Giovanetti, Brenciani et al. 2005).  One of the most common methods to examine
the clonality of such macrolide resistant and sensitive streptococcal isolates
involves restriction of genomic DNA with SmaI endonuclease, followed by Pulse
Field Gel Electrophoresis (PFGE) analysis (Tenover, Arbeit et al. 1995; Bert,
Branger et al. 1997; Ripa, Zampaloni et al. 2001).  Recently, however, a number
of epidemiological studies have reported that the DNA from a diverse group of
erythromycin resistant streptococci could not be digested with SmaI (Ripa,
Zampaloni et al. 2001; Bingen, Leclercq et al. 2002; Martin, Green et al. 2002;
Giovanetti, Brenciani et al. 2005; Malhotra-Kumar, Lammens et al. 2005).  This
finding prompted the use of alternative restriction enzymes, such as ApaI, EagI,
and SfiI in the analysis, subsequently making it difficult to directly compare the
clonality of strains that differ in macrolide susceptibility and to relate the results of
different epidemiological studies (Bingen, Leclercq et al. 2002; Martin, Green et
al. 2002; Malhotra-Kumar, Lammens et al. 2005).
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While analyzing the clonality of erythromycin resistant S. pyogenes strains from
the pharyngitis outbreak in Pittsburgh, PA, referenced above (Martin, Green et al.
2002), we found that the presence of  Φ10394.4 in the genome was associated
with streptococcal genomic DNA being refractory to SmaI restriction.  Since SmaI
cleavage is blocked by CpG methylation at the enzyme recognition site
(REBASE: http:// rbase.neb.com) (Roberts, Vincze et al. 2005), we hypothesized
that a 5-methylcytosine methyltransferase (MTase) encoded on Φ10394.4 may
be methylating the genomic DNA, thereby inhibiting SmaI restriction.  In the work
presented here, we confirmed this hypothesis through the allelic replacement,
cloning and characterization of the gene encoding the MTase from Φ10394.4.
We classified this MTase gene as spyIM and its gene product as M.SpyI
following the updated nomenclature of Roberts et al. (Roberts, Belfort et al. 2003)
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7.2 MATERIALS AND METHODS
7.2.1 Bacterial strains and growth conditions.
S. pyogenes isolates obtained from a longitudinal study on the epidemiology of
streptococcal infections of elementary school children in Pittsburgh, PA (Martin,
Green et al. 2002; Martin, Green et al. 2004) are described in (Table 7.1).  These
isolates were previously characterized based on emm-type, macrolide
susceptibility, mechanism of macrolide resistance, and clonality (Martin, Green et
al. 2002; Martin, Green et al. 2004).  In subsequent analyses the isolates were
screened for the presence of the mefA gene, the Φ10394.4 element, and its
insertion into the comEC gene by PCR and Southern blot hybridization.  The
primers used for this analysis are described under the chimeric element heading
in Table 7.2.  E. coli  One Shot Top10 (Invitrogen) was used as the host strain for
plasmid construction and recombinant protein expression.
E. coli was cultured in Luria-Bertani (LB) broth and on LB agar at 37°C.  S.
pyogenes strains were grown at 37°C in Brain Heart Infusion broth (Difco) and on
Proteose Peptone Agar (Difco) supplemented with 4% defibrinated sheep blood
(Cleveland Scientific).   When required, media was supplemented with antibiotics
at the following concentrations:  ampicillin at 100 µg/ml for E. coli, erythromycin
at 2 µg/ml for S. pyogenes, kanamycin at 50 µg/ml for E. coli and 250 µg/ml for
S. pyogenes, and spectinomycin at 20 µg/ml for E. coli and 100 µg/ml for S.
pyogenes.
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Table 7.1.  Bacterial strains and plasmids for M.SpyI studies.
TABLE 1.  Strain and plasmid table
Streptococcus pyogenes
1PM6 M6 Pittsburgh isolate Sensitive - + (36)
2PM6 M6 Pittsburgh isolate Resistant + - (36)
3PM6 M6 Pittsburgh isolate Resistant + - (36)
4PM6 M6 Pittsburgh isolate Resistant + - (36)
5PM6 M6 Pittsburgh isolate Sensitive + - (36)
6PM6 M6 Pittsburgh isolate Sensitive + - (36)
7PM6 M6 Pittsburgh isolate Sensitive - + (36)
8PM6 M6 Pittsburgh isolate Sensitive - + (36)
9PM6 M6 Pittsburgh isolate Sensitive + - (36)
10PM6 M6 Pittsburgh isolate Resistant + - (36)
3PM6ΔRM 3PM6 with R-M replaced with aacA/aphD  gene; Kan
r
Resistant + + This study
3PM6ΔRM-C 3PM6ΔRM with pLZ12spec-spyIM plasmid; Specr Resistant + - This study
Escherichia coli
Oneshot Top10 Used for cloning and recombinant protein expression Invitrogen
Plasmids
pFW13 E. coli -streptococcal shuttle vector with E. coli origin of replication (42)
pLZ12spec E. coli -streptococcal shuttle vector with gram-positive origin of replication (10)
pBADTOPO For recombinant expression of proteins under control of L-arabinose promoter Invitrogen
pFW13EX pFW13 with region upstream of R-M inserted into MCS I This study
pFW13AA pFW13 with region downstream of R-M inserted into MCS II This study
pFW13EA Combined pFW13EX + pFW13AA for R-M allelic replacement vector This study
pLZ12spec-spyIM pLZ12spec with spyMI  gene and promoter region This study
pBADTOPO-spyIM pBADTOPO with spyMI  gene under control of L-arabinose promoter This study
    b  Erythromycin susceptibility determined by Martin et al. and confirmed by methods described in text.
    c  Presence of Φ10394.4 in the streptococcal genomes was determined by PCR and Southern blot hybridization as described in methods.
       a Abbreviations used:  Kanr, kanamycin-resistant; Specr, spectinomycin-resistant; R-M, restriction-modification cassette; MCS, multiple 
cloning site.
Strain or plasmid
Reference 
or source
Erythromycin 
susceptibilityb
Presence of 
Φ10394.4c
Cleaved 
by SmaICharacteristics
a
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Table 7.2.  PCR and sequencing primers for M.SpyI studies.
Chimeric element
mefA gene mefA-M2F AGTATCATTAATCACTAGTGC
mefA-M2R TTCTTCTGGTACTAAAAGTGG
across  attpR attpR-M5F GCCTGATGAAGCAAAGGTTG
attpR-M5R ACGCGTATGGAAGTTCTGGT
Intact comEC comECF GCAGGTGCGACAACGAGT
comECR TGTCCGACCAGTCAAACGAA
M.SpyI E. coli  expression
spyIM  gene MetR ATGACCTTTGATAGACACATTTTAG
MetFI CTATTTTTTTAGGACGGCTAGTAT
R-Md  allelic replacement
Adjacent region up-stream of R-M UpFEagI ATTCTCCGGCCGCTCTTCAAAGT
UpRXhoI AATTGCTCGAGAAATACTAGCCGTCC
Adjacent region down-stream of R-M DoFAvrII TTGTATCCTAGGTTAGAGGCAATTATTAAG
DoRAgeI TAGTAACCGGTTCTAATGCATACCCT
M.SpyI  S. pyogenes  expression
spyIM  gene + promoter region MetxBamHI GATAGAGGATTCGATGCTATTCTGC
MetxSphI ATTTTGCATGCAGAATTAAAAAAGTCTAT
Bisulfite reaction
bi-F TTGAAAGTGTGGGGAGTAAATA
bi-R CTAACTCCTAATAAATTACCTCACC
bi-Fs1 AGTAAATAGGATTAGATATTTTGGTAGTTT Seq This study
bi-Fs2 TGTTTTTTTATGATTTGGGTTATATA Seq This study
bi-Rs1 TAACAACAACCATACACCACCATC Seq This study
bi-botF TTGGTTTTTAATAGGTTATTTTATTGATTT
bi-botR AAAACTCAAAAACATAAAAAACAAACAA
bi-botFs1 GAGTTGATGATAATTATGTATTATTTGTTA Seq This study
a Mutated nucleotides are in boldface and introduced restriction sites are underlined.                                                                                                                                                                          
Product 
lengthc 
Primer   
typeb
PCR / Seq
PCR / Seq
This study
This study
This study
Sense strand of bisulfite modified DNA, 
16S rRNA gene region
Anti-sense strand of bisulfite modified 
DNA, 16S rRNA gene region
PCR
PCR
PCR
This study
This study
and M.SpyI expression primers below
944
Primer sequencea , 5' → 3' Amplified region Primer name
816
PCR
PCR
PCR
PCR
Reference  
or source
346
4781
(3)
(3)
705
1016
1227
This study
This study
701
1409
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7.2.2 DNA manipulations.
Streptococcal genomic DNA was isolated with either the DNeasy Tissue Kit or
the Blood & Cell Culture DNA Kit (Qiagen) following the manufacturerʼs
protocols, except for the substitution of a modified lysis buffer (50 mM Tris-Cl pH
6.6, 50 mM EDTA, 0.5% Tween-20, 0.5% TritonX-100) supplemented with 500U
of plyC, a streptococcal bacteriophage lysin (Nelson, Schuch et al. 2006) and
250 ng/ml of RNase A (Qiagen).  Plasmid DNA was isolated from E.coli using the
QIAprep Spin Miniprep Kit or HiSpeed Plasmid Midi Kit (Qiagen).  DNA
fragments were gel purified from 1% Agarose gels using the QIAquick Gel
Extraction Kit (Qiagen).  T4 DNA ligase, M.HpaII MTase, and all restriction
enzymes were purchased from New England Biolabs and used according to the
manufacturerʼs instructions.  Oligonucleotides were obtained from Sigma-
Genosys.  PCR was performed using AmpliTaq Gold DNA polymerase, Gold
Buffer, 1.5 mM MgCl2, and 200 µM dNTPS (Applied Biosystems) following
standard protocols with the Eppendorf Mastercycler.  DNA sequencing was
performed by GENEWIZ, Inc. (North Brunswick, NJ).  DNA sequence analysis,
comparison, and manipulation required Lasergene software modules (DNASTAR
Inc.) and the CLUSTALX (Thompson, Gibson et al. 1997) and BOXSHADE
(http://www.ch.embnet.org/software/BOX_form.html) programs.  DNA primers
were designed with MacVector software (Accelrys Inc.).
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7.2.3 PFGE molecular analysis.
Agarose discs of genomic DNA from the Pittsburgh isolates (Table 7.1) were
prepared according to a protocol modified from Chung et al. (Chung, de
Lencastre et al. 2000), in which 500U of plyC was substituted for lysozyme and
lysostaphin enzymes in the cell lysis solution (Chung, de Lencastre et al. 2000;
Nelson, Schuch et al. 2006).  DNA was digested with SmaI or XmaI (40U)
overnight at 25°C or 37°C, respectively, and subjected to PFGE with the CHEF-
DR II system (Bio-Rad) as previously described (Chung, de Lencastre et al.
2000).  DNA bands were visualized by staining the gel with ethidium bromide and
the images captured by an Alpha imager (Alpha Innotech Corp.).  DNA banding
patterns were analyzed by previously described methods (Tenover, Arbeit et al.
1995; Chung, de Lencastre et al. 2000).
7.2.4 Construction of the pBadTOPO-spyIM E.coli expression plasmid.
The spyIM gene was PCR amplified from genomic DNA of strain 3PM6 using the
MetR and MetFI primers described under the M.SpyI E. coli expression heading
in Table 7.2.  The 1227 bp PCR product was gel purified, ligated into pBAD-
TOPO vector, and transformed into E.coli One Shot TOP10 using the pBAD
TOPO TA Expression Kit (Invitrogen).  Transformants were screened for proper
insert orientation by colony PCR and DNA sequencing.  Positive clones were
screened for MTase expression by the SmaI protection assay below.
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7.2.5 SmaI endonuclease protection assay.
Expression and activity of the recombinant M.SpyI was tested using a
combination of protocols described previously (Card, Wilson et al. 1990;
Klimasauskas, Steponaviciene et al. 1990) and the instructions of the
pBADTOPO TA Expression Kit.  Briefly, recombinant M.SpyI expression was
induced by the addition of 0.2% or 2% L-arabinose to cultures at an OD600 of 0.5,
and growth then continued for 2 or 4 hours at 37°C, respectively.  L-arabinose
concentrations and induction times were varied to determine the most efficient
expression conditions. The cultures were centrifuged at 3000 x g for 10 min.  The
cell pellets were washed once in 50mM Tris-HCl pH 7.5, resuspended in MTase
reaction buffer (50 mM Tris-HCl pH 7.5, 5 mM 2-mercaptoethanol, 10 mM EDTA)
and frozen at  -20°C overnight.  Cells were lysed by two freeze-thaw cycles,
followed by sonication for 5 min with a W-380 Sonicator (Heatsystems-
Ultrasonics Inc.).  The crude lysate was centrifuged at 16,000 x g for 20 min at
4°C to collect the supernatant.  The lysate supernatant (10 ul), supplemented
with 80 µM of S-adenosylmethionine (SAM) (New England Biolabs), was then
incubated for 2 hours at 37°C with 1 µg of λ phage DNA (New England Biolabs)
as the substrate for the methylation reaction.  The reaction was heat inactivated
for 20 min at 65°C and then the λ DNA was subjected to SmaI digestion for 2
hours at 25°C by the addition of NEBuffer 4 (40 µl), supplemented with 10 mM
MgCl2 and 20U SmaI. Digestion or protection of λDNA was analyzed by 1%
Agarose gel electrophoresis.
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7.2.6 Allelic replacement of the restriction-modification (R-M) cassette in
Φ10394.4.
The strategy for allelic replacement of the R-M cassette is outlined in Figure 7.1.
First, DNA regions flanking spyIM and the adjacent restriction enzyme genes
(944 bp upstream and 1016 bp downstream) were PCR amplified from the
genomic DNA of strain 3PM6 using the two primer sets described under the R-M
KO heading in Table 7.2.  The PCR products were treated with a combination of
either EagI and XhoI or AvrII and AgeI and were purified by Qiaquick PCR
Purification Kit (Qiagen).  The upstream and downstream fragments were
individually cloned into shuttle vector pFW13 (Podbielski, Spellerberg et al.
1996).  The two resulting vectors, pFW13EX and pFW13AA, were then digested
with NheI and NcoI, and religated to produce the R-M allelic replacement vector,
pFW13EA.  The pFW13EA vector was treated with the M.HpaII MTase, following
the manufacturer suggestions (New England Biolabs), to methylate 5ʼCCGG
residues and to prevent vector digestion by the cognate restriction enzyme of the
R-M cassette within the streptococci.  The methylated vector was electroporated
into 3PM6 following the streptococcal transformation protocol of Kimoto et al.
(Kimoto and Taketo 2003) and transformants were selected on proteose peptone
blood agar supplemented with kanamycin.  Allelic replacement of the R-M
cassette with the KanR gene (aacA/aphD) was confirmed by PCR, Southern blot
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analysis and DNA sequencing.  The resulting mutant strain (3PM6ΔRM) lacked
the genes that encoded the M.SpyI and the adjacent restriction enzyme subunit.
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Figure 7.1.  Construction of the allelic replacement vector pFW13EA.
This diagram outlines the steps to construct vector pFW13EA.  Top panel shows
the location of the adjacent regions upstream and downstream of the R-M
cassette that were PCR amplified and digested with the appropriate restriction
enzymes by methods detailed in the text.  Each amplicon was separately ligated
into plasmid pFW13 to create pFW13EX and pFW13AA.  Both plasmids were
subsequently digested with NheI and NcoI and ligated to produce pFW13EA, the
allelic replacement vector, which contains the kanamycin resistance gene
(aacA/aphD) flanked by the regions adjacent to the R-M cassette. Grey arrows
and blocks indicate the regions PCR amplified for insertion into the pFW13
vector.  ΔR-M bracket indicates the region of the restriction-modification cassette
that was replaced with the kanamycin resistance gene (aacA/aphD).  Plasmid
diagrams indicate relevant restriction sites, kanamycin resistance gene
(aacA/aphD) and E. coli origin of replication (ori).
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7.2.7 Construction of pLZ12spec-spyIM GrAS expression plasmid.
A 1409 bp region encompassing both the spyIM gene and upstream promoter
region was PCR amplified from the genomic DNA of strain 3PM6 using the
primers described under the M.SpyI S. pyogenes expression heading of (Table
7.2.)  The amplicon was then digested with BamHI and SphI and cloned into
pLZ12spec, an E. coli -streptococcal shuttle vector (Caparon and Scott 1991), to
produce pLZ12spec-spyIM ( Table 7.1).  This construct was electroporated into
the mutant strain 3PM6ΔRM to produce the complemented strain 3PM6ΔRM-C
(Table 7.1).  Trans-complementation of the MTase knockout by pLZ12spec-
spyIM was tested by PFGE molecular analysis described above.
7.2.8 Bisulfite analysis of 5-methylcytosine residues.
Streptococcal genomic DNA (500 ng) was modified by bisulfite treatment with the
EZ DNA Methylation-Gold kit (Zymo Research) according to manufacturer
instructions.  The bisulfite-modified DNA was used as the template for PCR using
primer pairs specific for the sense (bi-F and bi-R) or anti-sense (bi-botF and bi-
botR) strands of the modified DNA, as described in (Table 7.2) under the bisulfite
reaction heading.  The amplicons were then purified and sequenced in both the
5ʼ and 3ʼ directions using the primers listed under bisulfite reaction heading in
(Table 7.2).  The DNA sequences were aligned with the published sequence of
S. pyogenes strain MGAS10394 using the MegAlign program (DNAstar Inc.) to
help identify methylated cytosine residues.
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7.3 RESULTS
7.3.1 Genomic DNA harboring Φ10394.4 is resistant to SmaI restriction.
To further differentiate the clonality of the S. pyogenes strains isolated from an
outbreak of erythromycin resistant pharyngitis in Pittsburgh school children
(Martin, Green et al. 2002), PFGE was performed on SmaI digested genomic
DNA from isolates that were positive or negative for the chimeric element
Φ10394.4 (Table 7.1 & Figure 7.2).  Analysis of the PFGE patterns revealed that
SmaI was able to digest DNA from strains that did not contain Φ10394.4.
Conversely, genomic DNA from strains containing Φ10394.4 was resistant to
SmaI digestion (Table 7.1 & Figure 7.2).  Furthermore, SmaI did not digest the
genomic DNA of three erythromycin susceptible isolates (Table 7.1 & Figure 7.2).
PCR and sequence analysis showed these strains also contained the Φ10394.4
chimeric-element but had mutations in the mefA gene (Table 7.1 & data not
shown).  These observations suggested that resistance to SmaI cleavage of
genomic DNA was not directly related to erythromycin resistance, but rather the
presence of the Φ10394.4 chimeric element.
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Figure 7.2.  Pulse field gel electrophoresis (PFGE) analysis of S. pyogenes M6
isolates from school children in Pittsburgh, PA.
(A) PFGE patterns of SmaI digested genomic DNA from isolates that were
negative (strains 1, 7, and 8PM6) or positive (strains 2, 3, 4, 5, 6, 9, and 10PM6)
for the 58 kb mefA-encoding chimeric element Φ10394.4 (Table 7.1). λ, Lambda
Ladder PFG Marker (New England Biolabs).  (B) Comparison of PFGE patterns
of SmaI and XmaI digested genomic DNA from the Φ10394.4 positive isolate
3PM6.
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7.3.2 Genomic DNA harboring Φ10394.4 is partially digested by XmaI.
SmaI restriction of DNA can be blocked by CpG methylation at the restriction
enzyme cleavage site, 5ʼ-CCC ↓ GGG, [REBASE: http:// rbase.neb.com]
(Roberts, Vincze et al. 2005).  To determine if this type of methylation was
protecting the genomic DNA of Φ10394.4−containing isolates, DNA preparations
were treated with XmaI, an isoschizomer of SmaI that cleaves DNA at the
sequence:  5ʼ-C ↓ CCGGG.  Unlike SmaI, XmaI is not fully blocked, but partially
impaired, by CpG methylation overlapping the SmaI recognition site  [REBASE:
http:// rbase.neb.com] (Roberts, Vincze et al. 2005).  PFGE analysis showed that
while SmaI was inhibited, XmaI partially cleaved the genomic DNA from the
Φ10394.4-containing strain 3PM6 (Figure 7.2).  Taken together, the difference in
digestion patterns between XmaI and SmaI may be explained by the location of
their distinct cleavage sites within the same methylated recognition sequence.
These results suggest that the partial digestion by XmaI and the inability of SmaI
to cleave 3PM6 DNA may indeed be caused by methylation.
7.3.3 5-methylcytosine MTase identified on Φ10394.4.
Analysis of the published sequence of Φ10394.4 revealed that the
bacteriophage-like region of this chimeric element contains a putative type II
restriction-modification (R-M) cassette encoding a type II restriction
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endonuclease (in two subunits) and an adjacent MTase gene (spyIM) (Figure
7.3) (Banks, Porcella et al. 2003; Banks, Porcella et al. 2004).
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Figure 7.3. Schematic of a 28 kb segment of the chimeric element Φ10394.4.
Top panel shows the positions of the mefA gene and the restriction-modification
cassette, which contains the spyIM gene, within the predicted ORFs of
Φ10394.4.  Numbers below the sequence indicate relative size in kb.  Black
arrows denote regions that have transposon and bacteriophage-like
characteristics, as detailed in the text.  Bottom panel is a close-up of the
predicted ORFs and their corresponding Spy numbers from the genome
sequence of S. pyogenes MGAS10394, GenBank accession number CP000003.
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A BLASTP comparison of the predicted amino acid sequence of this MTase
(M.SpyI) to proteins in the REBASE database
[http://tools.neb.com/~vincze/rebhit/blast.php3] (Altschul, Madden et al. 1997;
Roberts, Vincze et al. 2005), revealed high sequence similarities to other 5-
methylcytosine MTases that recognize the DNA sequence: 5ʼ-CCNGG (Table
7.3).
Table 7.3.  BlastP comparison of M.SpyI with other cytosine MTases.
M.SpyIc CCNGG C5 0.0 YP_060478.1
M.Spy1207ORFAPd CCNGG C5 0.0 AAT72355.1
M1.ScrFI CCNGG C5 0.0 AAB66696.1
M.StyD4I CCNGG C5 e-168 BAA11167.1
M.Ecl18kI CCNGG C5 e-168 CAA76526.1
M.SenPI CCNGG C5 e-168 AA645971.1
M.SsoII CCNGG C5 e-167 AAA98279.1
     b  C5, 5-methylcytosine MTase.
     c  We reclassified M.Spy10394ORF1160P (YP_060478.1) as M.SpyI.
     a When known, the sites of methylation are indicated by bold letters in the 
recognition sequence.                                                                                                                                                         
     d  M.Spy1207ORFAP is identical to M.SpyI and is the uncharacterized MTase 
in the chimeric element Tn1207.3.
GenBank 
accession numberMTase
bMTase
Recognition 
sequencea
E-Value
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The comparison also identified M.Spy1207ORFAP, which is located in the DNA
sequence of Tn1207.3, as an identical ORF to M.SpyI (Santagati, Iannelli et al.
2003).  Of note, no corresponding ORF to M.SpyI has yet been identified in the
tetO-mefA chimeric elements (D'Ercole, Petrelli et al. 2005).  A CLUSTALW
alignment of the amino acid sequences from the BLASTP search showed M.SpyI
contained the 10 conserved motifs that are present in the 5-methylcytosine
MTases, in the proper order, and significant homology within the variable region
making up the target recognition domain (TRD) of these enzymes (Figure 7.4).
These conserved features suggested that spyIM may encode a 5-methylcytosine
MTase that could recognize the DNA sequence: 5ʼ-CCNGG. This recognition
sequence is included within the DNA sequence recognized by SmaI (5ʼ-
CCCGGG).  Therefore, we were interested in determining if M.SpyI methylates
CpG sites on the streptococcal chromosome, such as those contained in the
SmaI DNA recognition sequence.
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Figure 7.4.  Alignment of the amino acid sequence of M.SpyI with the five closest
5-methylcytosine MTases from a REBASE BLASTP search.
Alignment of the sequences: M.SpyI, M1.ScrFI, M.StyD41, M.Ecl18kI, M. SenPI,
and M.SsoII was carried out using the ClustalX program and amino acids shaded
with the Box Shade program. Black boxes highlight identical residues, while grey
boxes highlight conserved residues.  Gaps are indicated by dashes.  The
locations of the 10 conserved amino acid motifs present in 5-methylcytosine
MTases are indicated by black lines above the amino acid sequences and
numbered I to X.  The variable region, making up the target recognition domain
(TRD) of 5-methylcytosine MTases is indicated by a grey line above the amino
acid sequences.  M.Spy1207ORFAP was not included in the alignment because
it is the identical ORF to M.SpyI in the Tn1207.3 chimeric element.
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7.3.4 Recombinant M.SpyI protects λ DNA from SmaI digestion.
To investigate whether M.SpyI was capable of modifying DNA to inhibit SmaI,
recombinant M.SpyI was expressed in E. coli and tested for MTase activity.  Cell
lysates from cultures in which M.SpyI was either induced or not induced were
separately incubated with λDNA as a substrate and then subsequently subjected
to SmaI digestion.  This analysis revealed that SmaI did not cleave λDNA that
was incubated with recombinant M.SpyI induced under various conditions (Figure
7.5) Conversely, λDNA incubated with non-induced cell lysates (i.e. M.SpyI not
present) was cleaved by the action of SmaI (Figure 7.5).  Taken together these
results indicated that the M.SpyI was able to modify the DNA to render it resistant
to SmaI digestion.  Furthermore, cell lysates containing M.SpyI that were not
supplemented with SAM in the methylation reaction did not protect λDNA from
SmaI digestion (Figure 7.5).  Since SAM is an essential co-factor in Type II
methyltransferase reactions (Wilson and Murray 1991; Roberts, Belfort et al.
2003), this result suggests that DNA methylation is the modification responsible
for SmaI inhibition.
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Figure 7.5.  Recombinant M.SpyI protects λDNA from digestion with the SmaI
endonuclease.
λ DNA was first incubated with the crude lysate of E.coli cells that expressed
recombinant M.SpyI, and then was subjected to SmaI digestion.  Digestion patterns
were analyzed by electrophoresis on a 1% agarose gel.  Lane 1, undigested l DNA; lane
2, non-lysate treated l DNA alone with SmaI; lanes 3 and 4, l DNA incubated with crude
lysate (supplemented with 80 µM of SAM) in which M.SpyI was induced with 0.2%
arabinose for 2 hr or 2% arabinose for 4 hr, respectively; lane 5, λ DNA incubated with
M.SpyI induced crude lysate without SAM; lane 6, λ DNA + crude lysate from a non-
induced culture, 0% arabinose for 4hr; M, 1 kb Plus DNA Ladder (Invitrogen).
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7.3.5 Allelic replacement of the R-M cassette allows cleavage of genomic DNA by
SmaI and XmaI.
Deletion of the spyIM gene in Φ10394.4 would confirm the role of the MTase in
methylation of the genomic DNA and provide a useful tool to further dissect the
functions of the R-M system genes from the rest of those encoded on the chimeric
element.  Since an active MTase enzyme is usually necessary to protect host DNA from
being digested by the cognate restriction enzyme of the R-M cassette (Kobayashi
2001), we sought to inactivate both enzyme activities by allelic replacement of part of
the R-M cassette with a kanamycin resistance gene from vector pFW13EA (Figure 7.1).
This resulted in the mutant strain 3PM6ΔRM, which lacked the spyIM gene and the
adjacent ORF encoding one of the restriction enzyme subunits (Figure 7.1 and Table
7.1).  PFGE analysis of digested genomic DNA from this strain showed that it was
completely cleaved by both SmaI and XmaI (Figure 7.6).  These results indicated that
methylation of the genomic DNA by M.SpyI is responsible for the inhibition of SmaI
digestion and the partial inhibition of XmaI digestion of the genomic DNA.
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Figure 7.6.  PFGE patterns of digested genomic DNA.
From 3PM6 (spyIM positive strain), 3PM6ΔRM (spyIM deletion mutant), and 3PM6ΔRM-
C (trans-complemented spyIM mutant).  Panel (A) shows the restriction patterns of
SmaI digested genomic DNA:  Lane 1, undigested DNA (3PM6); lane 2, 3PM6; lane 3,
3PM6ΔRM; lane 4, 3PM6ΔRM-C.  Panel (B) shows the restriction patterns of XmaI
digested genomic DNA:  Lane 1, 3PM6; lane 2, 3PM6ΔRM; lane 3, 3PM6ΔRM-C.
Arrows in both panels identify fragments that are different from the predicted digestion
pattern of S. pyogenes strain MGAS10394 due to the allelic replacement of part of the
RM cassette with the kanamycin resistance gene (aacA/aphD).
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To confirm that the digestion of 3PM6ΔRM DNA was due to a lack of M.SpyI activity in
the mutant, the spyIM gene was trans-complemented into 3PM6ΔRM on the
pLZ12spec-spyIM vector and the genomic DNA was tested for inhibition of the
restriction enzymes.  Both the inhibition and the partial inhibition of genomic DNA
digestion by SmaI and XmaI, respectively, were restored in the M.SpyI complemented
mutant (Figure 7.6).  These results confirmed that M.SpyI was responsible for protecting
the DNA from the actions of these restriction enzymes in vitro.
7.3.6 M.SpyI recognizes the genomic DNA sequence CCNGG.
Bisulfite modification of DNA converts nonmethylated cytosine residues to uracil, while
5-methylcytosine residues are protected and remain unaltered in the reaction.
Subsequent PCR amplification of the modified DNA changes the uracil residues into
thymine so that only the 5-methylcytosine residues are identified as cytosine when the
amplicon is sequenced (Frommer, McDonald et al. 1992).  To determine the nucleotide
sequence that was methylated by M.SpyI, we used the bisulfite reaction to modify the
genomic DNA from the Φ10394.4-containing strains 3PM6 and 10PM6, the 3PM6ΔRM
deletion mutant, and 8PM6, a Φ10394.4 negative strain (Table 7.1).  A 700 bp DNA
sequence inside the 16S rRNA genes of these strains was chosen to be PCR amplified
and sequenced because it contained all combinations of the 5ʼ-CCNGG DNA sequence,
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including the SmaI DNA recognition site and other potentially methylated CpG
sequences.
The modified sequences were aligned to 600 bp of the published genome sequence of
MGAS10394 to identify the methylation patterns of each strain.  The alignment in Figure
7.7 shows that in the DNA sequences of strains that do not contain the spyIM gene
(3PM6ΔRM mutant and 8PM6), all cytosines were converted to thymine.  Conversely,
DNA from spyIM positive strains (3PM6 and 10PM6) contained unchanged cytosines on
the inner C residue of the 5ʼ-CCNGG DNA sequences (denoted in boxes, Figure 7.7),
suggesting that M.SpyI methylates this specific cytosine residue (5ʼ-CCmNGG).
Additionally, both inner C residues were methylated in the SmaI recognition sequence,
5ʼ-CCmCmGGG (dashed box in Figure 7.7).  This methylation pattern fits with the above
results because the SmaI recognition sequence actually consists of two overlapping 5ʼ-
CCNGG DNA sequences (5ʼ-CCCGG and 5ʼ-CCGGG).  Analysis of the DNA sequence
from the opposite strand of the same 700 bp showed an equivalent cytosine methylation
pattern (data not shown), indicating that these sites have the same cytosine residue
methylated on both strands of the DNA, a finding consistent with most type II restriction-
modification MTases (Wilson and Murray 1991; Roberts, Vincze et al. 2005).  The
specificity and activity of M.SpyI was also confirmed by bisulfite analysis of two other
regions outside the 16S rRNA genes and with λ DNA methylated with recombinant
M.SpyI (data not shown).
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Taken together, these results confirm that the DNA sequence modified by M.SpyI
is 5ʼ-CCNGG, as predicted by the BLASTP comparison of M.SpyI to other 5-
methylcytosine MTases above.  These results further indicate that M.SpyI
methylation of the DNA is responsible for the inhibition of the of SmaI cleavage of
the genomic DNA from the Φ10394.4-containing isolates.
86
87
Figure 7.7.  Sequence comparison of PCR products from bisulfite modified
streptococcal genomic DNA to identify cytosines methylated by M.SpyI.
Sequences were aligned to the published genomic sequence of the S. pyogenes M6
strain MGAS10394 on the top line of each row.  Unmodified nucleotides that were
identical to the residues in the MGAS10394 reference sequence (GenBank accession
number CP000003) have been illustrated with a dot.  Methylated-cytosines have been
defined as cytosine nucleotides that were not converted to thymine residues by bisulfite
treatment and are highlighted by an asterisk above the DNA sequences. Boxes indicate
the putative DNA recognition sequences for M.SpyI, with the dashed box highlighting
the overlapping sequence recognized by SmaI.  Line 1, MGAS10394 reference
sequence; Line 2-3, modified DNA from Φ10394.4-containing isolates 3PM6 and
10PM6, respectively; Line 4, modified DNA from the spyIM deletion mutant 3PM6ΔRM;
Line 5, modified DNA from the Φ10394.4 negative isolate 8PM6. Numbering of the
sequence in line 1 corresponds to the published numbered DNA sequence of
MGAS10394.  Numbering of the other lines corresponds to the position of the
nucleotides from the start of the bi-F primer in the sense strand amplicon of the bisulfite
reaction (Table 7.2).
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7.4 DISCUSSION
PFGE analysis of SmaI digested genomic DNA has been used in many
epidemiological studies to successfully characterize the clonality of multiple
serotypes of S. pyogenes (Tenover, Arbeit et al. 1995; Stanley, Desai et al. 1996;
Nakashima, Ichiyama et al. 1997; Nguyen, Levy et al. 1997).  However,
numerous studies have reported that the DNA from some macrolide resistant
isolates are refractory to SmaI digestion (Ripa, Zampaloni et al. 2001; Bingen,
Leclercq et al. 2002; Martin, Green et al. 2002; Giovanetti, Brenciani et al. 2005;
Malhotra-Kumar, Lammens et al. 2005); an observation recently associated with
the “M phenotype” of erythromycin resistance, which is imparted by the Tn1207.3
or Φ10394.4 chimeric elements (Ripa, Zampaloni et al. 2001; Giovanetti,
Brenciani et al. 2005).  The results of our study agree with these previous
reports.  Here, we also found that SmaI could not digest the genomic DNA from
streptococcal isolates containing Φ10394.4; this led to the identification of a type
II R-M cassette on Φ10394.4, which encodes two subunits of a restriction
endonuclease and an adjacent MTase gene (spyIM).
 We cloned, expressed and characterized the spyIM gene, encoding the 5-
methylcytosine MTase, which we named M.SpyI.  Through the heterologous
expression of M.SpyI, we provided evidence that it is capable of protecting DNA
from SmaI digestion.  The allelic replacement of the spyIM gene in S. pyogenes
combined with bisulfite methylation analysis confirmed that the DNA sequence
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that was methylated was CCmNGG and that M.SpyI alone was responsible for
the methylation leading to the partial digestion by XmaI and the inhibition of SmaI
digestion of streptococcal DNA in vitro.  Although spyIM is encoded on a mobile
element, to our knowledge, this is the first MTase gene to be cloned and
characterized from S. pyogenes.
The possible in situ roles for the MTase and the adjacent restriction enzyme
subunits of the type II R-M system are currently being investigated.  However,
previous studies have shown that type II MTases act in concert with their cognate
type II restriction enzymes, which usually recognize and cleave the overlapping
DNA sequence that is acted upon by the MTase, to protect the bacteria from
foreign DNA (reviewed in (Wilson and Murray 1991)).  Methylated genomic DNA
is protected from the action of the cognate restriction enzyme, while
nonmethylated DNA from other lytic or lysogenic bacteriophages are restricted so
that they cannot kill or sabotage the survival of the bacteria (Wilson and Murray
1991).  This suggests another example of how Φ10394.4 may increase host
strain survival in the population and provides another reason why erythromycin
resistant isolates encoding mefA are increasing in the streptococcal population
(Kataja, Huovinen et al. 1999; Ripa, Zampaloni et al. 2001; Hsueh, Teng et al.
2002; Silva-Costa, Ramirez et al. 2006).   In fact, analysis of DNA sequences
from 23 of the published lysogenic bacteriophages of S. pyogenes show that they
contain an average of 17 CCNGG sites in their genomes (data not shown)
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(Ferretti, McShan et al. 2001; Beres, Sylva et al. 2002; Smoot, Barbian et al.
2002; Banks, Porcella et al. 2004). Interestingly, all seven of the other
bacteriophages present in the published sequence of the MGAS10394 strain, in
which Φ10394.4 was classified, contain 5ʼ-CCNGG sites (Banks, Porcella et al.
2004).  The presence of these sites could have allowed the restriction enzyme to
cleave their incoming bacteriophage DNA if the R-M cassette was already
integrated into the genome, suggesting that Φ10394.4 might have been the most
recent element acquired by this streptococcal strain.
Another potential role for the R-M cassette might be to promote maintenance of
the mefA chimeric element in the bacterial chromosome, through the post-
segregational killing of strains that have had a recombinational event, which
cured the strain of Φ10394.4 (Handa, Nakayama et al. 2001; Kobayashi 2001;
Robinson, Sutcliffe et al. 2006). Strains that have lost Φ10394.4 and its
associated MTase may initially contain residual restriction enzyme that could
digest any nonmethylated regions of genomic DNA, resulting in the suicidal death
of the bacteria (Kulakauskas, Lubys et al. 1995; Naito, Kusano et al. 1995; Ichige
and Kobayashi 2005).   This process would select for isolates that have
preserved Φ10394.4 and the mefA gene in the population, and thus possibly
maintain macrolide resistance even when the selective antibiotic is not present in
the bacterial environment.
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Our results also provide an explanation for a finding from past epidemiological
studies that the genomic DNA of some streptococcal isolates with the “M-
phenotype” of macrolide resistance cannot be digested with SmaI (Ripa,
Zampaloni et al. 2001; Bingen, Leclercq et al. 2002; Martin, Green et al. 2002;
Giovanetti, Brenciani et al. 2005; Malhotra-Kumar, Lammens et al. 2005). We
have shown that the M.SpyI MTase, encoded by Φ10394.4 and other similar
chimeric elements, is directly responsible for this phenotype.  In the future, we
recommend the use of alternative restriction enzymes, which recognize identical
DNA sequences to SmaI but are not blocked by this type of methylation; such as
the Crf9I endonuclease (Fermentas Inc.), recently used to compare the clonality
of macrolide resistance isolates of S. pyogenes from Portugal (Silva-Costa,
Ramirez et al. 2006).  We are currently examining another role that the Φ10394.4
chimeric element may play in regulating the increased invasiveness observed in
some erythromycin resistant isolates of streptococci.  To further explore this
phenotype we are utilizing the phage counter-selection and curing method
described below to create an isogenic GrAS mutant lacking the Φ10394.4.
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8 Chapter 2
8.1 INTRODUCTION
Starting in the 1930ʼs it was shown that group A streptococci contain lysogenic
bacteriophage (Evans 1934; Evans 1940), however it was not until the early
1960ʼs that it was discovered that these prophage are associated with
streptococcal virulence factors or “toxins” (Zabriskie 1964), and that the
frequency of GrAS  lysogeny is quite high (>90%) (Yu and Ferretti 1989; Yu and
Ferretti 1991).  In 2001, Ferretti et al. reported the first complete genome
sequence of an M1 serotype strain, SF370, isolated from a wound infection
(Ferretti, McShan et al. 2001). The SF370 genomic sequence confirmed the
intimate relationship between prophage and GrAS by revealing that this
streptococcal strain is poly-lysogenized, and that the integrated prophages
encode a number of putative virulence factors.
The genome of SF370 contains four major bacteriophage elements (Φ370.1,
Φ370.2, Φ370.3 and Φ370.4). Only one prophage (Φ370.1) has been reported to
be induced upon mitomycin C treatment, whereas the other three appear to be
defective prophages (Ferretti, McShan et al. 2001; Canchaya, Desiere et al.
2002).  Phage Φ370.1 has a 41 kb genome and encodes the speC superantigen
gene, the spd1 DNase gene, and the hylp1 hyaluronidase gene.  Phage Φ370.2
has a 43 kb genome and encodes two potential superantigen genes (speH and
speI) and a hyaluronidase gene (hylp2).  Initial sequence analysis indicated that
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Φ370.2 is a complete phage, but closer inspection revealed two inactivating
mutations, one in the replisome organizer (involved in initiating induced phage
DNA replication) and the other in the portal protein (involved in the packaging of
phage chromosome into the prohead).  Phage Φ370.3 has a 33 kb genome and
contains another DNase gene (spd3) and hyaluronidase gene (hylp3).  It also
contains a stop mutation in the replisome organizer.  Phage Φ370.4 has a 13kb
genome that has undergone extensive deletion, eliminating any identifiable
structural, lysis, or virulence genes (Ferretti, McShan et al. 2001; Canchaya,
Desiere et al. 2002).
Subsequently, the genome sequences of thirteen other GrAS genomes have
been completed, representing 10 different serotypes (M1, M2, M3, M4, M5, M6,
M12, M18, M28, and M49) from a variety of streptococcal diseases (Ferretti,
McShan et al. 2001; Beres, Sylva et al. 2002; Smoot, Barbian et al. 2002;
Nakagawa, Kurokawa et al. 2003; Banks, Porcella et al. 2004; Green, Zhang et
al. 2005; Beres and Musser 2007; Holden, Scott et al. 2007; McShan, Ferretti et
al. 2008).  Like SF370, all sequenced GrAS genomes are poly-lysogenized,
containing from two to eight phage-like elements.  These prophages encode
multiple novel virulence factors including: superantigens (e.g. SpeH, SpeK, and
SpeM), DNases (e.g. Spd4, Sda, and Sdn), phage-encoded hyaluronidases
(Hlyp), antibiotic resistant cassettes (MefA) and phospholipases (Sla)
(summarized in (Beres and Musser 2007; McShan, Ferretti et al. 2008).
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Including these virulence factors, the prophage open reading frames (ORFs)
represent an average of 10% of the streptococcal genome. But while they
represent a minor fraction of the total genome, they account for up to 74% of the
variation in gene content between GrAS strains (Banks, Beres et al. 2002). This
data clearly shows that the differences in the combinations of integrated
prophage and the types of virulence factors they encode could have an impact
on the variety of diseases caused by these different strains.
The fact that integrated prophage account for the greatest genetic variation
between genomes of S. pyogenes strains (both inter and intra-serotype
differences) suggests that the creation of a strain in which the prophages could
be manipulated would be a useful tool to further understand the role
bacteriophage play in streptococcal pathogenicity and evolution.  A comparison
of isogenic strains of S. pyogenes that differ in specific bacteriophage genes or in
overall bacteriophage content would allow us to study the direct effects that
individual bacteriophage have on streptococcal virulence and may provide insight
into the evolution of pathogenicity of specific strains before and after prophage
integration events occurred.
In this study, two different approaches were used to manipulate the SF370 strain
in order to produce isogenic mutants that differ in bacteriophage gene content.
First, individual bactriophage genes encoding potential GrAS virulence or
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regulatory factors were targeted for allelic replacement using previously
established methods and protocols (Podbielski, Spellerberg et al. 1996; Euler,
Ryan et al. 2007).  Second, we developed a novel approach to select for isolates
of the SF370 strain that were cured of lysogenic bacteriophage.  To accomplish
this, we used allelic replacement techniques to exchange an individual
bacteriophage gene with a two gene cassette containing: 1) the (aacA-aphD)
gene, responsible for kanamycin resistance (KanR) (Podbielski, Spellerberg et al.
1996), which provides the first level of selection to insert the cassette into the
bacteriophage.  2) The wild-type (WT) rpsL gene, encoding the ribosomal subunit
protein S12, the target of the antibiotic, streptomycin (Reyrat, Pelicic et al. 1998).
While mutations in the rpsL gene provide a high level of resistance to
streptomycin (SmR), the resistance is recessive if a wild-type copy of the rpsL
gene (such as on the above cassette) is also expressed in the same cell
(Lederberg 1951; Reyrat, Pelicic et al. 1998).  Therefore, in a bacterial strain that
harbors a chromosomal SmR rpsL mutation, it is possible to select for clones that
have subsequently lost the inserted copy of the WT rpsL allele (rpsLWT) by plating
the bacteria to media containing streptomycin (Reyrat, Pelicic et al. 1998).
Isolates that retain the rpsLWT copy will be streptomycin sensitive (SmS), while
strains that lose the rpsLWT gene will be SmR.  This counter-selectable WT rpsL
gene marker has been used before in S. pyogenes strains to select against
transformed recombinant shuttle vectors or single crossover integration events
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(McIver and Myles 2002), and similar methods have been applied to delete
pathogenicity islands from other bacteria (Rajakumar, Sasakawa et al. 1997).
In our approach, the cassette is inserted into a bacteriophage gene, allowing for
selection of bacteriophage presence and absence based on streptomycin
sensitivity and resistance, respectively. Using this method, which allowed for a
more precise manipulation of phage lysogeny, we have been able to create
mutants of the modern S. pyogenes strain SF370 that have been cured of some
or all of the integrated bacteriophage. In total we have created 15 different
mutants that encompass every permutation of SF370 phage knockout (KO):
single, double, and triple knockouts, as well as a mutant strain that is completely
cured of all bacteriophage elements (a loss of ~10% of the genome). To our
knowledge, this is the first time such mutants of S. pyogenes have been
successfully created.
These isogenic mutants were compared to SF370 for phenotypes that may affect
virulence and survival of S. pyogenes and were further characterized to
investigate bacteriophage-GrAS interactions at the molecular level. The derived
phage KO strains should be useful tools to study the dynamics of phage
lysogeny, to allow for a more thorough analysis of the role phage play both in
virulence and in the regulation of chromosomal genes, and to provide insight into
the evolution of streptococcal pathogenicity.
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8.2 METHODS
8.2.1 Bacterial strains and growth conditions.
S. pyogenes strain SF370 (an M1 serotype) was originally isolated from a wound
infection and kindly provided by J. Ferretti, University of Oklahoma Health
Sciences Center.  Unless otherwise stated, a spontaneous streptomycin-resistant
derivative of SF370 (discussed below) will be referred to as wild type or SF370
throughout these studies and all isogenic phage-KO mutants were derived from
this GrAS background (Table 8.1).  E. coli strain One Shot DH5α (Invitrogen) was
used as the host strain for plasmid construction and vector propagation.
E. coli was cultured in Luria-Bertani (LB) broth and on LB agar at 37°C.  S.
pyogenes strains were grown at 37°C in Brain Heart Infusion (BHI) broth or Todd
Hewitt broth + 0.5% Yeast Extract (THY) and on Proteose Peptone Blood Agar
(i.e. supplemented with 4% defibrinated sheep blood (Cleveland Scientific)) or
Colombia Blood Agar plates.   When required, media was supplemented with
antibiotics at the following concentrations: erythromycin at 200 µg/ml for E. coli
and 15 µg/ml for S. pyogenes; kanamycin at 50 µg/ml for E. coli and 250 µg/ml
for S. pyogenes; streptomycin at 200 µg/ml for S. pyogenes.  All antibiotics were
supplied by Sigma and all media was supplied by Difco (BD, Becton, Dickinson
and Company) unless stated otherwise.
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Table 8.1.  Bacterial strains for phage deletion mutants.
Streptococcus pyogenes
SF370 None Sensitive (1)
SF370ΔspeH speH ErmR This study
SF370SMR , SF370, WT None SmR This study
CEM1KRΔspeC speC (370.1 superantigen) KanR SMS This study
CEM1KRΔspeH speH (370.2 superantigen) KanR SMS This study
CEM1KRΔspd3 spd3  (370.3 DNase) KanR SMS This study
CEM1KRΔSPy2136 SPy2136 (370.4 primase) KanR SMS This study
Single phage KOs
CEM1Δ1 370.1 Kans SMR This study
CEM1Δ2 370.2 Kans SMR This study
CEM1Δ3 370.3 Kans SMR This study
CEM1Δ4 370.4 Kans SMR This study
CEM1KRΔ2-speC 370.2, speC KanR SMS This study
CEM1KRΔ1-spd3 370.1, spd3 KanR SMS This study
CEM1KRΔ1-SPy2136 370.1, SPy2136 KanR SMS This study
CEM1KRΔ2-spd3 370.2, spd3 KanR SMS This study
CEM1KRΔ2-Spy2136 370.2, SPy2136 KanR SMS This study
CEM1KRΔ4-spd3 370.4, spd3 KanR SMS This study
Double phage KOs
CEM1Δ1,2 370.1, 370.2 Kans SMR This study
CEM1Δ1,3 370.1, 370.3 Kans SMR This study
CEM1Δ1,4 370.1, 370.4 Kans SMR This study
CEM1Δ2,3 370.2, 370.3 Kans SMR This study
CEM1Δ2,4 370.2, 370.4 Kans SMR This study
CEM1Δ3,4 370.3, 370.4 Kans SMR This study
CEM1KRΔ1,2-spd3 370.1, 370.2, spd3 KanR SMS This study
CEM1KRΔ1,2-Spy2136 370.1, 370.2, SPy2136 KanR SMS This study
CEM1KRΔ1,4-spd3 370.1, 370.4, spd3 KanR SMS This study
CEM1KRΔ2,3-spd3 370.2, 370.4, spd3 KanR SMS This study
Triple phage KOs
CEM1Δ1,2,3 370.1, 370.2, 370.3 Kans SMR This study
CEM1Δ1,2,4 370.1, 370.2, 370.4 Kans SMR This study
CEM1Δ1,3,4 370.1, 370.3, 370.4 Kans SMR This study
CEM1Δ2,3,4 370.2, 370.3, 370.4 Kans SMR This study
CEM1KRΔ1,2,4-spd3 370.1, 370.2, 370.4, spd3 KanR SMS This study
Quadruple phage KO
CEM1ΔΦ 370.1, 370.2, 370.3, 370.4 Kans SMR This study
Re-Lysogenized strain
CEM1ΔΦC1 370.2, 370.3, 370.4 Kans SMR This study
Escherichia coli
One Shot DH5α Invitrogen
Straina
Antibiotic resistance 
phenotypeb
Refererence 
or sourcec
   a  SF370SmR is referred to throughout this study as wild type of SF370.  Phage number or 
gene to the right of the Δ symbol have been deleted; KR, contains counter-selection cassette 
((aacA-aphD)  / rpsL WT).                                                                                                                      
  b Abbreviations used:  ErmR, Erythromycin resistant; KanR, kanamycin-resistant; KanS , 
Kanamycin-sensitive; SmR, streptomycin-resistant; SmS, streptomycin-sensitive.
Bacteriophage and/or gene 
deleted
   c Source (1); (Ferretti, McShan et al. 2001). 
Used for cloning and propagation of the counter-
selection vectors 
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8.2.2 DNA manipulations.
Streptococcal genomic DNA was isolated with either the DNeasy Tissue Kit or
the Blood & Cell Culture DNA Kit (Qiagen) following the manufacturerʼs
protocols, except for the substitution of a modified lysis buffer (50 mM Tris-Cl pH
6.6, 50 mM EDTA, 0.5% Tween-20, 0.5% TritonX-100) supplemented with 500U
of plyC, a streptococcal bacteriophage lysin (Nelson, Schuch et al. 2006) and
250 ng/ml of RNase A (Qiagen).  Plasmid DNA was isolated from E.coli using the
QIAprep Spin Miniprep Kit or HiSpeed Plasmid Midi Kit (Qiagen).  DNA
fragments were gel purified from 1% Agarose gels using the QIAquick Gel
Extraction Kit (Qiagen).  T4 DNA ligase and all restriction enzymes were
purchased from New England Biolabs and used according to the manufacturerʼs
instructions, unless otherwise stated.  Oligonucleotides were obtained from
Fisher Scientific-Operon.  PCR was performed using AmpliTaq Gold DNA
polymerase, Gold Buffer, 1.5 mM MgCl2, and 200 µM dNTPS (Applied
Biosystems) following standard protocols with the Eppendorf Mastercycler.  DNA
sequencing was performed by GENEWIZ, Inc. (North Brunswick, NJ).  DNA and
RNA sequence analysis, comparison, and manipulation required Lasergene
software modules (DNASTAR Inc.).  DNA primers were designed with MacVector
software (Accelrys Inc.).
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8.2.3 PFGE molecular analysis.
Agarose discs of genomic DNA from WT and mutant isolates (Table 8.1) were
prepared according to a protocol modified from Chung et al. (Chung, de
Lencastre et al. 2000), in which 500U of PlyC was substituted for lysozyme and
lysostaphin enzymes in the cell lysis solution (Chung, de Lencastre et al. 2000;
Nelson, Schuch et al. 2006).  DNA was digested with SmaI overnight at 25°C and
subjected to PFGE with the CHEF-DR II system (Bio-Rad) as previously
described (Chung, de Lencastre et al. 2000; Euler, Ryan et al. 2007).  DNA
bands were visualized by staining the gel with ethidium bromide and the images
captured by an Alpha imager (Alpha Innotech Corp.).  DNA banding patterns
were analyzed by previously described methods (Tenover, Arbeit et al. 1995;
Chung, de Lencastre et al. 2000).
8.2.4 Allelic replacement of the speH gene in SF370.
The strategy for allelic replacement of speH gene was followed as previously
described (Euler, Ryan et al. 2007).  Briefly, upstream and downstream DNA
regions flanking speH (662 bp upstream and 888 bp downstream) were
separately amplified using the primer sets listed in (Ryan, Kirk et al. 2007). PCR
products were treated with the appropriate restriction enzymes, according to
manufacturer instructions. Fragments were gel purified and the respective
upstream and downstream regions of speH were sequentially ligated into the
allelic replacement vector pFW15 (Podbielski, Spellerberg et al. 1996), creating
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plasmid pFWΔspeH.   To construct deletion mutants of the speH gene the vector
was electroporated into S. pyogenes SF370 following the transformation protocol
of Kimoto et al. (Kimoto and Taketo 2003).  Transformants were selected on
proteose peptone blood agar supplemented with erythromycin.  Allelic
replacement was confirmed by both PCR and RT-PCR analyses of total RNA
extracted (as described above) from both mid-logarithmic (A600 0.4) and
stationary phase (A600 1.0) bacterial cultures using gene specific primers.  Total
RNA from strain SF370 served as control. The resulting strain, SF370ΔspeH,
lacked the speH gene (Table 8.1).
8.2.5 Isolation of SF370 with a genomic mutation conferring streptomycin
resistance.
Spontaneous streptomycin-resistant mutants were selected for by serial passage
of strain SF370 in brain heart infusion broth (BHI) containing increasing
concentrations of the antibiotic (0 – 200 µg/ml). A streptomycin resistant (SmR)
colony was picked from proteose peptone agar containing 200 µg/ml
streptomycin and 4% defibrinated sheep blood.  Genomic DNA isolated from this
mutant served as a template for the PCR amplification of the rpsL gene, in which
the amplicon was subsequently purified from a 1% agarose gel using the
QIAquick Gel Extraction Kit (Qiagen) and then sequenced.  The nucleotide
sequences of the mutant rpsL gene were compared to the published rpsL
sequences from both the Wild type SF370 genome and from other types of SmR
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bacteria, in order to confirm that a mutation in the rpsL gene caused the SmR
phenotype (Funatsu and Wittmann 1972; Finken, Kirschner et al. 1993; Ferretti,
McShan et al. 2001; Martin-Galiano and de la Campa 2003).  The resulting SmR
strain was used in all subsequent bacteriophage deletion experiments and is
referred to as wild type or SF370 in these studies.
8.2.6 Construction of bacteriophage counter-selection vector, pFWKR.
To generate the counter-selection vector pFWKR, the pFW13 streptococcal
shuttle vector, which contains an E. coli origin of replication (ori) and a
kanamycin resistance gene (aacA-aphD) flanked by two multiple cloning sites
(MCSI and MCSII) (Podbielski, Zarges et al. 1996) was modified to include a WT
streptococcal rpsL gene between the kanamycin gene and the MCSII. To
accomplish this modification, a 676 bp fragment containing both the WT rpsL
gene and its upstream promoter region was PCR amplified from SF370 genomic
using the following primers: rpsLF1; 5ʼ-
AGGTTCCACCAGGTATCTAAGTGATGCATTC-3ʼ, and rpsLR1; 5ʼ-
TTACGACTCATGAGCTCTTATCCCCCTTCTA-3ʼ.  The amplicon was digested
with restriction enzymes MabI (SibEnzyme) and EcoICRI (Promega), and the
pFW13 plasmid was digested with enzymes MabI and SwaI.  After gel
purification of both digestion reactions, the amplicon was ligated into the plasmid.
The recombinant vector was transformed into E. coli cells, and transformants
were selected on LB agar containing kanamycin.  Plasmid DNA was isolated
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from the kanamycin resistant transformants and sequenced to verify proper
insertion of the WT rpsL gene into the vector.  This plasmid (pFWKR) was used
as the backbone to make the rest of the phage counter-selection vectors.
8.2.7 Counter-selection Step 1.  Allelic replacement of the speH gene
using pFWKR-speH.
The strategy for the allelic replacement of the speH gene (encoded by Φ370.2)
essentially followed the protocol described above and by Ryan et al. (Ryan, Kirk
et al. 2007), which was used to replace the speH gene in SF370. In these
experiments, however, the genomic speH gene was replaced with the ((aacA-
aphD) / rpsLWT) cassette contained in the pFWKR-speH vector.  Briefly, the DNA
regions flanking speH were separately PCR amplified from the genomic DNA of
strain SF370  (662 bp upstream and 888 bp downstream) using the two primer
sets described by Ryan et al. (Ryan, Kirk et al. 2007).  The amplicons and
pFWKR vector were digested with the corresponding restriction enzymes, gel
purified, and the individual upstream and downstream fragments were cloned
into the MCSI and MCSII, respectively.  The resulting plasmid DNA was PCR
amplified and sequenced to confirm the creation of the pFWKR-speH vector.
The pFWKR-speH vector was then electroporated into the SF370 strain following
the protocol of Kimoto and Taketo (Kimoto and Taketo 2003), and transformants
were selected on proteose peptone blood agar containing kanamycin.  Next,
kanamycin (KanR) resistant colonies were transferred to PPB agar containing
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kanamycin (250 µg/ml) and streptomycin (200 µg/ml) to verify streptomycin
sensitivity, which was conferred by the presence of the WT rpsL gene in the
replacement cassette.  (KanR / SmS) mutants were then screened by PCR and
Southern blot analyses for the proper allelic replacement of the speH gene with
the ((aacA-aphD) / (rpsL WT) cassette.  The resulting mutant strain
CEM1KRΔspeH was then used to screen for the loss of the entire Φ370.2
bacteriophage (Table 8.1).
8.2.8 Counter-Selection Step 2.  Selection for the loss of the Φ370.2 phage
from CEM1KRΔspeH.
To allow the bacteria to cure itself of the Φ370.2 phage, strain CEM1KRΔspeH
was inoculated into antibiotic free BHI and grown overnight at 37°C.  The
overnight culture was then streaked onto PPB agar containing streptomycin (200
µg/ml), and incubated overnight at 37°C to select for colonies that had lost the
counter-selection cassette.  As a confirmation, SmR colonies were replica plated
to proteose peptone blood agar containing kanamycin to identify mutants that
had also become KanS due to the loss of the (aacA-aphD) kanamycin resistance
gene of the counter-selection cassette, which further indicated potential loss of
bacteriophage.  (SmR / KanS) mutants identified in this screen were then verified
for the complete loss of the Φ370.2 phage by PCR (using primer sets that span
the bacteriophage attachment sites), Southern blot hybridization analysis (with
Φ370.2 specific gene probes), DNA sequence analysis, and PFGE analysis.  The
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resulting mutant strain, CEM1Δ2, no longer contained the integrated Φ370.2
DNA in the streptococcal chromosome (Table 8.1).
8.2.9 Selection for the loss of the remaining bacteriophage from SF370.
Unless otherwise stated in the results, the counter-selection and loss of the other
three integrated bacteriophage elements from the genome of the SF370 strain
was selected for and screened by following the two-step protocol described
above for the deletion of the Φ370.2 bacteriophage. The ((aacA-aphD) / (rpsL WT)
cassette was targeted to replace putative virulence factor genes in each of the
remaining phage.  Adjacent DNA regions (600 bp  – 800 bp) from each prophage
were PCR amplified and individually inserted into the either side (MCSI and
MCSII) of the counter-selection cassette on plasmid pFWKanR. The resulting
vectors were individually transformed into SF370, CEM1Δ2, and each
subsequent bacteriophage deletion mutant, to insert the counter-selection
cassette into the respective bacteriophage.  These KanR/ SmS recombinant
mutants were grown without antibiotics, then were plated to streptomycin plates
to select for loss of the associated bacteriophage (SmR / KanS phenotype).  As
described above loss of each phage was confirmed by PCR (using primer sets
that span the bacteriophage attachment sites), Southern blot hybridization
analysis (with phage specific gene probes, e.g. integrases and virulence factor
genes), DNA sequence analysis, and PFGE analysis.  In the multiple phage
deletion mutants, the experimental order of phage counter-selection and phage
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loss always followed: Φ370.2, Φ370.1, Φ370.4, Φand 370.3, first to last
respectively.  This process was repeated until every permutation of phage loss
(15 in all) was obtained, including a strain that was devoid of all major
bacteriophage-like DNA sequences named CEM1ΔΦ (Table 8.1).
8.2.10 In vitro pharyngeal cell adherence and internalization assays.
Assays on streptococcal adherence and internalization with human pharyngeal
cell line Detroit 562 (D562) were performed as described previously (Ryan,
Pancholi et al. 2001), with the modifications described in (Ryan, Kirk et al. 2007).
Briefly streptococcal stock cultures (of both wild type and mutant strains) were
pre-incubated at 37 °C for thirty minutes in minimal essential media (MEM)
without serum.  Aliquots of streptococcal stock cultures (1 ml containing 1 x107
CFUs) were added in triplicate to confluent monolayers of D562 cells grown in
twenty-four well tissue culture plates (1 x105 D562 cells / well for an M.O.I. of
100).  Co-cultures were incubated for 2.5 hours at 37 °C plus 5% CO2 and then
monolayers were washed three times with PBS (1 ml/well/wash) to remove
associated (non-adherent) streptococci.
Internalization assay wells were treated with 1ml of MEM containing 100 µg/ml
penicillin and 600 µg/ml of gentamicin. Aliquots of MEM without antibiotics were
added to wells used to assay adherent bacteria.  Plates were incubated for one
hour at 37°C to allow sufficient time for the antibiotics in the internalization wells
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to kill any non-internalized bacteria.  Wells were then treated with 100 µl of
0.25% trysin-0.02% EDTA for 15 min at 37 °C to desorb the eukaryotic
monolayer and streptococci from the tissue culture wells.  Next 400 ul of 0.025%
Triton X-100, containing 100 units of Benzonase Nuclease (Novagen), in PBS at
4 °C was added to the wells and incubated at room temperature for five minutes
to lyse the pharyngeal cells and release adherent and internalized bacteria.
Aliquots of the cell suspensions were then serially diluted and plated to Colombia
blood agar plates.  Plates were incubated at 37°C plus 5% CO2 overnight and
streptococcal colonies enumerated the next day.
The number of adherent streptococcal cells was calculated as the difference
between the average number of colony forming units (CFU) from the adherence
assay wells and the average number of CFU from the internalization assay wells.
For each comparison the results from three independent experiments were
tabulated and then averaged for each isolate.  Both data sets were expressed as
the percentage of cells from the bacterial inoculum that adhered to the
pharyngeal cells or were internalized by the pharyngeal cells.
8.2.11 Comparison of DNase activity in bacteriophage cured strains.
Overnight cultures of SF370 and phage cured mutants were streaked onto
DNase Test Agar with Methyl Green (Difco).  After overnight incubation at 37°C,
the size of clearing zones surrounding colonies (which indicated DNase activity
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on the DNA-methyl green substrate in the agar) were compared for qualitative
DNAse activity of each strain.
8.2.12 RNA isolation for RT-PCR.
S. pyogenes strain SF370 and the Φ370.1 phage knockout mutant (CEM1Δ1)
were grown to early log-phase (A 600 0.25), mid-log phase (A600 0.5) and late log-
phase (A600 0.7) in Brain Heart Infusion broth as described above. Recovered
streptococci were washed three times in PBS.  PlyC lysin was added to the
bacterial samples (2U / 1x108 CFU) and incubated for 15 min at room
temperature, which preliminary experiments indicated to be optimum for
complete streptococcal lysis (Nelson, Schuch et al. 2006). Total RNA was
isolated immediately after lysis using the PureLink Total RNA Purification System
(Invitrogen). RNA was digested with TURBO™ DNase I (Ambion Applied
Biosystems) following the manufacturerʼs instructions and quantitated using the
Nanodrop UV-Vis Spectrophotometer (Thermo Fisher Scientific).
8.2.13 RT-PCR of pepD RNA transcript.
Forward (F) and reverse (R) primers to amplify the pepD transcript from the
genomes of SF370 (PepD-SF370-F and -R) and CEM1Δ1 phage knockout
mutant (PepD-KO-F and –R) were constructed. Four different forward primers
(PepD-KO-F1, 2, 3 and 4) were constructed for the Φ370.1 knock-out mutant, to
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represent the primer associated with the ATG start codon (F1) as well as three
additional primers (F2, F3 and F4) to amplify the RNA transcript beginning at
three different sites upstream of the start codon. The primer sequences are as
follows: PepD-S370-F (5ʼ-ATGGATAAAAAAATACAGCG-3ʼ) and PepD-SF370-R
(5ʼ-AAACGATTGGTCATTAGATT); PepD-KO-F1 (5ʼ-
ATGGCATGTACAACTATACTC-3ʼ); PepD-KO-F2 (5ʼ-
GACTGATAATGGCATGTAC-3ʼ) PepD-KO-F3 (5ʼ-
GACTGATAATGGCATGTACAAC-3ʼ); PepD-KO-F4 (5ʼ-
TAACGTTTGTAAAGGAGACTG-3ʼ); PepD-KO-R (5ʼ-
AAACGATTGGTCATTAGATT-3ʼ). The generation of amplicons by RT-PCR was
performed with the SuperScript III One-Step RT-PCR system with Platinum Taq
DNA polymerase (Invitrogen) in reaction mixtures (50 µl) containing 0.2 µM of
each gene specific forward and reverse primer and 0.5 µg of DNase-treated,
purified total RNA. All remaining components were added as per manufacturer
specifications. We included control reactions, in which Taq DNA polymerase was
substituted for the reverse transcription enzyme mixture, to confirm that genomic
DNA was not present in the RNA preparations. RNA was converted to cDNA (48-
50°C depending on the primer set, for 30 min), which was then PCR amplified in
the same tube (45 cycles of the following conditions: 94°C for 15 sec, 52°C for 30
sec, and 68°C for 2 min).  Resulting DNA fragments were separated on 1%
agarose gels in TAE buffer and visualized by ethidium bromide staining.
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8.2.14 Responses of CEM1Δ4 and SF370 to UV light irradiation.
Bacteria with defects in RuvA have increased sensitivity to UV irradiation
(Iwasaki, Shiba et al. 1989).  To assess such increased sensitivity in the Φ370.4
KO mutant, CEM1Δ4, both this mutant and strain SF370 were grown overnight in
THY broth at 37° C.  After dilution in fresh THY to an A600 0.05, cells were
harvested at mid-logarithmic phase (A600 0.3-0.4) and stationary phase (A600 >
0.6). The latter time point coincides with the integrative state of the Φ370.4
prophage (Scott, Thompson-Mayberry et al. 2008).  The cells were harvested by
centrifugation (6,000 x g, 5 minutes) and resuspended in sterile 0.1 M MgSO4 to
a final absorbance of 0.5 at 600 nm.  A calibrated 254 nm germicidal lamp (120
µW/cm2) was pre-warmed for 30 minutes prior to strain exposure.  For each
strain, 10-fold serial dilutions of each were made in 0.1 M MgSO4 and 2 µl of
each dilution was spotted in multiple columns to proteose peptone agar.  Since a
homolog of photolyase is present in the S. pyogenes genome, the UV irradiation
was carried out in a darkened room.  Cell dilutions were exposed to UV light for
increasing periods of time (30, 60, 90, or 120 seconds), and then the plate was
incubated in the dark at 37° C for 24 hours.  Comparisons between SF370 and
the CEM1Δ4 mutant were based on the highest dilutions of each strain that
contained multiple surviving CFUs.
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8.2.15 Sensitivity of CEM1Δ4 and SF370 to Ethidium Bromide Killing.
Strains were grown overnight in THY broth at 37°C.  After dilution in fresh THY to
an A600 0.05, cells were grown to early-logarithmic phase (A600 0.15-0.2), mid-
logarithmic phase (A600 0.3), or stationary phase (A600 > 0.6) to account for the
different integrative states of the Φ370.4 prophage (Scott, Thompson-Mayberry
et al. 2008).  Cultures were then divided and ethidium bromide (EtBr) added in
increasing final concentrations (0µM, 1.25µM, 2.5µM, 5.0µM, 7.5µM, 10µM and
20µM).  Bacteria were incubated overnight at 37°C then plated to proteose
peptone blood agar plates to enumerate surviving CFUs from each growth phase
and EtBr concentration.  Results were tabulated as the average of three
independent experiments and were expressed as the percentage of CFU that
survived treatment compared to the control without EtBr.
8.2.16 Mitomycin C induction of prophage.
Mitomycin C induction of prophage was performed by using a modification from
McShan et al. (McShan, Tang et al. 1997).  Briefly, a single colony of SF370
(SmS) or CEM1ΔΦ was picked from proteose peptone plates supplemented with
5% sheep blood and used to inoculate a 10 ml aliquot of BHI, which was
subsequently incubated overnight at 37°C.  The overnight culture was diluted
1:30 (v/v) into 100 ml of pre-warmed BHI at 37°C, and the culture was incubated
at 37°C until early logarithmic growth (A600 0.2).  This culture was divided into two
50-ml cultures, and one cultures received mitomycin C (Sigma) at a final
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concentration of 0.2 µg/ml.  The cultures were incubated at 37°C and after two
hours the absorbance readings for the mitomycin C induced culture of SF370
began to drop (this effect was absent in the non-induced cultures and the
mitomycin C treated CEM1ΔΦ culture).  Cells were pelleted by centrifugation at
4,000 rpm for 10 min at 4°C.  Supernatants were collected and filtered twice
through 0.22 µm filters.  Filtrates (15 mls x 2) were applied separately to two
50,000 MWCO Amicon Ultra-15 centrifugal filter devices (Millipore), which were
spun at 4,000 rpm at 25°C for 45 minutes to achieve a final volume of 500 µl in
each concentrator.  Next, 10 mls of prophage suspension buffer (0.15 M NaCl,
10 mM Tris HCl [pH 7.5], 5 mM MgCl2, 1 mM CaCl2) described in (Vlaminckx,
Schuren et al. 2007), was added to the concentrators, which were then
centrifuged at 4,000 rpm at 25°C for 45 minutes to again achieve a final volume
of 500 µl in the concentrator.  The concentrated supernatants were stored at 4°C
until further use.
8.2.17 Analysis of bacteriophage plaques and selection for lysogens.
As potential indicator strains, SF370, CEM1ΔΦ, and the single phage KO
mutants from (Table 8.1) were grown overnight at 37°C in BHI containing 200
µg/ml of streptomycin.  Aliquots (100 ul) of the overnight cultures were added to 3
ml of melted BHI soft agar (7.5%) at 50°C, mixed, and poured on top of proteose
peptone agar plates.  Plates were allowed to dry and then 10 µl serial dilutions (in
prophage suspension buffer) of the concentrated mitomycin C supernatants
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(described above) were spotted onto the plates.  As a control for bacterial
contamination, supernatants were also spotted to proteose peptone agar plates
alone.  After allowing sufficient time for the spots to dry, the plates were
incubated overnight at 37°C plus 5% CO2.  The following day, the plates were
analyzed for growth inhibition or bacteriophage plaques in the location of the
spots and any bacterial growth in the spots from the non-overlaid plates.  If
plaques or growth inhibition was observed, colonies in or around the edge of
these areas were picked and streaked for single colonies on proteose peptone
blood agar plates containing 200 µg of streptomycin to inhibit potential
contaminating bacteria.  After overnight incubation at 37°C plus 5% CO2,
streptomycin resistant colonies were screened for potential lysogeny by PCR
analysis using primers specific for bacteriophage genes from each of the four
prophage of SF370.  Colonies that were positive by this initial PCR screen for
phage genes were further screened by PCR with primers specific for phage
attachment sites to ascertain proper phage integration.  Potential lysogen
genomic DNA was subjected to PFGE analysis as described above.
8.3 RESULTS
8.3.1 Effect of SpeH on GrAS interactions with pharyngeal cells.
While analyzing the global transcriptional response of S. pyogenes strain SF370
during in vitro adherence to Detroit 562 human pharyngeal epithelial cells, we
found eleven prophage genes that were differentially expressed with significance
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during adherence as compared to non-adherent (associated) bacteria (Ryan, Kirk
et al. 2007).  These eleven genes were localized to the defective bacteriophage
Φ370.2, suggesting that this defective phage is not transcriptionally silent
(Ferretti, McShan et al. 2001; Ryan, Kirk et al. 2007).  One of the phage genes,
speH, was induced, while the remaining ten phages genes (located in the phage
replication and regulation modules) were down-regulated during cell adherence.
The speH gene encodes a functional superantigen (Proft, Moffatt et al. 1999)
reportedly induced in other strains of GrAS during polymorphonuclear leukocyte
phagocytosis (Voyich, Sturdevant et al. 2003) but has not been implicated
previously in adherence.
To determine if SpeH plays a direct role in the initial events of GrAS colonization,
a deletion mutant (SF370ΔspeH) was created by replacing the speH gene in
SF370 with an erythromycin resistance gene (ermAM). The absence of SpeH
was confirmed by PCR (not shown) and RT-PCR (Figure 8.1).  The ability of
SF370ΔspeH to adhere to and be internalized by human pharyngeal cells was
tested in a number of in vitro co-culture assay experiments (Ryan, Kirk et al.
2007).  There was no significant difference in adherence or internalization
between the wild type (SF370) and SF370ΔspeH (Figure 8.1).
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Figure 8.1. Confirmation of speH deletion mutant and pharyngeal cell adherence
and internalization assays.
(A) Results of RT-PCR and PCR analyses of total RNA preparations isolated
from mid-log (A600 0.4) and stationary phase (A600 1.0) cultures of the ΔspeH
deletion mutant (ΔL and ΔS, respectively), and stationary phase cultures of the
SF370 parental strain (P).  RNA was reverse-transcribed as described in
Methods.  To assess genomic DNA contamination, control reactions containing
Taq DNA polymerase instead of reverse transcriptase were included.  The cDNA
products were separated on a 1% agarose gel and visualized by ethidium
bromide staining.  Lanes containing products from either the RT-PCR or PCR
analysis are designated at the bottom of the panel.  Lanes labeled MW contain 1
kb Plus DNA ladder (Invitrogen).  (B) Results of the pharyngeal cell adherence
and, (C) internalization assays (detailed in Methods), comparing parental strain
SF370 with the deletion mutant SF370ΔspeH (abbreviated ΔspeH).  Adherent
and internalized streptococci are reported as the percentage of total number of
streptococci added as inoculum to pharyngeal cell monolayers.  Statistical
significance (reported as p value) was determined by Student's t-test.
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8.3.2 Loss of the Φ370.2 bacteriophage from SF370.
The Φ370.2 phage encodes three virulence factors, a hyaluronidase (hlyP1) and
two superantigen genes speH and speI.  The phage is integrated into the 3ʼ end
of a dTDP-glucose-4,6-dyhydrase leaving the gene intact.  As a proof of principle
for our phage counter-selection technique, we first chose to eliminate the Φ370.2
prophage sequence from the SF370 genome to assess the role of speH and the
other ten Φ370.2 genes differentially expressed during GrAS adherence to
pharyngeal cells (Ryan, Kirk et al. 2007).  Our first step was to isolate a mutant
strain of SF370 that had become spontaneously resistant to streptomycin.  DNA
sequence analysis of the rpsL region in the genome of this mutant showed a
single point mutation in the rpsL gene (lysine 56 to arginine (K56R)), which was
consistent with other rpsL mutations that confer streptomycin resistance in
different bacteria species (Funatsu and Wittmann 1972; Finken, Kirschner et al.
1993; Martin-Galiano and de la Campa 2003).  This streptomycin resistant
mutant was transformed with the counter-selection vector, pFWKR-speH, to
replace the speH gene and create mutant CEM1KRΔspeH (Table 8.1).   This
mutant was then passed in media without antibiotics and plated on streptomycin
agar plates to select for a recombinational event that resulted in the loss of the
Φ370.2 prophage.  Confirmation of the entire Φ370.2 DNA loss and absence of
gross chromosomal alterations were confirmed by sequencing PCR products
generated across the attB phage integration site and PFGE analysis (Figure 8.2).
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Figure 8.2.  Pulse field gel electrophoresis (PFGE) analysis of S. pyogenes
SF370 phage deletion mutants.
PFGE patterns of SmaI digested genomic DNA from the wild type (WT) SF370
strain and fifteen different permutations of phage deletion mutants are shown.
The DNA bands representing each individual (intact) phage genome in SF370
are indicated in red on the left side of the figure. The lanes corresponding to each
phage deletion mutant is indicated at the top of the figure. The specific phages
deleted in each mutant are indicated with numbers (1-4), which corresponding to
the individual phages in SF370 (Φ370.1-4).  The absence or change in size of a
phage genome band represents a phage deletion.   The asterisks (*) indicate
incorrect phage banding patterns, which were found to be correct on additional
PFGE gels (data not shown).  λ, indicates the Lambda Ladder PFG Marker, and
DNA fragment sizes are indicated in the right column (New England Biolabs).
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The resulting mutant strain, CEM1Δ2 (Table 8.1), lacked the integrated Φ370.2
DNA and recapitulated the attB bacterial attachment site seen in the genome
sequence of the modern M1 S. pyogenes strain, MGAS5005, which does not
contain bacteriophage integrated into the homologous genome location (Data not
shown) (Sumby, Porcella et al. 2005).  Gross colony morphology and growth
curve comparisons of CEM1Δ2 versus SF370 showed no difference in colony
morphology or growth rate between the phage deletion mutant and the wild type
strain (data not shown and Figure 8.3).
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Figure 8.3.  Growth curve comparisons of two different cultures of the wild type
SF370 and the Φ370.2 phage deletion mutant (370.2 KO).
Overnight cultures were diluted 1:50 in 10 ml of pre-warmed BHI and incubated
at 37°C.  Culture absorbance (A600) was measured at varying time points using a
spectronic 20D spectrophotometer (Thermo Electron Corporation) and the results
were plotted.
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8.3.3 Analysis of Φ370.2 in GrAS interactions with pharyngeal cells.
To assess the role of the Φ370.2 genes products, including the 10 ORFs on
Φ370.2 previously identified as down regulated during streptococcal adherence
to human pharyngeal cells (Ryan, Kirk et al. 2007), CEM1Δ2 was compared to
SF370 in an in vitro co-culture assay described above.  As shown in (Figure 8.4),
the lack of the Φ370.2 genome in CEM1Δ2 had no significant effect on either
GrAS adherence to, or subsequent internalization by, pharyngeal epithelial cells.
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Figure 8.4.  Pharyngeal cell adherence and internalization assays with Φ370.2
KO mutant (CEM1Δ2).
(A) Results of the pharyngeal cell adherence and (B) internalization assays
(detailed in Methods), comparing parental strain SF370 with the Φ370.2 KO
phage deletion mutant (CEM1Δ2). Adherent and internalized streptococci are
reported as the percentage of total number of streptococci added as inoculum to
pharyngeal cell monolayers.  Statistical significance (reported as p value) was
determined by Student's t-test.
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8.3.4 Loss of the Φ370.1 bacteriophage from SF370.
The mitomycin C inducible prophage Φ370.1 encodes three putative virulence
factors, a hyaluronidase gene (hlp1) and a two-gene cassette containing the
speC superantigen gene and the spd1 DNase gene.  To select for loss of the
Φ370.1 phage, the speC gene was replaced with the counter-selection cassette
to create mutant PFWKRΔspeC.  This mutant was passaged in BHI media and
plated to streptomycin agar plates.  SmR/ KanS colonies were screened as above
and PFGE analysis confirmed that Φ370.1 was lost and that there were no
aberrant recombination events for the mutant CEM1KRΔ1 (Figure 8.2 and Table
8.1).  Using this procedure Φ370.1 was also cured from CEM1KRΔ2 to make the
Φ370.1and Φ370.2 double phage deletion mutant CEM1KRΔ1,2 (Figure 8.2 and
Table 8.1).
8.3.5 Expression of the peptidase gene, pepD, from an alternate
bacteriophage promoter.
Prophage Φ370.1 is integrated into the 5ʼ end of the dipeptidase gene (pepD)
replacing the first nine N-terminal amino acids and the upstream promoter
sequence with bacteriophage-specific DNA (Figure 8.5) (Canchaya, Desiere et
al. 2002).  This suggests that Φ370.1 integration may affect the expression of the
pepD gene or overall activity of the peptidase.  In a preliminary analysis, RT-PCR
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was used to screen the expression profiles of pepD during growth of the SF370
wild type (WT) strain and the Φ370.1 deleted mutant, CEM1Δ1.  Using primers
specific for either the WT type pepD transcript or the phage KO pepD, each was
individually tested for expression from their respective cDNA during early-log,
mid-log, and late-log phases of growth.  As shown in (Figure 8.5) pepD is
expressed during all growth phases in both the SF370 and CEM1Δ1, suggesting
that the Φ370.1 specific DNA sequences in the SF370 wild type strain also
contain a functional promoter sequence for pepD.  To further explore the
dynamics of Φ370.1 integration, excision, and pepD expression, we performed
RT-PCR on the cDNA of the SF370 wild type strain using primers specific for the
upstream region of pepD when the Φ370.1 phage is deleted or excised.  Results
showed that both transcripts of pepD (when phage Φ370.1 is integrated in the
genome and when it is excised) are expressed in SF370 during all phases of
growth in (Figure 8.5).  This suggests that Φ370.1 is excising from the genome in
a certain population of SF370 cells throughout the bacterial growth cycle.
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Figure 8.5.  RT-PCR analysis of the pepD transcript in SF370 and phage knock-out
mutant.
Panels (A) and (B) are schematic representations of the pepD genomic region in SF370
and the phage knock-out mutant, respectively. Putative promoter regions (-35 and -10
sites) are designated and the putative transcriptional start site is labeled in large, bold
purple font. Both regions were predicted by programs available for prokaryotic genomes
on the Berkeley Drosophila Genome Project website (www.fruitfly.org). The predicted
Shine-Delgarno ribosomal binding site (RBS) was determined as described previously
(Ryan, Kirk et al., 2007). Start codons (ATG) are appropriately labeled. The translated
amino acids are listed below the sequence. The red block arrow shows the region
encoded on bacteriophage Φ370.1 and the blue rectangle shows the ORF of the pepD
gene in both genomes. Positions of the Forward (5ʼ) primers for RT-PCR are indicated
by arrows above nucleotide sequences.
Panel (C) shows the results of RT-PCR analysis on mRNA from WT SF370 (S) and the
full-phage knock out mutant (Δ). mRNA was isolated from early-log phase (Early), mid-
log phase (Mid) or late-log phase (Late) cells (indicated above panel) and reverse
transcribed with various primer combinations, which are indicated below the panel as
primer sets 1, 2, 3 and 4. Primer set 1 (PepD-SF370-F and -R) was used to amplify
SF370 RNA from all growth stages. Primer set 2 (PepD-KO-F1 and PepD-KO-R), set 3
(PepD-KO-F3 and PepD-KO-R) and set 4 (PepD-KO-F4and PepD-KO-R) were used to
amplify RNA from the knock-out mutant at different sites along the transcript. The 5ʼ
forward primer was different in each such primer set, while the 3ʼ reverse primer
remained the same. Primer sequences are listed in Methods. cDNA products were
separated on a 1% agarose gel and visualized by ethidium bromide staining. The
expected sizes of resulting cDNAs from SF370 using primer set 1 is 1403 bp, primer set
2 is 1382 bp, primer set 3 is 1390 bp, and primer set 4 is 1406 bp. Control reactions (C)
containing mRNA and Taq DNA polymerase instead of reverse transcriptase are
indicated.  Additional controls (NT) containing primers alone with no template are
indicated. Lane M contains 1-kb Plus DNA ladder (1 µg, Invitrogen).
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8.3.6 Loss of the Φ370.4 bacteriophage from SF370.
Prophage Φ370.4 is integrated between the mutS gene and the 5ʼ region of the
mutL gene in a methyl-directed mismatch repair (MMR) operon that includes
several other DNA repair genes.  The dynamic nature of prophage Φ370.4
excision, replication, and reintegration in response to growth was previously
described by Scott et al. (Figure 8.6) (Scott, Thompson-Mayberry et al. 2008).
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Figure 8.6.  Prophage regulation of the MMR operon in GAS.
Integration of prophage SF370.4 separates mutL, lmrP, ruvA, and tag from the
promoter, which is upstream of mutS, and prevents expression of these genes.
Loss of mutL inactivates MMR, allowing mutations to accumulate, resulting in a
mutator phenotype.  Loss of ruvA expression leaves cells unable to repair DNA
damage from shortwave UV light, increasing cell sensitivity to UV irradiation.
Phage excision from the host chromosome restores transcription of the
polycistronic message from mutS to tag.  The excised phage circularizes and
replicates in host cell as an episome.  Prophage Φ370.4 is defective and does
not contain genes for phage particle production or cell lysis. Abbreviations: mutS
and mutL = DNA mismatch repair proteins, lmrP = multidrug resistance
transporter, tag = base excision repair glycosylase, ruvA = Holliday Junction DNA
helicase. Figure was designed by Michael McShan, and reproduced with
permission.
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By applying our counter-selection method we hoped to cure SF370 of prophage
Φ370.4 to better measure the phenotypes under the dynamic control of this
phage.   Since the Φ370.4 does not encode a putative virulence factor, we chose
to insert the counter-selection cassette in place of the phage primase gene
(Spy2136) to create the CEM1KRΔSpy2136 mutant (Table 8.1).  Deletion of the
primase gene was thought to interfere with replication of the excised circular form
of Φ370.4, potentially promoting loss of the phage during cell division.  When this
mutant was grown without antibiotics overnight and plated to proteose peptone
blood agar containing streptomycin (to select for isolates that had lost the Φ370.4
prophage) all of the resistant colonies that grew (> 500 CFU) were SmR/ KanR,
suggesting a rate of recombination or mutation in the rpsL WT that was
signifigantly higher than the loss of the Φ370.4 prophage (Sung, Li et al. 2001).
To further increase the odds of isolating a cured mutant, CEM1KRΔSpy2136 was
plated directly to streptomycin plates from antibiotic free cultures at multiple times
during early exponential growth (A600 of 0.1, 0.2, 0.3, 0.4) since this when Φ370.4
was shown to excise from the chromosome (Scott, Thompson-Mayberry et al.
2008).  All the resulting streptomycin resistant colonies screened (>1000 CFU)
were also SmR/ KanR.  This confirmed previous results (using recombinational
and conventional methods) that Φ370.4 was difficult to cure from SF370
(McShan, Personal communication).  Curing of 370.4 was finally achieved by
growing CEM1KRΔSpy2136 in BHI overnight at an increased temperature of
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42°C and plating to streptomycin plates, following an adapted protocol from
(Verheust, Fornelos et al. 2005).  Of the 650 streptomycin resistant colonies
screened, 13 were SmR/ KanS and all were confirmed to have lost Φ370.4 by
PCR, Southern blot, and PFGE analysis with one mutant designated as CEM1Δ4
(Table 8.1 and Figure 8.2).  Of note Φ370.4 was cured much easier from the
CEM1Δ1, CEM1Δ2, and CEM1Δ1,2 mutants using the normal counter-selection
protocol above with growth conditions at 37°C to produce the double and triple
phage cured mutants listed in (Table 8.1).
8.3.7 Sensitivity to UV irradiation is associated with phage 370.4.
The operon containing mutS and mutL is also predicted to contain the
downstream gene ruvA (Figure 8.6).  Transcription of this gene would also be
interrupted by the presence of Φ370.4, resulting in increased sensitivity to killing
by UV irradiation (Iwasaki, Shiba et al. 1989; Scott, Thompson-Mayberry et al.
2008).  As shown in (Figure 8.7), the SF370 wild-type strain displays increased
resistance to killing during exposure to 254-nm irradiation when actively dividing
in mid-log phase as compared to stationary phase when Φ370.4 is integrated.
Conversely, the mutant strain (CEM1Δ4) lacking Φ370.4 shows an increased
resistance to UV light in either phase of growth and is at least 100 times more
resistant than stationary SF370 cells at a 30 second UV exposure (data not
shown and Figure 8.7).
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Figure 8.7.  Growth dependent UV sensitivity in SF370 is lost when Φ370.4 is
deleted.
WT Strain SF370 shows a growth dependent increase in resistance to UV
irradiation when the cells are rapidly dividing (mid-log, middle panel) as
compared to cells in stationary phase (right panel).   The mutant deleted for
Φ370.4 by contrast is equally resistant at either phase of growth (left panel and
not shown).  For each assay, replicates of ten-fold serial dilutions (top to bottom)
of cells were spotted onto a THY agar plate and exposed to increasing doses of
UV light (0 to 120 seconds, left to right).  Prior to dilution, bacterial cells densities
(A 600) were equalized.
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8.3.8 Sensitivity to EtBr is associated with phage Φ370.4.
Encoded in the MMR operon, LmrP is a proton motive force-dependent drug
transporter that confers resistance to lipophilic antimicrobial agents, such as
ethidium bromide (EtBr) (Bolhuis, Poelarends et al. 1995).  We found that SF370
is more sensitive to EtBr killing than strain CEM1Δ4 in both early logarithmic
growth (A600 0.35) and stationary phases (A600 > 0.6), although the distinction is
less pronounced in stationary phase (Figure 8.8 A, B).  The difference in the
overall sensitivity to EtBr in the log phase cells of the two strains is significant (p
< 0.01).   Alternatively, at a very early log phase of growth (A600 0.15 - 0.20),
when the SF370.4 prophage is thought to excise from the chromosome, the
percentage of bacterial survival is almost identical between the SF370 and the
CEM1Δ4 (Figure 8.8 C).
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Figure 8.8.  Sensitivity to EtBr killing is associated with presence of Φ370.4.
Cultures of SF370 and CEM1Δ4 were exposed to increasing concentrations of
EtBr (0µM, 1.25µM, 2.5µM, 5.0µM, 7.5µM, 10µM and 20µM) for 12 hours at 37°C
and then plated to measure CFUs.  Results are expressed as the percent
survival of the non-treated cultures.  The panels represent the results from each
growth phase: (A) Early logarithmic growth (A600 0.3 – 0.4); (B) Stationary phase
(A600 > 0.6); (C) Earlier log phase of growth (A600 0.15 - 0.200).  The results were
tabulated as the average and SD of three replicate experiments. Certain error
bars are not visible as SD values were extremely small, indicating good
reproducibility. The difference in the overall sensitivity to EtBr in the log phase
cells of the two strains is significant (p < 0.01).
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8.3.9 Curing of prophage Φ370.3 to make the full phage KO CEM1ΔΦ.
Phage 370.3 has a 33 kb genome and contains another DNase gene (spd3) and
hyaluronidase gene (hylp3). To select for loss of the Φ370.3 phage, the spd3
gene was chosen for allelic replacement with the counter-selection cassette.
Using our two-step allelic replacement technique, we successfully created a
knockout mutant of this phage in SF370 to derive strain CEM1Δ3.  Of note, the
same vector and methods were used to delete Φ370.3 from the triple KO mutant
CEM1Δ1,2,4 to derive the full phage KO CEM1ΔΦ (Table 8.1 and Figure 8.2).
We examined the basic phenotypes of CEM1ΔΦ compared to the SF370 wild
type strain and found no differences in microscopic analysis of cell shape or
chain length, colony morphology, blood hemolytic pattern, or in growth
characteristics in liquid culture (data not shown and Figure 8.9).
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Figure 8.9.  Growth comparison of the wild type SF370 strain and the full phage
deletion mutant (CEM1ΔΦ).
Overnight cultures where diluted 1:50 in 10 ml of pre-warmed BHI and incubated
at 37°C.  Absorbance of cultures (A600) was measured at different time points
using a spectronic 20D spectrophotometer (Thermo Electron Corporation) and
the results were plotted.
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8.3.10 Comparison of CEM1ΔΦ to SF370 interactions with pharyngeal cells.
To assess if any of the lysogenic bacteriophage of SF370 play a role in
streptococcal adherence to, and internalization by, pharyngeal epithelial cells, the
fully phage cured strain (CEM1ΔΦ) was compared to SF370 in the co-culture
adherence assay.  As shown in (Figure 8.10), no significant differences were
observed between CEM1ΔΦ and SF370 in adherence to pharyngeal cells or
subsequent internalization.
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Figure 8.10.  Pharyngeal cell adherence and internalization assays on the full
phage KO.
(A) Results of the pharyngeal cell adherence and (B) internalization assays
(detailed in Methods), comparing parental strain SF370 with the phage free
mutant (CEM1ΔΦ). Adherent and internalized streptococci are reported as the
percentage of total number of streptococci added as inoculum to pharyngeal cell
monolayers.  Statistical significance (reported as p value) was determined by
Student's t-test.
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8.3.11  Decreased expression of DNase in bacteriophage-free mutant
CEM1ΔΦ.
The genome of SF370 contains three genes encoding secreted DNases:  one
chromosomally encoded (spd/mf1) and two phage-encoded (spd1 on Φ370.1
and spd3 on Φ370.3).  To begin to assess the effects of the phage encoded
DNases, the prophage-cured strain CEM1ΔΦ and the wild-type strain SF370
were plated to DNase Test Agar with Methyl Green.  After overnight growth,
colonies from SF370 produced larger and more distinct clearing zones of DNA
lysis than the CEM1ΔΦ colonies (Figure 8.11).  This suggests that phage
DNases contribute significantly to the total activity of DNases secreted from
SF370.
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Figure 8.11.  DNase activity of WT SF370 and the full-phage knock-out mutant
CEM1ΔΦ.
Both strains were cultured on DNase Test Agar with Methyl Green for 17 h.  The
upper half of the plate contains WT colonies and the lower half of the plate
contains the full phage knock-out mutant CEM1ΔΦ colonies.  DNase activity is
indicated by a clearing zone around the colonies, which represents hydrolysis of
the DNA and methyl green substrate.  The figure includes both a color and a
black and white photograph of the same plate taken at the same time, to aid in
discerning colonies and DNAse activiy.
8.3.12 Interactions of CEM1ΔΦ with SF370 induced bacteriophage.
To test if the CEM1ΔΦ phage-cured mutant could be lysed and / or lysogenized
by induced SF370 bacteriophages, concentrated supernatants of induced or non-
induced cultures were spotted onto BHI soft agar overlays containing the SF370
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or CEM1ΔΦ as indicator strains.  No growth inhibition or plaque formation was
observed for any supernatant applied to the SF370 indicator plate (Figure 8.12).
Additionally, no growth inhibition or plaque formation was observed on the
CEM1ΔΦ indicator strain from any non-induced culture or the mitomycin C
induced CEM1ΔΦ supernatant. Conversely, the supernatant of the mitomycin C
induced SF370 culture produced growth inhibition and plaque formation on the
lawn of the CEM1ΔΦ indicator strain (Figure 8.12)
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Figure 8.12.  Analysis of bacteriophage plaque formation on phage deletion
mutants.
Concentrated supernatants from mitomycin C induced cultures of either the WT
SF370  (top half of plates) or CEM1ΔΦ full phage deletion mutant (bottom half of
plate) were spotted (10µl) across BHI soft agar overlays containing either
CEM1ΔΦ, SF370, or CEM1Δ1.  Plates were incubated overnight at 37°C and
then observed for plaque formation and/or growth inhibition. An asterisk (*)
indicates an area where a drop of SF370 supernatant accidentally fell on the
plate.
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To begin to assess which SF370 bacteriophage may be involved in the plaque
formation, mitomycin C induced supernatants were dropped onto soft agar
overlays containing the single phage deleted mutants (CEM1Δ1, CEM1Δ2,
CEM1Δ3, and CEM1Δ4) or CEM1ΔΦ.  Growth inhibition was only observed in
response to the SF370 mitomycin C induced supernatant on the lawns of the
CEM1ΔΦ and CEM1Δ1 mutants (Data not shown and Figure 9.1).  This suggests
that Φ370.1 is the functional phage responsible for the majority of initial plaques
on the lawns of CEM1ΔΦ.
To assay for lysogeny, CEM1ΔΦ colonies were picked from inside the plaque
zones from the SF370 mitomycin C-induced supernatants and an isolate was
identified that had the Φ370.1 speC phage gene.  Confirmation of proper
insertion into the original Φ370.1 integration attB site was achieved by
sequencing across the phage-bacterium junction and PFGE (Data not shown).
8.4 DISCUSSION
Comparative genomic studies of the published sequences of S. pyogenes,
isolated from different streptococcal infections and diseases, have confirmed the
important relationship between S. pyogenes and the many lysogenic
bacteriophages contained within the genome of this species.  While phage have
been shown to play a role in streptococcal pathogenesis because of the virulence
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factors they encode, the molecular interactions between the phage and the host
need further dissection.  As such, a comparison of isogenic strains of S.
pyogenes that differ in specific bacteriophage genes or in bacteriophage content
would allow us to study the direct effects that individual bacteriophage have on
streptococcal genome and /or virulence. 
In this study, we first used allelic replacement techniques to target bacteriophage
genes encoding potential GrAS virulence or regulatory factors for allelic
replacement.  In previous microarray studies on SF370, we observed that 11
genes from the Φ370.2 prophage were differentially expressed when in contact
with human pharyngeal epithelial cells (Ryan, Kirk et al. 2007). One of these
genes (speH) encoding a putative superantigen was up-regulated, suggesting
that it may play a novel role in streptococcal colonization. Adherence-mediated
up-regulation of speH was likely not simply the result of phage induction, as the
remaining phage Φ370.2 genes identified in that analysis were down-regulated.
Instead, increased expression of speH during pharyngeal cell adherence
suggested that the SpeH exotoxin is either necessary for adherence or is a
component of a downstream infection process.  To answer this question, the
speH gene was replaced with an erythromycin resistant gene, and the mutant
strain was subsequently compared to the wild-type SF370 strain in various in
vitro co-culture assays with human pharyngeal cells.  No discernable effects on
adherence, internalization or intracellular survival were seen between SF370 and
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the isogenic mutant lacking the speH gene in the pharyngeal cell assay.  These
results suggest that SpeH is not involved directly in attachment, internalization or
survival during contact with pharyngeal cells.  The significant up-regulation of the
speH gene seen by Ryan et al. during adherence suggests that the gene product
may function instead during a subsequent stage of infection (Ryan, Kirk et al.
2007).
To discriminate whether the 10 other genes from Φ370.2, which were
differentially expressed during pharyngeal cell adherence (Ryan, Kirk et al.
2007), had a role in GrAS pharyngeal cell adherence or internalization, we
decided to delete the entire Φ370.2 bacteriophage from the streptococcal
genome.   In order to accomplish a precise phage deletion, a second approach
was developed to select for isolates of SF370 that were cured of lysogenic
bacteriophage.  Using allelic replacement techniques to exchange individual
bacteriophage genes with the counter-selection cassette ((aacA-aphD) / rpsLWT),
it was possible to select for strains that had lost the various phage of interest.
This counter-selection technique was applied to the Φ370.2 prophage, resulting
in a mutant strain (CEM1Δ2) that had excised and deleted the Φ370.2 phage and
recapitulated the original attB phage integration site in the chromosome.  A
comparison of CEM1Δ2 and SF370 in the pharyngeal co-culture assays showed
that the absence of Φ370.2 from the streptococcal genome had no effect on
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GrAS adherence to, or internalization by, pharyngeal epithelial cells.  This
suggests that the 10 other Φ370.2 genes that were differentially expressed
during adherence have alternative functions during the interaction of S. pyogenes
with epithelial cells (Ryan, Kirk et al. 2007).
Although we were unable to detect a difference in adherence or internalization in
the Φ370.2 knock-out mutant, the successful curing of Φ370.2 from SF370
served as proof of principle that we could specifically manipulate prophage gene
content in S. pyogenes using our phage counter-selection technique.  This
methodology was then applied to the remaining bacteriophages in the SF370
genome and we successfully created a total of fifteen mutants encompassing
every permutation of phage knockout (KO): single, double, and triple knockouts,
as well as a mutant strain that was completely cured of all bacteriophage
elements, CEM1ΔΦ. These isogenic mutant strains have given us the tools
necessary to further analyze the role that phage may play in streptococcal
survival, and to examine the molecular interactions of the lysogenic
bacteriophage within GrAS.
Since 10% of the genome of SF370 had been deleted in the phage-free mutant,
we first compared the basic phenotypes of the CEM1ΔΦ mutant to the wild type
SF370 strain. Despite the fact that a large portion of the total genomic content of
SF370 had been removed, we found no discernable differences in bacterial cell
150
shape, chain length, colony morphology, hemolytic patterns on blood agar, or on
the growth curves of cultures cultivated in liquid media. These results showed
that the phage of SF370 do not affect the basic growth properties or colony
characteristics of SF370, which caused us to look for alternative phenotypes that
may indeed be phage-related.
To assess the role that all phages of SF370 play in the initial events of GrAS
infection, we compared the full phage knock out CEM1ΔΦ to SF370 in the
pharyngeal cell co-culture assay.  No difference was observed in either
adherence or internalization between the wild type and the mutant strains,
suggesting that in this particular in vitro model, lysogenic bacteriophage genes
do not facilitate the initial attachment or internalization of GrAS at the pharyngeal
epithelial surface.  These results led us to explore other ways in which the
lysogenic phage of SF370 may contribute to pathogenesis.
Recently, others have shown that bacteriophage DNases can protect
streptococci from neutrophil-formed extracellular traps (NETs), which are
composed of neutrophil granule components linked to DNA and which function to
trap and kill extracellular bacteria and fungi (Knetsch, Schafers et al. 2001;
Brinkmann, Reichard et al. 2004; Sumby, Barbian et al. 2005).  The genome of
SF370 contains three genes encoding secreted DNases:  one chromosomally
encoded (spd/mf1) and two phage-encoded (spd1 on Φ370.1 and spd3 on
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Φ370.3).  A comparison of activity on DNase Test Agar showed that the full
phage deletion mutant CEM1ΔΦ had lower DNase activity then did the wild type
SF370 strain.  This suggests that although the chromosomal spd/mf1 gene is
present in the knock-out genome, the two phage DNases may contribute
significantly to the total DNase activity secreted from SF370. We hypothesize
that such DNase activity may play a role in GrAS survival during streptococcal
infection by allowing the organism to escape entrapment within the NETs.  Future
experiments will use more quantitative assays to compare the DNase activity of
CEM1ΔΦ and SF370 to that of the single phage deletion mutants (CEM1Δ1 and
CEM1Δ3), so that the activity of the individual DNases in SF370 can be
analyzed.  The phage deletion mutants will be also tested for their ability to
survive during in vitro neutrophil extracellular killing assays and murine models of
infection (Sumby, Barbian et al. 2005; Buchanan, Simpson et al. 2006).
One example of how bacteriophages interact with GrAS can be classified as
integrational or positional effects, and is associated with the chromosomal
location of phage integration and the method by which such integration occurs.
Prophage integration occurs through homologous recombination between a
common sequence shared between the phage and bacterial DNA (attP and attB,
respectively), which inserts the prophage into the bacterial chromosome between
adjacent duplications of the attachment site (attL and attR) (Campbell 1992).
Most bacteriophages integrate into the 3ʼ end of a host gene, leaving the ORF
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intact either by duplication or by providing an alternative carboxy terminal
sequence (Campbell, Schneider et al. 1992; Campbell 1992).  However, GrAS
prophages frequently integrate into the 5ʼ end of genes or into gene promoters
(Fischetti 2006), and thus, could potentially disrupt or alter host gene expression.
In the genome of SF370, two of the four bacteriophages (Φ370.1 and Φ370.4)
integrate into the 5ʼ region of particular genes.  We decided to further explore
how prophage integration may regulate the expression of these particular
disrupted genes by comparing their transcriptional profiles or putative
phenotypes in wild-type SF370 and in single phage deletion mutants.
Prophage Φ370.1 is integrated into the 5ʼ end of the dipeptidase gene (pepD),
which replaces the first nine N-terminal amino acids and the upstream promoter
sequence with bacteriophage specific DNA (Canchaya, Desiere et al. 2002).  The
altered amino terminal sequence and promoter element suggests that
Φ370.1integration into this gene may directly affect or disrupt the expression of
the pepD gene or the activity of its gene product.  In our preliminary analysis, we
screened pepD expression by RT-PCR at different stages of growth in the SF370
wild type (WT) strain and the Φ370.1 KO mutant, CEM1Δ1.  Interestingly, while
one might expect pepD to be inactivated by the insertion of Φ370.1 directly into
the promoter region and into the sequence encompassing the start site of this
gene, the pepD transcript was present during all phases of growth in both
CEM1Δ1 and the wild-type strain SF370.  These results suggested that there
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was a functional promoter for pepD encoded within the Φ370.1 DNA itself.
Additional sequence examination identified a strong gram-positive promoter
sequence and Shine-Delgarno sequence in the bacteriophage DNA (Figure 8.5).
While there are multiple dipeptidases encoded in the genome of SF370 (Ferretti,
McShan et al. 2001), this PepD peptidase might be important to the growth and
survival of S. pyogenes since evolution has selected for the integrated phage to
retain a promoter sequence within its 3ʼ region, presumably  to not disrupt pepD
function. A conserved domain search of the PepD amino acid sequence
(http://www.ncbi.nlm.nih.gov/Structure) indicated that PepD belongs to the
peptidase C69 super-family, which encompasses a large group of dipeptidases
with numerous substrates.  A substrate has not yet been identified, so we could
not compare activities of the PepD peptidases expressed by CEM1Δ1 and
SF370.  Once a substrate is identified, we hope to determine (in future
experiments) if both pepD gene products are equally active, given that the 5ʼ end
of the pepD gene sequence is different when the phage is integrated and when it
is not. Experiments to delete pepD from the streptococcal genome are also
underway to ascertain its function in S. pyogenes.
Because we had found in this analysis that both the presence and absence of
Φ370.1 within the SF370 genome allows for a pepD RNA transcript to be
produced, we were interested in analyzing if both pepD transcripts were
produced in the WT strain. The reverse transcription analysis allowed us to
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differentiate the two transcripts, and we found that during early, mid, and late log
growth phases both the WT type pepD (pepDΦ) and the phage KO pepD
(pepDKO) were being expressed. The finding that the two different transcripts
were produced by SF370 indicates that Φ370.1 is actually excising from the
genome in a certain population of cells during all phases of growth, and that the
presence of prophage Φ370.1 in the streptococcal genome may be more
dynamic than previously thought.  Prophage Φ370.1 is a functional phage, and
as such, is able to make viral particles (Ferretti, McShan et al. 2001), which leads
us to further speculate about the dynamics and outcome of the excision event.
Specifically we are interested in determining if the pepDKO transcript observed in
SF370 cells indicates that the cell is entering the lytic cycle, or if the Φ370.1 DNA
is excising from the chromosome, replicating episomally and then reintegrating
into the genome. This latter mechanism is similar to excision and reintegration
dynamics of the Φ370.4, which is discussed in more detail below (Scott,
Thompson-Mayberry et al. 2008).  We plan to use more sensitive transcript
analysis (i.e. QRT PCR) to calculate the concentrations of the pepDΦ and
pepDKO transcripts, in addition to quantitating the transcripts of any lytic and
lysogenic regulatory genes in the wild type SF370.  These future studies will
likely provide a better understanding of the dynamics of Φ370.1 and the
regulation of the pepD gene during phage integration and excision.
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While Φ370.4 appears to be a defective lytic phage, its genome has retained
intact direct sequence repeats (attL and attR) at the junction between the phage
and bacterial DNA sequences and also encodes ORF modules homologous for
integration, lysogeny control, replication and regulation (Canchaya, Desiere et al.
2002).  These findings suggest that this phage-element may be able to perform
some phage functions within the GrAS genome.  Prophage Φ370.4 is integrated
between the mutS gene and the 5ʼ region of the mutL gene in the methyl-directed
mismatch repair (MMR) operon that includes several other DNA repair genes.
Phage integration separates mutL from its shared promoter upstream of mutS,
and thus is predicted to inactivate mutL expression and disrupt MMR in SF370,
resulting in a fixed mutator phenotype.  Recently, Scott et al. reported that in
rapidly dividing cells or following DNA damage, SF370 expresses both mutS and
mutL, but only expresses mutS in stationary phase cells.  (Scott, Thompson-
Mayberry et al. 2008). The authors concluded that the differential expression of
mutL results from excision, circularization and reintegration of the Φ370.4
prophage in a growth phase dependent manner (summarized in Figure 8.6).
Furthermore, they showed Φ370.4-containing strains in stationary phase had a
higher mutation rate and increased sensitiviy to UV irradiation then non-
homologous strains with an intact MMR operon (Scott, Thompson-Mayberry et al.
2008).  Unfortunately, in these experiments they were not able to compare the
direct effect of the Φ370.4 prophage on MMR phenotypes because they could
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not cure SF370 of the Φ370.4 prophage to compare isogenic strains (McShan
personal communication and (Scott, Thompson-Mayberry et al. 2008).
When we applied our counter-selection technique to cure SF370 of prophage
Φ370.4, we also experienced difficulties in deleting this phage from the genome
of SF370.  Although the phage excises from the genome during early log growth,
which would suggest that the chance of getting a cell division event that causes a
loss of phage might be good, we speculate that this phage is difficult to cure
because of its ability to excise and replicate episomally (similar to that of a high
copy number plasmid).  In fact, the Φ370.4 replicase and primase genes are
homologous to DNA replication genes from plasmid pST106 of Streptococcus
thermophillus (Scott, Thompson-Mayberry et al. 2008).  Interestingly, we created
a deletion mutant of the Φ370.4 primase gene, but found that the  genome was
still able to replicate episomally, thus preventing its elimination.  This finding
suggested that another primase may be complementing the Φ370.4 primase
mutant.  A search for primases in the genome sequence of SF370 showed that
Φ370.2 (and possibly Φ370.1) contain hypothetical phage primases, which may
be “helping” Φ370.4 replicate its genome.  This hypothesis is supported by our
later results that showed that the Φ370.4 phage was easier to cure (following the
normal counter-selection protocol) in mutants that had Φ370.1 or Φ370.2
previously deleted from the SF370 genome.  Future experiments will examine
these relations between the phage using additional primase deletion mutants and
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QRT-PCR to look at primase and episomal phage concentrations in our KO
mutants.  We were finally successful at curing SF370 of Φ370.4 by increasing the
temperature of the overnight incubation to 42°C (a method often used to cure
bacteria of plasmids), which may have disrupted the replication efficiency of the
episomal phage (Verheust, Fornelos et al. 2005).
With the creation of the isogenic Φ370.4 phage deletion mutant (CEM1Δ4) we
were able to compare the direct effects of the Φ370.4 phage genes on the MMR
operon in SF370.  Our results support previous studies that showed that SF370
has a growth-dependent increase in resistance to UV irradiation when cells are
rapidly dividing compared to cells in stationary phase (Scott, Thompson-
Mayberry et al. 2008).  Additionally, we show that the absence of Φ370.4
restores UV resistance to CEM1Δ4 at any stage of growth.  Confirming that the
excision (or deletion) of Φ370.4 restores transcription of the MMR polycistronic
message, which subsequently allows for the expression of the ruvA gene.
To explore other phenotypic changes that might be under the dynamic control of
Φ370.4, we examined the activities of another gene product, LmrP, in the MMR
operon.  Protein LmrP is a proton motive force-dependent drug transporter that
was originally described in the gram-positive bacterium Lactococcus lactis
(Bolhuis, Poelarends et al. 1995).  It is a predicted membrane protein with 12
transmembrane regions, which confers resistance to lipophilic antimicrobial
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agents, such as ethidium bromide (EtBr) and daunomycin in L. lactis.
Inactivation of the lmrP gene or the use of a proton pump inhibitor results in
increased killing of L. lactis following antimicrobial treatment in a concentration
dependent manner (Bolhuis, Poelarends et al. 1995; Mazurkiewicz, Poelarends
et al. 2004). According to the model of prophage Φ370.4 regulating genes of the
MMR operon, LmrP should not be expressed when the prophage is integrated
into the bacterial chromosome at mutL (Scott, Thompson-Mayberry et al. 2008).
This inhibition of LmrP should result in an increased sensitivity to EtBr and similar
agents (Bolhuis, Poelarends et al. 1995).  Accordingly, we found that compared
to CEM1Δ4, the wild type SF370 strain had a significant increase in EtBr induced
death during early log and stationary phases.  However, we observed that during
very early log growth, when Φ370.4 is excised from the genome, the survival of
the SF370 and the Φ370.4 deletion mutant were essentially identical.  We
interpret these results to indicate that the LmrP protein is turned over rapidly, so
that its expression in SF370 occurs mainly in very early log growth, when Φ370.4
is excised, and continually diminishes over time.  Expression of LmrP also
appears to be diminished in stationary phase cells of CEM1Δ4, as these
organisms experience increased sensitivity to EtBr. This phenomenon may also
result from a decreased level expression of the polycistronic message from the
mutS promoter.
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We are currently examining other potential roles of Φ370.4 in the control of LmrP,
and the effect that such regulation may have on streptococcal pathogenesis.
Preliminary evidence from other groups suggests that expression of LmrP
increases survival of GrAS at low pH values (McShan, personal communication),
which may aid in increasing streptococcal survival inside phagosomes of human
leukocytes (Beck, Bergner-Rabinowitz et al. 1969; Bassoe and Bjerknes 1985),
and that this phenotype may also be under the control of phage integration and
excision.  We hope to use our phage knock out mutants to determine the basis
for this observation. We are also examining if the Φ370.4 phage-controlled
mutator phenotype affects mutation rates of a two-component regulatory system
(covR / covS), which has been shown to influence GrAS survival in a murine
model of subcutaneous infection (Kansal, Datta et al. ; Graham, Virtaneva et al.
2005; Graham, Virtaneva et al. 2006; Sumby, Whitney et al. 2006).
We have demonstrated, in the work presented here, that the phage-cured
mutants are useful tools to analyze the role of phage in GrAS pathogenesis and
to study the molecular interactions of phage genes and the streptococcal
chromosome.  These mutants can also be used to study the mechanisms of
lysogeny and phage-phage interactions, as well as to identify phenotypes
associated with additional novel lysogenic phages that insert into the SF370
genome. We hypothesized that our phage-free mutant strains would likely be
more amenable to future lysogenization by other bacteriophage since there are
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no prophage at the potential bacteriophage integration sites or other
bacteriophage encoded proteins that could interfere with subsequent
bacteriophage infection (e.g. bacteriophage CI-repressors and superinfection
exclusion genes) (Canchaya, Desiere et al. 2002).  To test this hypothesis, we
exposed the mutant strains to supernatants from mitomycin C induced cultures of
SF370, and found that the phage cured CEM1ΔΦ mutant was capable of being
infected and subsequently lysed by lytic bacteriophage.  We then used the single
phage deletion mutants to identify which infecting phages may be responsible for
the lytic effect.  Plaque formation was only seen in the CEM1Δ1 mutant,
suggesting that Φ370.1 was the only induced phage.  This was confirmed by
isolating a lysogen of the CEM1ΔΦ mutant that contained Φ370.1 re-integrated
into the original attB site on the chromosome.  These findings are in agreement
with previous studies that suggested Φ370.1 is the only inducible phage after
mitomycin C treatment (Ferretti, McShan et al. 2001), but are still novel because
the authors of that study did not examine if the inducible phage particles were
actually capable of re-infecting and/or lysogenizing GrAS bacteria.  Thus we
were able to show, for the first time, that Φ370.1 from SF370 is a fully functional
lysogenic bacteriophage and proved that our phage knock out mutants derived
from our novel counter-selection method are capable of being infected and
lysogenized. We will continue to study the lysogenic potential of the additional
phage deletion mutants using both SF370 induced cultures, as well as cultures of
other strains of S. pyogenes that contain novel phage not found in SF370.
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We are also currently using microarray analyses to compare the gene expression
profiles of the full phage deletion mutant CEM1ΔΦ to the wild type SF370 strain
during different growth stages in liquid culture. These experiments will assess the
effects that both bacteriophage integration and phage genes have on
chromosomal gene expression. These studies will establish a foundation for
future studies, in which the global transcriptional effects of phages can be
analyzed in both in vitro and in vivo models of GrAS infection.
This is the first report of a method that systematically cures S. pyogenes of all
phage elements.  Our counter–selection technique allows for precise
manipulation of lysogeny to analyze the role phage play in both virulence and the
regulation of chromosomal genes. The derived KO strains have allowed us to
begin to directly examine novel bacteriophage interactions with GrAS and
elucidate their specific roles in streptococcal survival, pathogenicity, and
evolution.  The techniques developed in this study could easily be modified for
other bacterial-bacteriophage systems, and thus could be beneficial to the study
of not just streptococcal-phage interactions but to other areas of research in
microbial pathogenesis, ecology or biotechnology.
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9 Chapter 3
9.1 INTRODUCTION
Staphylococcus aureus is an opportunistic pathogen inhabiting human skin and
mucous membranes and is the causative agent of variety of skin and soft tissue
infections as well as serious infections such as pneumonia, meningitis,
endocarditis, and osteomyelitis.  S. aureus exotoxins also cause disease
syndromes such as bullous impetigo, scalded skin syndrome, and toxic shock
syndrome.  While outbreaks of cutaneous infections in otherwise healthy people
can be managed well without antibiotics (Rajendran, Young et al. 2007), in
compromised individuals staphylococci are an important cause of life-threatening
nosocomial infections such as ventilator-acquired pneumonia (VAP) (Kollef,
Morrow et al. 2006).  The spread of methicillin resistant S. aureus (MRSA) has
been of critical concern to health care providers, and the further distribution of
Panton-Valentine Leucocidin (PVL) carrying community acquired MRSA strains
to the hospital (Popovich, Weinstein et al. 2008) poses a threat that is even more
serious than that of MRSA alone due to the striking pathogenicity of this toxin
(Boyle-Vavra and Daum 2007).
Currently, 40-60% of nosocomial infections of S. aureus are resistant to oxacillin
(Massey, Horsburgh et al. 2006) and greater than 60% of the isolates are
resistant to methicillin (Gill, Fouts et al. 2005).  Treating infections caused by the
drug-resistant S. aureus has become increasingly difficult and is therefore a
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major concern among healthcare professionals.  To combat this challenge,
development of new and effective antibiotics belonging to different classes are
being aggressively pursued.  A number of new antimicrobial agents such as
linezolid, quinupristin–dalfopristin, daptomycin, telavancin, new glycopeptides
and ceftobiprole have been introduced or are under clinical development (Aksoy
and Unal 2008).  However, clinical isolates of MRSA with resistance to these new
classes of antibiotics have already been reported (Tsiodras, Gold et al. 2001;
Mangili, Bica et al. 2005; Skiest 2006).  Consequently, there is an urgent need to
develop novel therapeutic agents or antibiotic alternatives that are active against
MRSA.   As an option, current antibiotics for which MRSA are resistant may be
resurrected as viable candidates in the treatment of MRSA when used in
combination with other agents, offering a new dimension to a dwindling list of
potential anti-infectives for this pathogen.
Carriage of both MSSA and MRSA in the human anterior nares is the major
reservoir for S. aureus infection.  Studies have shown that roughly 80% of the
population could be nasally colonized by S. aureus, and that colonization
increases the risk factor for developing other more serious S. aureus infections
(Kluytmans, van et al. 1997). Elimination of nasal carriage in the community or in
the hospital setting could possibly reduce the risk of infection and slow the
spread of drug resistant S. aureus (Kluytmans, van et al. 1997). Only one agent,
intranasal mupirocin, has been approved in this indication. Mupirocin ointment
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must be applied twice daily to the anterior nares for 3-5 days. When used in this
manner, mupirocin ointment has been shown to significantly reduce the risk of
post-operative staphylococcal infection in patients who were S. aureus carriers
(Perl, Cullen et al. 2002).  However, the value of mupirocin is compromised by a
relatively high rate of resistance mutations (Coates, Bax et al. 2009) and by
potential compliance issues associated with its method of use. Despite these
issues, pre-operative prophylaxis with mupirocin is already mandated for
cardiovascular surgery (Engelman, Shahian et al. 2007) and has also been
recommended for orthopedic surgery (Wilcox, Hall et al. 2003). Clearly a superior
product for intranasal prophylaxis in at-risk patients would be valuable.
Bacteriophage endolysins (lysins) are a new class of novel antimicrobial agents
that are emerging as effective agents for the prophylactic and therapeutic
treatment of bacterial infections.  Lysins are cell wall hydrolases that are
produced during the infection cycle of double-stranded DNA bacteriophages
enabling the release of progeny virions.  When applied exogenously, native or
recombinant lysins are able to cleave the integral peptidoglycan bonds of
susceptible gram-positive bacteria resulting in rapid cell lysis (Nelson, Loomis et
al. 2001).  Lysins have been developed against a number of Gram-positive
pathogens including S. pyogenes (Nelson, Loomis et al. 2001), S. pneumoniae
(Loeffler, Nelson et al. 2001), Bacillus anthracis (Schuch, Nelson et al. 2002),
enterococci (Yoong, Nelson et al. 2004), Group B streptococci (Cheng, Nelson et
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al. 2005), and Staphylococcus aureus (O'Flaherty, Coffey et al. 2005; Rashel,
Uchiyama et al. 2007).  The efficacy of most of these lysins has been
demonstrated in in vivo models.  Several unique characteristics of lysins make
them attractive antibacterial candidates against Gram-positive pathogens.  These
include i) rapid antibacterial activity both in vitro and in vivo; ii) narrow lytic
spectrum (species-specific); iii) strong receptor-binding affinity, typically in the
nanomolar range; iv) very low probability of developing resistance since the
binding epitopes on the bacteria are essential for viability; v) safe; and vi) relative
ease of modification by genetic engineering (Fischetti, Nelson et al. 2006).
Development of a highly active S. aureus-specific lysin has been challenging
either due to lack of expression in a heterologous host, insolubility of the
expressed protein, or poor expression, except one report to our knowledge of a
S. aureus-specific lysin from phage phiMR11 (Rashel, Uchiyama et al. 2007).  To
circumvent these issues a few studies have reported the construction of
truncated (Horgan, O'Flynn et al. 2009) or chimeric versions of lysins
(Manoharadas, Witte et al. 2009).
Typically, lysins have two distinct functional domains consisting of an N-terminal
catalytic domain for peptidoglycan hydrolysis and a C-terminal binding domain for
recognition of surface moieties on the bacterial cell walls.  The catalytic domains
are relatively conserved among lysins and the activities can be classified into
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three basic groups based on peptidoglycan bond specificity: i) glycosidases that
hydrolyze linkages within the amino sugar moieties; ii) endopeptidases that
cleave the peptide moiety; iii) and amidases that hydrolyzes the amide bond
connecting the glycan strand and stem peptide.  The binding domains however
are not conserved among lysins.  Hence the binding domain often imparts
species-specificity because the binding targets, often carbohydrates associated
with the peptidoglycan, display species-specific distribution (Fischetti 2007).  The
modular architecture of lysins is an important feature with respect to their
development as antimicrobial agents.  This enables creation of chimeric enzymes
by swapping lysin domains and thereby altering binding specificity or enzymatic
activity or both (Croux, Ronda et al. 1993; Sheehan, Garcia et al. 1996; Lopez,
Garcia et al. 1997; Donovan, Dong et al. 2006).
In this chapter we describe the genetic engineering of a novel chimeric lysin
constructed by fusing the catalytic domain of a Staphylococcus-specific phage
lysin with a unique binding domain from a different Staphylococcus-specific lysin.
This engineered lysin called ClyS (for chimeric lysin for staphylococci) was
soluble, highly active and displayed rapid and specific lytic activity against
susceptible and drug-resistant staphylococci.  We demonstrate the lytic activity of
ClyS in in vivo colonization and septicemia models as well as its synergistic
activity with oxacillin in in vitro and in vivo models.  These results highlight the
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potential of ClyS as a novel therapeutic agent for the treatment of MRSA and
other staphylococcal infections.
9.2 MATERIALS AND METHODS
9.2.1 Bacterial strains.
Bacterial strains (Table 9.1) were stored at -80°C and routinely grown at 37°C.
Staphylococcal strains used in this study were grown in Trypticase Soy Broth
(TSB) media, streptococcal strains were grown in THY (Todd–Hewitt broth, 1%
wt/vol yeast extract) media, B. cereus and P. aeruginosa were grown in BHI
(Brain Heart Infusion) media while E. coli was cultivated in LB (Luria Bertani)
media.  Unless stated otherwise, all media was supplied by Becton, Dickinson
and Company (Sparks, MD).
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Table 9.1.  Bacterial strains for ClyS lysin studies.
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9.2.2 Construction of ClyS.
The chimeric lysin was constructed by amplifying and ligating individual domains
from respective genes.  For this, the gene fragment encoding the Twort
endopeptidase domain was PCR amplified from plasmid pCR2.1plyTW, which
contains the entire lysin (plyTW) gene using primers TW-Endo-NcoI-F: 5ʼ-
CTAGCCATGGAAACCCTGAAACAAGCAG-3ʼ and TW-Endo-PstI-R: 5ʼ-
ACATGCTGCAGAACCATATTGTAATTAATATTAGTTCTATC-3ʼ.  The gene
fragment encoding the cell wall targeting (CWT) domain was PCR amplified from
S. aureus strain 8325 genomic DNA containing the phiNM3 bacteriophage using
primers NM3-CBD-PstI-F: 5ʼ-ACATGCTGCAGGGTAAA
TCTGCAAGTAAAATAACAG-3ʼ and NM3-CBD-Hind-R: 5ʼ-
CCCAAGCTTAAAACACTTC TTTCACAATCAATCTC-3ʼ.  The two PCR
amplicons were ligated using the PstI restriction endonuclease site.  The ligated
product was cloned into pBAD24 vector using the NcoI-HindIII cloning sites to
generate recombinant plasmid pAD127.  In the second step, the entire DNA
fragment corresponding to clyS was PCR amplified from pAD127 using primers
NM3-Lys-Xba-F: 5ʼ-CTAGTCTAGAGGTGGAATAATGAAAA
CATACAGTGAAGCAAG-3ʼ and primer NM3-CBD-Hind-R.  The PCR product
was cloned into expression vector pJML6 to generate pAD138. The DNA
sequence of clyS was confirmed through DNA sequencing of the pAD138
plasmid by Genewiz, Inc. (South Plainfield, NJ).  The recombinant plasmid
170
pAD138 was transformed into E. coli DH5α cells (Invitrogen Corporation,
Carlsbad, CA).
9.2.3 Over-expression and purification of ClyS.
ClyS was induced overnight from E. coli DH5α (pAD138) cells with lactose
(10g/500ml final concentration) at 30°C.  Cells were harvested by centrifugation,
resuspended in buffer A (20 mM phosphate buffer (PB), 1 mM DTT) and lysed at
4°C by an EmulsiFlex-C5 high-pressure homogenizer (Avestin).  The lysates
were cleared by centrifugation (2x 50,000xg) for 30 min. at 4°C and the
supernatant applied to a CM-sepharose column (Amersham Pharmacia,
Piscataway, N.J.).  ClyS was eluted with buffer A + 1M NaCl using a linear
gradient of 0-50% B in 15 columns volumes.  Fractions were analyzed for lytic
activity as previously described (Nelson, Loomis et al. 2001).  Fractions
displaying lytic activity were pooled and dialyzed overnight against buffer B (PB,
1 mM DTT, 50mM NaCl).  The dialyzed sample was applied to a hydroxylapatite
(MacroPrep TypeII 40µm, BioRad) column and eluted with elution buffer (500
mM PB + 50 mM NaCl+ 1 mM DTT) using a linear gradient of 0-100% B in 20
columns volumes.  The fractions were analyzed by SDS-PAGE and for lytic
activity.  Active and pure fractions of ClyS were pooled and dialyzed against
buffer B.  Protein concentration was determined with the BCA method (Sigma,
St. Louis, MO).
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9.2.4 Quantification of ClyS activity.
 ClyS activity was measured as previously described (Nelson, Loomis et al. 2001;
Coates, Bax et al. 2009), with some modifications. Briefly, S. aureus strain 8325-
4 was grown to an OD600 of 0.25-0.3, centrifuged, and resuspended in PB to a
final OD600 of 0.8-1.0.  Two-fold serial dilutions of purified ClyS (100µl) were
added to 100µl of bacterial suspension in 96-well plates (Costar) and the
decrease in OD600 was monitored by a Spectramax Plus 384 spectrophotometer
(Molecular Devices) over 30 min at 37°C.  A unit of ClyS activity per milliliter was
defined as the reciprocal of the highest dilution of lysin that decreased the
absorbance by 50% in 15 min.
9.2.5 In vitro ClyS activity.
The effect of ClyS on bacterial viability was tested as previously described
(Nelson, Loomis et al. 2001).  Briefly, log phase cultures of an S. aureus strain
8325-4 were resuspended in PB to an OD600 of 0.8-1.0.  250 µg of ClyS or the
corresponding volume of PB was added to bacterial cells and aliquots were
removed, serially diluted, and plated at 1, 5, 10, 30, and 60 min to assess the
viability of the treated and control cells.  All experiments were performed in
triplicate.  The activity of ClyS was also tested on various bacterial strains as
described previously (Schuch, Nelson et al. 2002).  Briefly, log phase bacterial
cells were treated with 250 µg of ClyS at 37°C for 15 min.  The samples were
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serially diluted and plated.  Control experiments with the addition of phosphate
buffer (pH 7.0) were performed under the same conditions.
9.2.6 Electron Microscopy.
S. aureus strain 8325-4 was grown to log-phase, centrifuged and resuspended in
PBS to an absorbance at 600 nm of 1.0. The bacterial suspension was incubated
with 250 µg  of ClyS at room temperature.  The lytic reaction was terminated after
1 min and 5 min by adding glutaraldehyde (final concentration 2.5%). The
suspension was pelleted by centrifugation and overlaid with 2.5% glutaraldehyde
in 0.1 M cacodylate buffer (pH 7.4). The samples were then post-fixed in 1%
osmium tetroxide, block stained with uranyl acetate and processed according to
standard procedures by The Rockefeller University Electron Microscopy Service.
Fluorescent labeling and binding analyses of phiNM3 CWT.  S. aureus strain
8325-4 genomic DNA was used to amplify the gene fragment encoding the
putative CWT of phiNM3 lysin using primers NM3-FWD 5ʼ-
CATGCCATGGGTAAATCTGCAAGTAAAATAACAG-3ʼ and NM3-REV 5ʼ-
CCCAAGCTTAAAACACTTCTTTCACAATCAATCTC-3ʼ.  The resulting amplicon
was cloned into the arabinose-inducible expression vector pBAD24 (ATCC,
Manassas, VA).  Positive clones containing the insert were confirmed by
sequencing.  The ~10-kDa phiNM3 CWT protein was expressed in E. coli DH5α,
which were lysed as above, and the protein was purified in one step by cation-
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exchange chromatography.  The purified protein (1mg/ml) was incubated for 1 hr
with 10 µl of FITC (1 mg/ml, Sigma).  Excess FITC was removed on a desalting
column.  The labeled-protein (50 µg) was incubated with bacterial cells for 10
min, washed 3x with phosphate-buffered saline (pH 7.4) and observed under an
Eclipse E400 microscope (Nikon) using the QCapture Pro® version 5.1 imaging
software.
9.2.7 Immunological assays.
To test whether ClyS-specific antibodies would neutralize the activity of ClyS, two
rabbits were hyperimmunized with purified ClyS using a standard protocol:
primary immunization with complete Freundʼs adjuvant and three monthly boosts
in incomplete Freundʼs adjuvant.  ELISA titers were >100,000 for each animal
(reciprocal of the highest dilution with an OD405 of ≥1.0).  ClyS was diluted in 2-
fold dilutions through 11 wells in a microtiter plate beginning at 800 µg.  10 µl of
either hyperimmune rabbit serum, preimmune serum or PBS was added to each
well and incubated at 21°C for 15 minutes.  An equal volume of staphylococci
(prepared as described above) was then added to each well and immediately
assayed as described above.  The rate of OD600 decrease by ClyS was
measured in each well for the hyperimmune serum and compared to PBS and
preimmune serum for the same dilution of ClyS.
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9.2.8 Synergy testing of ClyS with oxacillin or vancomycin.
ClyS and oxacillin/vancomycin interactions were assessed by the standard
checkerboard broth microdilution assay as described before (Loeffler and
Fischetti 2003).  Briefly, ClyS and antibiotic were diluted two-fold horizontally and
vertically, respectively, in a final volume of 50 µl with an inoculum of 3x105 to
5x105 CFU per well.  MRSA strain COL was used to test ClyS - oxacillin
interaction while VISA strain Mu50 was used to test ClyS – vancomycin
interaction. The plates were incubated at 37°C with intermittent shaking in a
spectrophotometer.  Growth was determined by reading the plates at OD600 over
20 hrs.  The fractional inhibitory concentrations (FICs) of ClyS and antibiotics
were determined and plotted in an x/y plot called an isobologram.  The FIC index
(Σ) was calculated as the MIC of the drug when used in combination with ClyS
divided by the MIC of the drug when used alone (Loeffler and Fischetti 2003).  In
all cases the ΣFICs were found to be <0.5. Synergy was defined as an ΣFIC of
≤0.5.
9.2.9 In vivo murine infection models.
All in vivo protocols were approved by The Rockefeller Universityʼs Institutional
Animal Care and Use Committee.  A modified method from Kiser et al., (Kiser,
Cantey-Kiser et al. 1999) was used for the intranasal colonization model.  Briefly,
MRSA strain 191-SMR was grown overnight at 37°C, with shaking at 250 rpm, in
TSB media plus 200 µg/ml of streptomycin.  The culture was then diluted 1:50
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and grown as above to mid log-phase (OD600 0.5), centrifuged and re-suspended
in 0.9% saline for injection (Hospira, Inc., Lake forest, IL) to a predefined titer
(5x109 CFU/ml) for mouse infection.  Actual inoculum titers were derived from
plating serial dilutions of each inoculum onto Spectra MRSA agar plates (a
selective chromogenic medium developed to diagnostically detect MRSA nasal
colonization, Remel, Lenexa, KS) and Columbia blood agar (Becton, Dickinson &
Co., Sparks, MD).  Six-week-old female C57BL/6J mice (weight range 22 to 24 g,
Charles River Laboratories, Wilmington, MA) were fed water that contained 5 g/L
of streptomycin for 48 hours prior to infection.  Mice were anesthetized with a
mixture of ketamine (Fort Dodge Animal Health, Fort Dodge, IA, 1.2 mg/animal)
and xylazine (Miles Inc., Shawnee Mission, KS, 0.25 mg/animal), and were
inoculated with two consecutive doses of 15 µl per nostril of the 191-SMR
bacterial suspensions. Twenty-four hours after infection the animals were divided
into 2 groups (n = 20) and administered 60 µl (20µl per nostril and 20 µl orally) of
either 20 mM phosphate buffer or 960 µg ClyS.  Mice were sacrificed one hour
after treatment and subjected to nasal dissection.  The excised nasal cavities
were aseptically bisected, suspended in 500 µl of phosphate buffered saline
(PBS) and vortexed for 60 seconds to suspend adherent bacteria and dilutions of
the bacterial suspensions were plated to Spectra MRSA agar plates and
Columbia Sheepʼs Blood agar plates for CFU determination.   No significant
differences in CFU were obtained between plating to Spectra MRSA agar or
Columbia blood agar (Data not shown).  Three independent experiments were
176
performed to evaluate a total 20 mice for each treatment group.  Nasal
colonization rates of the treatment groups were analyzed statistically by an
ANOVA test (http://www.danielsoper.com/statcalc/) and Studentʼs T-test
(program).
For the systemic infection model, 4-5 week old female FVB/NJ mice (weight
range 15 to 20 g) were obtained from The Jackson Laboratory (Bar Harbor, ME).
The PVL toxin encoding MRSA strain MW2 was initially passaged twice through
the FVB/NJ mice to select for isolates that might be more capable of causing
systematic infection in mice.  Briefly, MW2 was grown in TSB media to mid log-
phase, centrifuged and suspended in saline to a predefined titer of 1x109
CFU/ml.  0.5 ml of the bacteria suspension was injected intraperitoneally and
bacteria were isolated, on Spectra MRSA plates, from the spleens and hearts of
the mice upon death 18-20 hours later.  The bacterial isolates were then grown in
TSB overnight and aliquots frozen in 30% glycerol at - 80°C.  For intraperitoneal
(IP) infection, a 10 µl loop of MRSA from a frozen aliquot the mouse passaged
MW2 was inoculated into 10 ml of TSB media and grown overnight at 37°C with
shaking.  This culture was then diluted 1:50 in TSB media and grown for 2 hours
at 37°C to mid log-phase (OD600 0.5).  The bacteria were then centrifuged,
washed once with saline for injection, and re-suspended in saline to a predefined
titer of 1 x108   to 5x108 CFU/ml.    This suspension was serially diluted with 5%
hog gastric mucin (Sigma) in saline to a bacterial titer of 5x105 to 1x106 CFU/ml
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and 0.5 ml of the bacterial suspension was injected intraperitoneally into each
mouse.  For each experiment, actual bacterial inoculation titers were calculated
by serial dilution and plating to Columbia blood agar plates.
For the ClyS in vivo efficacy experiments, three hours post infection the animals
were divided into 2 treatment groups and were intraperitoneally administered 0.5
ml of either 20 mM phosphate buffer (n =14) or 2 mg/ml ClyS.  For the in vivo
synergy experiments, three hours post IP infection the animals were divided into
3 to 8 treatment groups and were intraperitoneally administered a combination of
0.5 ml of 0.33 mg/ml ClyS (166 µg) or 20 mM phosphate buffer along with a 100
µl intramuscular (IM) injection of 10 µg to 100 µg oxacillin in saline or saline
alone control.  The survival rate for each experimental group was monitored
every 4 hours for the first 24 hours then every 12– 24 hours up to 10 days post
infection.  The data was statistically analyzed by Kaplan Meier Survival curves
and a Logrank test performed for 95% confidence intervals using the Prism
computer program (GraphPad Software; La Jolla, CA).
9.3 RESULTS
9.3.1 Identification of a unique cell wall targeting (CWT) domain in
Staphylococcus lysins.
Previous studies have indicated that the penta-glycine peptide cross-bridge
within the staphylococcal peptidoglycan functions as the receptor for the CWT
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domain of lysostaphin, a staphylolytic enzyme produced by Staphylococcus
simulans (Grundling and Schneewind 2006).  The CWT domain of lysostaphin
has homology with the bacterial SH3-like (SH3b) domain, suggesting that lysins
with SH3b domains might also utilize the peptide cross-bridge as their receptor
(Grundling and Schneewind 2006; Lu, Fujiwara et al. 2006).  Since resistance to
lysostaphin can be due to small alterations within the peptide cross-bridges
(Grundling and Schneewind 2006), we sought to identify a CWT domain within
staphylococcal lysins that was unique and not homologous to SH3b domains.
Our hypothesis was that such a CWT domain would bind to alternative epitope(s)
such as cell wall-associated carbohydrates in the staphylococcal cell wall instead
of the peptide cross-bridges, thereby reducing the likelihood of becoming the
target of resistance.
Conserved domain searches of Staphylococcus-specific phage and prophage
lysin sequences in the GenBank database
(http://www.ncbi.nlm.nih.gov/Genbank/index.html) identified a few lysins that did
not display homology to a C-terminal SH3b domain.  These included the S.
aureus phage phiNM3 lysin (protein accession #: YP_908849), S. aureus
prophage phi13 amidase (accession #: NP_803402) and S. aureus prophage
MW2 amidase (accession #: NP_646703.1).  These three lysins share 100%
sequence identity with each other (data not shown).  We thus characterized the
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region corresponding to the putative CWT domain of the phiNM3 lysin with
respect to its biochemical and functional properties.
Figure 9.1.  Schematic diagram of phiNM3 lysin showing the putative CHAP and
the CWT domains.
The numbers represent the amino acid positions and the domain limits.  The
CWT domain of ClyS is shown as green box.
9.3.2 The phiNM3 CWT binds specifically to staphylococci.
The putative CWT domain corresponding to amino acid residues 158-251 of
phiNM3 lysin, (Figure 9.1) was cloned and expressed in E. coli.  The ~10-kDa
protein was highly soluble and was purified to homogeneity (data not shown).  To
determine the binding specificity of this domain toward bacterial cells, the purified
protein was labeled with FITC and exposed to log-phase S. aureus, S.
epidermidis and a mixed population of S. aureus and Bacillus cereus.  S.
pyogenes, E. coli and B. cereus served as controls.  The FITC-labeled phiNM3
CWT domain displayed species-specificity by binding specifically to S. aureus
(Figure 9.2-1) and S. epidermidis (Figure 9.2-3) cells and was able to bind
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specifically to the staphylococcal cells in mixed populations (Figure 9.2-6).  No
binding was observed to Bacillus (Figure 9.2-2), E. coli (Figure 9.2-4), or
streptococci (Figure 9.2-5), a characteristic of the specificity of many phage
lysins (Loeffler, Djurkovic et al. 2003; Mangili, Bica et al. 2005).  Binding of the
labeled-CWT domain was generally over the entire cell surface (Figure 9.2-1 and
Figure 9.2-3) with more intense localization near the polar and septal regions.
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Figure 9.2.  PhiNM3 CWT binds specifically to staphylococci.
Purified phiNM3 CWT was labeled with FITC and exposed to 1) S. aureus; 2) B.
cereus; 3) S. epidermidis; 4) E. coli; 5) S. pyogenes and 6) mixed suspension of
S. aureus and B. cereus cells.  P: phase-contrast image and F: fluorescent
image.
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9.3.3 Function-guided construction of chimeric lysin ClyS.
Previous attempts in our laboratory to clone and express a soluble and active
native staphylococcus-specific phage lysin have been unsuccessful.  Therefore,
we attempted to circumvent these problems by taking advantage of the modular
nature of lysins and develop lysin chimeras.  Many inactive chimeras were
generated in a series of logical but progressive steps (Figure 9.3), the most
successful of which was chimera AD127 composed of the lysin endopeptidase
domain of phage Twort fused amino-terminally of the phiNM3 CWT domain. The
AD127 chimera was soluble and highly active against staphylococcal cells but
suffered from poor expression in E. coli.  To overcome this, the ORF encoding
AD127 was cloned into expression plasmid pJML6 to get pAD138.  Plasmid
pJML6 was previously used to over express S. pneumoniae lysin Cpl-1 and PAL
in E. coli (Loeffler, Djurkovic et al. 2003).  Chimera AD138 was named ʻClySʼ for
Chimeric lysin for Staphylococcus.  ClyS is a 280 amino acid protein with a
deduced molecular mass of 31,956 Da and a theoretical isoelectric point of 9.17.
It was purified by a two-step column chromatography method to >90%
homogeneity (data not shown).
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Figure 9.3.  Chimeric lysin development.
A. schematic diagram of various chimeric lysins showing their respective
domains and the corresponding expression, solubility and activity of the protein
against S. aureus cells.  Similar domains are depicted in the same colors and are
labeled.  PlyB-cat: catalytic domain of Bacillus-specific lysin PlyB; Sa-aa: 16
amino acid residues specific for staphylococcal lysins; PlyB-CWT: CWT domain
of PlyB; Twort-CWT: CWT domain of S. aureus phage Twort lysin; Lysostaphin
CWT: CWT domain of lysostaphin; Se autolysin amidase: amidase domain of S.
epidermidis autolysin.
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9.3.4 In vitro activity of ClyS.
In preliminary experiments using varying quantities of ClyS with staphylococci it
was determined that 250 µg was an effective dose.  For example, when 250 µg
of ClyS was added to exponential phase of S. aureus 8325-4 cells, the OD600
dropped 3-4 fold within ~15 min (Figure 9.4).  To confirm that the observed loss
of turbidity corresponded to a decrease in viable cell counts, aliquots from the
spectrophotometric lysis assay were plated to TSB agar at various time points
and CFU were enumerated.  A decrease in viability of ~3-logs was observed in
30 min (Figure 9.4).
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Figure 9.4.  Activity of ClyS against S. aureus in vitro.
S. aureus strain 8325-4 cells were resuspended in 20 mM phosphate buffer (pH
7.4), incubated with 250 µg of ClyS and OD600 (filled circles) monitored by a
spectrophotometer.  Control experiments (filled squares) were performed under
the same conditions with buffer alone.  Cell viability (filled triangles) measured as
CFU/ml, was determined by serially diluting and plating the same cell
suspensions to TSB agar plates.
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The lytic effect on S. aureus 8325-4 cells exposed to 250 µg of ClyS for 1-3 min
was visualized by transmission electron microscopy (Figure 9.5 A and B).  Cells
exposed to ClyS showed localized degradation of the cell wall at single or
multiple sites, which is typical of lysin-mediated cell lysis. The sites of
degradation on the cell were randomly distributed over the entire cell surface.
This observation correlated with the binding of FITC-labeled CWT domain to the
whole surface of the staphylococcal cells.  The localized weakening of cell wall
resulted in extrusion and rupture of the cell membrane (Figure 9.5) and
subsequent loss of cytoplasmic contents and formation of cell-ghosts (Figure
9.5).
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Figure 9.5.  ClyS causes cell wall disruption and ultimately lysis of 8325-4 cells.
(A-C) Thin-section transmission electron micrographs (bars, 200 nm) of S.
aureus 3 minutes after exposure to 250 µg of ClyS.  The arrows indicate
cytoplasmic membrane extrusions through holes generated in the cell wall by
ClyS.  Ultimate lysis results in mostly “cell-ghosts” (D) after the loss of
cytoplasmic contents (bar, 500 nm).
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9.3.5 Specificity of ClyS.
Muralytic activity of ClyS was tested on a number of bacterial strains
representing a variety of genus and species that were divided into several sets
(Table 9.1 and Figure 9.6).  Set I consisted of methicillin-sensitive (MSSA) and
methicillin-resistant strains (MRSA) of S. aureus.  ClyS was very active against
both MSSA and MRSA although some differences were observed between S.
aureus strains.  ClyS lysin also effectively killed six vancomycin intermediate
resistant strains of staphylococci (VISA) and the lysostaphin resistant S. aureus
strain LyrA (Data not shown).  Set II consisted of different species of
staphylococci including S. epidermidis, S. simulans and S. sciuri (subsp. sciuri).
ClyS was not only active against S. epidermidis including the biofilm-forming
strain RP62A (Tao, Fan et al. 2006) but was also active against S. simulans and
S. sciuri (subsp. sciuri). Set III consisted of a mix of Gram-positive and Gram-
negative bacteria including representatives of group A, B, C and E streptococci,
the oral streptococcal species S. gordonii, and S. salivarius, as well as S. uberis,
Bacillus cereus, Pseudomonas aeruginosa and E. coli.  ClyS did not exhibit lytic
activity against any of these bacteria (Figure 9.6).
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Figure 9.6.  ClyS exerted specific killing of antibiotic-susceptible and resistant
staphylococci. 
Log-phase cultures of different bacteria were exposed to 250 µg of ClyS for 15
min.  Fold killing was calculated by dividing the number (CFU) of viable bacteria
after buffer treatment by the number (CFU) after exposure to ClyS enzyme.
Several MSSA and MRSA strains along with S epidermidis, S. simulans and S.
sciuri strains were tested for susceptibility to ClyS killing.  Control strains GAS:
group A streptococci; GBS: group B streptococci; GCS: group C streptococci and
GES: group E streptococci along with enterococci, other streptococci, bacilli,
pseudomonas and E. coli were also tested.
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9.3.6 Immune response to ClyS.
It was shown previously that lysins have the unique capacity to resist
neutralization by antibodies, both in vitro and in vivo assays (Loeffler, Djurkovic
et al. 2003; Mangili, Bica et al. 2005).  However, chimeric lysins have not evolved
naturally and as such may not retain this unique capacity. To address this, rabbit
hyperimmune serum raised against ClyS (ELISA titer of >100,000) was assayed
for its effect on lytic activity.  When the antibody was added to ClyS (100 µg) at a
1:10 dilution (10,000 final ELISA titer) and allowed to stand for 15 minutes before
adding staphylococci, no effect on the lytic activity was observed (Figure 9.7).  A
similar result was obtained with a second hyperimmune rabbit serum to ClyS
(data not shown).
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Figure 9.7.  Effect of hyperimmune rabbit sera on ClyS activity.
10 µl of either hyperimmune rabbit serum (final ELSA titer of 10,000), pre-
immune rabbit serum or PBS was added to 100 µl of ClyS (100 µg).  After 15
min, staphylococci were added and the change in OD600 was measured for 30
min.
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In vivo Nasal Decolonization of MRSA by ClyS.  To study the potential of ClyS to
reduce MRSA colonization of the nasal cavities, C57BL/6J mice were intranasally
inoculated with ∼5x109 of a spontaneously streptomycin resistant strain of MRSA
(191-SMR). Twenty-four hours post-infection mice were administered one dose of
either buffer or ClyS into the nasal passages.  An hour after the treatment, mice
were sacrificed and bacterial colonies were enumerated on Spectra MRSA agar.
Three independent experiments were performed to evaluate a total of 19 mice for
each treatment group (Figure 9.8). Compared to the buffer alone control (Avg.
120,197 CFU/cavity), a single ClyS treatment (Avg. 731 CFU/cavity) significantly
(p<0.002) reduced the mean CFU on the nasal mucosa by greater than 2 logs.
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Figure 9.8.  Effect of ClyS on nasal colonization by MRSA.
Nasal passages of C57BL/6J mice were inoculated with ∼5x109 of MRSA strain
191-SMR.  After 24 hours, mice were treated by a single intranasal administration
of 1 mg of ClyS or 20 mM phosphate buffer.  One hour after treatment the
bacteria from the excised nasal cavities were plated on Spectra MRSA agar to
enumerate CFU.  Data from three independent experiments were combined (19
mice per treatment group) and analyzed for statistical significance with the
Studentʼs T-test.
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9.3.7 ClyS Treatment of Systemic MRSA Infections.
In order to assess whether ClyS treatment could prevent death resulting from
systemic MRSA infections, 4 week old FVB/NJ mice were intraperitoneally
injected with ∼5x105 CFU of the community-acquired (PVL toxin-encoding)
MRSA strain MW2 in 5% mucin.  Preliminary experiments determined that 5x105
CFU was 10 fold the LD100 dose for a twenty-four hour period and that within 1-3
hours of IP injection the MRSA infection was systemic, (i.e. >1,000 MRSA CFUs
recovered from heart, liver, spleen, and kidney) (data not shown).  Treatment
occurred three hours post-infection, with either 20mM phosphate buffer or a
single 1 mg dose of ClyS in 20mM phosphate buffer injected IP.  Mice were then
monitored for survival over ten days.  The results from three independent
experiments were combined (ClyS treatment, n =16; buffer treatment, n =14) and
mouse survival data plotted with a Kaplan Meier Survival curve (Figure 9.9).
Within twenty-four hours of MRSA infection all of the control mice died of
bacterial sepsis, while only 2/16 of ClyS treated mice died at forty-eight hours.
The remaining ClyS treated mice (14/16, 88%) survived over the 10-day course
of the experiments (Figure 9.9).  Other experiments showed that treatment with
one dose of 1mg of ClyS / mouse at 1hr or 6hr post infection also rescued mice
from death (data not shown).
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Figure 9.9.  ClyS protected mice from death caused by MRSA septicemia.
FVB/NJ mice were intraperitonally injected with ∼5x105 CFU of MRSA strain
MW2 in 5% mucin. Three hours post-infection, mice received one intraperitoneal
injection of 20 mM phosphate buffer control or 1 mg of ClyS.  Mice were
monitored for survival over ten days.  The results from three independent
experiments were combined (ClyS treatment, n =16; buffer treatment, n =14) and
the mice survival data plotted with a Kaplan Meier Survival curve.
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9.3.8 ClyS shows synergistic interaction with Vancomycin and Oxacillin.
A standard checkerboard broth-microdilution assay was used to test the
interaction of ClyS with vancomycin and ClyS with oxacillin to determine synergy.
The ClyS MIC was 30 to 40 µg/ml for both strains tested while the vancomycin
MIC for VISA strain Mu50 was 16 µg/ml and the oxacillin MIC for MRSA strain
COL was 64 µg/ml.  Isobolograms were plotted for ClyS with vancomycin and
with oxacillin by transcribing the enzyme concentrations along the inhibitory line
on the microtiter plate in an x/y plot.  The shape of the curves for both antibiotics
were characteristic of highly synergistic interactions (Figure 9.10) and were
confirmed by calculating the ΣFIC for both interactions which were <0.5).
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Figure 9.10.  ClyS showed synergistic interaction with vancomycin or oxacillin.
Interactions between ClyS and antibiotics were tested by the checkerboard broth
micro-dilution assay.  Fractional concentrations of MICs along the inhibitory line
for enzyme or antibiotic were plotted on the x/y plot to generate an isobologram.
Error bars show standard errors of mean.
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9.3.9 In vivo Synergy of Oxacillin and ClyS in MRSA Infections.
To determine if the in vitro synergy observed between ClyS and oxacillin could
be translated in our MRSA septicemia model, FVB/NJ mice were intraperitoneally
injected with ∼5x105 CFU of MRSA strain MW2 as above. At three hours post
infection, the bacteremic mice were treated in parallel, with a low IP dose of ClyS
(166 µg/mouse) and different concentrations of oxacillin IM (ranging from 10–100
µg/mouse) or buffer controls by the same routes.  Preliminary experiments
determined that an ED30 dose of ClyS (166 µg/mouse) provided enough efficacy
to offer partial protection to mice while being a low enough concentration to
evaluate the effect of combinatorial treatment with oxacillin (data not shown).
Mice were monitored for survival for 10 days and the results of 5 independent
experiments were combined and plotted in a Kaplan Meier Survival curve (Figure
9.11).  While only 30% (6/20 alive) to 35% (8/23 alive) of mice survived with
individual treatments of either 166 µg/mouse of ClyS or 100 µg/mouse of
oxacillin, respectively, neither differed significantly from the survival rate of the
buffer alone (13%, 2/15 alive) control.  Conversely, a single dose of the
combined treatment of intraperitoneally injected ClyS with either 50 µg or 100 µg
of oxacillin injected intramuscularly significantly increased mouse survival (80%,
8/10 alive; 82%, 18/22 alive respectively) compared to the individual treatments
and buffer alone (Figure 9.11).
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Figure 9.11.  Synergistic effects of ClyS and oxacillin protected mice from MRSA
septicemia induced death.
FVB/NJ mice were intraperitoneally injected with ∼5x105 CFU of MRSA strain
MW2 in 5% mucin. Three hours post-infection, mice received an IP injection of a
suboptimal concentration of ClyS (166µg) or 20mM phosphate buffer along with
an IM injection of oxacillin (10µg - 100µg) or saline control. Mice were monitored
for survival for 10 days and the results of 5 independent experiments were
combined and plotted in a Kaplan Meier Survival curve.
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9.4 DISCUSSION
ClyS, a staphylococcal-specific lysin, has demonstrated synergistic interaction in
vitro (ΣFIC <0.5) with two antibiotics commonly used to treat staphylococcal
infections, namely oxacillin and vancomycin.  These results are in agreement
with previous studies suggesting a synergistic interaction between phage lysins
with different classes of antibiotics (Rashel, Uchiyama et al. 2007; Manoharadas,
Witte et al. 2009).  More importantly however, we have demonstrated the
synergistic interaction of ClyS with oxacillin in vivo, the first report to our
knowledge.  A suboptimal concentration of ClyS in combination with oxacillin was
able to significantly increase survival of mice infected with MRSA strain MW2
compared to each compound individually.  We speculate that the in vivo synergy
between oxacillin and ClyS may be due to enhanced lysis of the bacteria, similar
to what is observed with oxacillin treatment of the mgrA/sarA mutants of S.
aureus (Trotonda, Xiong et al. 2009).  Oxacillin inhibits cell wall assembly
enzymes resulting in increased expression of internal peptidoglycan hydrolases
and autolysins causing weakening of the cell wall peptidoglycan.  As an
endopeptidase, adding ClyS would elevate the total concentration of wall-
degrading enzymes further shifting the balance of the cell wall repair and
degrading machinery to cause increased degradation and thus lysis of the
bacteria.  These results could allow antibiotics now discontinued in the clinic, due
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to increased resistance issues, to be reinstated when combined with an
appropriate dose of ClyS.
Using ClyS alone may prove to be a viable treatment for more serious, S. aureus
diseases, such as soft tissue infections, bacteremia, infective endocarditis, and
pneumonia. Unlike antibiotics whose effects are only seen hours after
administration, lysins work immediately, reducing the accumulation of toxic
substances.  This is illustrated in recent studies showing the effectiveness of
phage lysins in treating systemic infections (Schuch, Nelson et al. 2002; Loeffler,
Djurkovic et al. 2003) and in one case the successful treatment of an established
pneumococcal pneumonia (Witzenrath, Schmeck et al. 2009).  In our study, a
single IP dose of ClyS in mice septic with MRSA resulted in significantly higher
survival rates (88%) than untreated septic mice (0%).  It is likely that the survival
rates of the treated mice could be increased further by changing the dosing to
either a higher dose of ClyS or by repeat dosing.
To accomplish these protection experiments, it was necessary to develop a
chimeric lysin in order to circumvent the solubility problems inherent in
staphylococcal phage lysins (Navarre, Ton-That et al. 1999; O'Flaherty, Coffey et
al. 2005) and our own unpublished data).   We took advantage of the modular
nature of lysins, which has been exploited by researchers, to swap different
catalytic and binding domains while retaining the activity and/or specificity,
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respectively, of the original lysin (Donovan, Dong et al. 2006).  Using biochemical
and functional assays as guidance, more than 15 chimeras were strategically
engineered to contain different combinations of catalytic and binding domains.
From these constructs a novel lysin, ClyS, was engineered that had the desirable
properties of a well expressed and highly soluble lysin that was active against
staphylococci.
ClyS is a chimera consisting of the N-terminal endopeptidase domain of the lysin
from phage Twort fused with the C-terminal CWT domain of phage phiNM3 lysin.
The phiNM3 CWT domain by itself was highly soluble and displayed binding
specificity toward staphylococcal cells.  Additionally, the CWT domain met a
second criterion wherein it did not have homology to the SH3b-like binding
domain associated with lysostaphin and some lysins.  SH3b binding domains are
presumed to bind the peptide cross-bridges in the bacterial cell wall
peptidoglycan (Grundling and Schneewind 2006).  These peptide bridges can be
readily altered by the bacteria rendering them resistant to these lytic enzymes
including lysostaphin.  This mechanism of resistance could presumably be
circumvented by engineering a chimeric lysin that contained a novel CWT
domain.  As such, the phiNM3 CWT domain of ClyS does not share homology to
any known domains in the GenBank database.  The absence of homology in the
binding domain is a common feature for lysins such as PlyG and Cpl-1 (Loeffler,
Nelson et al. 2001; Schuch, Nelson et al. 2002).  These lysins use carbohydrate
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and choline moieties respectively in the bacterial cell wall as their receptors.  The
uniqueness of the binding domains of such lysins complements the unique
structures present on the bacterial cell walls, thereby imparting to lysins their
characteristically exquisite specificity.  The binding domain of ClyS also
presumably recognizes a cell wall-associated carbohydrate or another moiety.
This in turn may make ClyS an attractive target for development as an alternative
therapeutic because of the lack of resistance as seen for PlyG (Schuch, Nelson
et al. 2002), Cpl-1, and other lysins (unpublished data).
Analysis of the spectrum of activity for ClyS supports the above assumptions for
ClyS since lysostaphin-resistant lyrA mutants of S. aureus, as well as the
lysostaphin-producer S. simulans were susceptible to ClyS (Grundling, Missiakas
et al. 2006; Grundling and Schneewind 2006).  Activity of ClyS against S.
simulans indicates that the binding domain is unaffected by the presence of a
serine residue in the peptide cross-bridges of S. simulans peptidoglycan, the
reason for its resistance to lysostaphin.  ClyS was also active against several
Staphylococcus sp. including all tested MRSA and VISA strains, as well as, S.
sciuri and biofilm-producing and non-producing strains of S. epidermidis
suggesting that the binding moiety of ClyS probably is a common cell wall
component found in all Staphylococcus species.  Such broad-spectrum activity of
ClyS seen against all staphylococci tested is uncommon among native phage
lysins, which typically display species specificity (Loeffler, Nelson et al. 2001;
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Schuch, Nelson et al. 2002).  However, the lack of activity of ClyS against other
Gram-positive or Gram-negative bacteria resembles the characteristic specificity
seen in native phage lysins.  The species specificity of ClyS and its ability to kill
multi-drug resistant as well as biofilm-producing staphylococci in vitro makes
ClyS a valuable treatment option for staphylococcal infection or decolonization of
skin and mucous membranes.
In humans, the nasal mucous membranes are the major reservoir of
staphylococci, including MRSA, and are an endemic risk factor for skin and soft
tissue infections as well as bacteremia in the patient population (Coates, Bax et
al. 2009).  A decline in nosocomial infection is reported with the reduction or
elimination of this reservoir.  Lysins have been successfully used in several
different animal models of mucosal colonization to decolonize a wide range of
pathogenic bacteria including staphylococci, pneumococci, and group A and
group B streptococci (Nelson, Loomis et al. 2001; Schuch, Nelson et al. 2002;
Loeffler, Djurkovic et al. 2003; Cheng, Nelson et al. 2005; Rashel, Uchiyama et
al. 2007).  When administered intranasally to mice, ClyS efficiently eliminated
MRSA by decolonizing the nasal passages.  A greater than two-log drop was
seen in an hour after a single treatment as compared to buffer alone.  The
currently accepted S. aureus decolonization regimen includes treatment with
mupirocin ointment nasally for 5 days, but recolonization and inadequate
clearance often results because of increasing resistance to the antibiotic or poor
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patient compliance (Coates, Bax et al. 2009; Udo and Sarkhoo 2009).  The fact
that ClyS works as a potent decolonizing agent suggests that lysin therapy is a
viable alternate treatment option in specific high-risk populations such as in
hospitals and in nursing homes etc. and may aid in decreasing primary and
secondary infection rates.  Furthermore, unlike antibiotics, the specificity of ClyS
to staphylococci may allow it to be used prophylactically, to reduce further
carriage of S. aureus and MRSA in health-care employees or in community
settings where MRSA resistance is becoming an increasing problem, such as
military bases, prisons, and sports teams (Coates, Bax et al. 2009).  Finally,
recent evidence indicates that >90% of deaths as a result of influenza pandemics
were caused from secondary infections caused by S. aureus, S. pneumoniae,
and S. pyogenes (Brundage and Shanks 2007; Morens, Taubenberger et al.
2009), and 30% of deaths from the recent H1N1 was complicated due to the
same causes (MMWR 2009). Thus, ClyS and other lysins may be used during flu
season to reduce colonization and/or treat secondary infections caused by these
pathogens in high-risk individuals.
The current standard of care for treatment of serious bacterial infections, pending
identification of the organism, is to cover the most likely organisms based on the
suspected site of infection, the patientʼs clinical condition, and any relevant
environmental factors (Dellinger, Carlet et al. 2004; Cunha 2008).  Since
staphylococci are ubiquitous organisms, anti-staphylococcal coverage is included
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in many empiric regimens.  Treatment of serious infections caused by S. aureus
has been a challenge for decades, because the bacteria rapidly develop
resistance mutations to novel antibacterials. Beta lactam antibiotics are among
the most widely used for treatment of serious infection, but no currently available
beta lactam agent is effective against MRSA. Furthermore, MRSA have
developed resistance to newer agents including glycopeptides (Huang, Hsiao et
al. 2008) and oxazolidinones (Wilson, Andrews et al. 2003). Lysins, because of
their low probability of bacterial resistance plus rapid activity and high specificity
could be an important addition to the medical armamentarium.
In summary, we report the development of a novel chimeric lysin with improved
biochemical properties and excellent lytic activity against all staphylococci
including MRSA and VISA strains.  We have demonstrated the effectiveness of
ClyS when used alone or in combination with existing antibiotics for treatment of
serious staphylococcal infections.  This alternative therapeutic option will provide
a viable tool to combat the increasing problem of infections caused by multidrug
resistant S. aureus.
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10 Conclusions
Although the existence of phage has been known and studied for over three
quarters of a century, we are far from having a full understanding of the many
interactions between bacteriophage and their hosts or the dynamic roles that
both play in bacterial pathogenesis and survival.  As more sophisticated
molecular biology and sequencing techniques have been developed, our
understanding and appreciation of the complex role that bacteriophage play in
the life cycle of both non-virulent and pathogenic bacteria have increased
accordingly.  We believe that our studies on the manipulation of phage genes
and the perturbation of phage-host interactions have further elaborated new and
novel mechanisms by which phages and their hosts interact at the molecular
level.   We hope the novel techniques that we have developed throughout these
studies will aid future scientists in the exploration of even more complex
relationships between these organisms.  For as our understanding of these
interactions increase, so does the potential for novel antimicrobials to be
developed in the treatment and prevention of bacterial diseases.   After all...
“ … the actions and reactions are not solely between these two beings,
bacterium and phage, for the scientist also intervenes; a third living being and
hence, a third variable is introduced”  (Euler 2010).
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